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Abstract	  
	  	   The	  mammalian	   CKS	   family	   consists	   of	   two	   highly	   conserved	   proteins,	   CKS1	   and	  CKS2.	  Both	  are	  able	  to	  bind	  to	  cyclin	  dependent	  kinases	  1	  and	  2	  (CDK1	  and	  CDK2)	  with	  high	  affinity	  and	  were	   suggested	   to	  modulate	  CDK	  activity	  and	   thus	   cell	   cycle	   control.	  CKS	  proteins	  have	  also	  been	  reported	  to	  facilitate	  the	  ubiquitination	  of	  cyclin	  A	  by	  the	  anaphase	   promoting	   complex	   (APC).	   Additionally	   CKS1	   has	   been	   shown	   to	   have	   an	  important	  role	  in	  the	  recognition	  of	  the	  cyclin	  dependent	  kinase	  inhibitor	  p27Kip1	  by	  the	  SCFSkp2	   (Skp1-­‐Cul1-­‐F-­‐box-­‐protein)	   ubiquitin	   ligase.	   Elevated	   expression	   of	   both	   CKS	  proteins	   is	  often	   found	   in	  a	  variety	  of	   tumours	  and	   is	   correlated	  with	  poor	  prognosis.	  This	  might	   indicate	   an	   involvement	   of	   CKS	   proteins	   in	   the	   process	   of	   transformation	  from	   normal	   to	   cancer	   cells.	   Previously	   it	   was	   shown	   that	   down-­‐regulation	   of	   CKS	  proteins	  in	  cancer	  derived	  cell	  lines	  results	  in	  a	  loss	  of	  their	  high	  proliferative	  capacity.	  	  I	   surmise,	   that	   a	   possible	   oncogenic	   effect	   of	   CKS	   proteins	   might	   be	   due	   to	   the	  deregulation	  of	  replication.	  	   To	   study	   the	   role	   of	   CKS	   proteins	   as	   oncogenes,	   different	   stages	   of	   cancer	  development	   were	   modelled	   in	   the	   human	   diploid	   fibroblast	   cell	   line,	   IMR90.	   Over-­‐expression	   of	   CKS	   proteins	   was	   combined	   with	   defined	   genetic	   events	   known	   to	   be	  associated	  with	  transformation	  such	  as	  activation	  of	  telomerase	  (hTERT)	  and	  blockage	  of	   the	   p53	   and	   RB	   pathways.	   Over-­‐expression	   of	   CKS	   variants	   in	   IMR90	   cells	   led	   to	  checkpoint	   activation	   and	   growth	   arrest	   reminiscent	   of	   oncogenic	   stress.	   Down-­‐regulation	  of	   the	   checkpoint	  proteins	  p53	  and	  RB	  however	   could	  alleviate	   the	  growth	  arrest	   and	   led	   to	   a	   slight	   growth	   advantage	   of	   the	   CKS	   over-­‐expressing	   fibroblasts.	  Analyses	  to	  understand	  the	  molecular	  mechanisms	  behind	  the	  checkpoint	  activation	  in	  primary	  IMR90	  were	  performed	  addressing,	  in	  particular,	  the	  involvement	  of	  an	  altered	  CDK	  activity.	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  tetracycline	  repressor	  rtTA	   reverse	  tetracycline-­‐controlled	  transactivator	  ROS	   reactive	  oxygen	  species	  SA-­‐β-­‐gal	   senescence-­‐associated	  β-­‐galactosidase	  SAHF	   senescence	  associated	  heterochromatic	  foci	  SASP	   senescence	  associated	  secretory	  phenotype	  SCF	  E3	  ligase	   SKP-­‐Cullin-­‐F-­‐box	  E3	  ligase	  SDS	   sodium	  dodecyl	  sulfate	  SIN	   self-­‐inactivating	  SKP	   S-­‐phase	  kinase	  associated	  protein	  S-­‐phase	   synthesis	  phase	  SV40	  TAg	   simian	  virus	  40	  large	  tumour	  antigen	  SWI/SNF	   switch/sucrose	  nonfermentable	  tetO	   tetracycline	  operator	  TetR	   tetracycline	  repressor	  TRAMP	   transgenic	  	  adenocarcinomas	  of	  the	  mouse	  prostate	  TRE	   tetracyclin	  responsive	  promoter	  element	  TGF-­‐β	   transforming	  growth	  factor	  beta	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Tyr	   tyrosine	  VEGF	   vascular	  endothelial	  growth	  factor	  VSV-­‐G	   vesicular	  stomatitis	  virus	  glycoprotein	  WB	   Western	  blotting	  wt	   wild-­‐type	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Chapter	  1	  -­‐	  Introduction	  	  
1.1 Intrinsic	  barriers	  to	  cancer	  progression	  
1.1.1 Models	  describing	  cancer	  development	  As	   early	   as	   1890,	   David	   von	  Hansemann	   studied	   carcinoma	   cells	  microscopically	   and	  described	  the	  presence	  of	  aberrant	  mitosis	  with	  asymmetric	  division	  of	  the	  cell.	  He	  saw	  that	   during	   these	   divisions,	   cells	   with	   altered	   chromatin	   content	   derive	   (Dell,	   2006;	  Marte,	  2006;	  von	  Hansemann,	  1890;	  Wunderlich,	  2011).	  	  	   In	   1914,	   Theodor	   Boveri	   built	   on	   these	   observations	   and	   developed	   his	   cancer	  theory	  based	  on	  studies	  using	  sea	  urchin	  eggs	  (Marte,	  2006).	  Via	  double	  fertilization	  of	  these	   eggs,	   he	   could	   induce	   multipolar	   mitosis	   which	   led	   to	   abnormal	   chromosome	  constitutions	  and	  cells	  with	  a	  cancer-­‐like	  phenotype	  (Boveri,	  1914;	  Weinberg,	  2008).	  He	  assumed	   that	   one	   chromosome	   bears	   several	   hereditary	   units	   and	   postulated	   that	   a	  perturbed	  combination	  of	  chromosomes	   leads	   to	  cancer	  development	   (Balmain,	  2001;	  Boveri,	  1914).	  Boveri	  also	  introduced	  the	  terms	  ‘proliferation	  inhibiting	  chromosomes’,	  which	  are	  lost	  in	  growing	  tumours	  and	  ‘proliferation	  assisting	  chromosomes’,	  which	  are	  amplified	  during	  tumour	  development	  (Balmain,	  2001;	  Boveri,	  1914;	  Dell,	  2006;	  Marte,	  2006).	   	   Today	   these	   ‘proliferation	   inhibiting	   and	   assisting	   chromosomes’	   are	  synonymous	  with	   tumour-­‐suppressor	  genes	  and	  oncogenes	  respectively.	  Tumours	  are	  believed	   to	   develop	   from	   one	   cell	   and	   tumour	   progression	   happens	   via	   sequential	  changes	   with	   increasing	   activity	   of	   growth-­‐stimulatory	   chromosomes	   and	   loss	   of	  growth-­‐inhibitory	   chromosomes.	   Boveri	   suggested	   that	   there	   is	   a	   predisposition	   for	  cancer	   by	   inheriting	   chromosomes	  with	   reduced	   ability	   to	   suppress	   cancer.	  When	   an	  individual	   is	  homozygous	  for	  such	  a	   ‘weak	  chromosome’,	   there	  is	  a	  high	  penetrance	  of	  cancer	  (Balmain,	  2001;	  Boveri,	  1914).	  He	  even	  imagined	  that	  certain	  agents	  as	  well	  as	  radiation	   or	   pathogens	   lead	   to	   cancer	   development	   by	   their	   influence	   on	   mitosis	   or	  other	  chromosome	  altering	  processes	  (Marte,	  2006).	  	   The	   term	   ‘somatic	   mutation’	   with	   respect	   to	   a	   tumour	   was	   first	   used	   by	   Ernest	  Tyzzer	   in	   1916	   who	   described	   a	   tumour	   as	   ‘manifestation	   of	   somatic	   mutation’	  (Knudson,	  2001;	  Tyzzer,	  1916).	  	  	  	   Hermann	   Muller	   postulated	   later	   on	   that	   several	   of	   these	   mutations	   in	   one	   cell	  would	  be	  necessary	  to	  transform	  a	  cell	   into	  a	  cancer	  cell.	  He	  also	   found	  X	  rays	  to	  be	  a	  cause	   for	   these	   mutations.	   The	   delay	   of	   the	   onset	   of	   the	   disease	   after	   exposure	   to	  radiation	   suggested,	   that	   ‘a	   row	  of	  mutations’	  were	   required	   (Knudson,	   2001;	  Muller,	  1927,	  1955).	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   Later	   on,	   inherited	   cancer	   syndromes	  were	   discovered.	   The	   development	   of	   skin	  cancer	   in	   Xeroderma	   Pigmentosum	   for	   example	   could	   be	   explained	   by	   a	   defect	   in	   an	  enzymatic	  mechanism,	  which	  is	  now	  known	  as	  excision	  repair	  (Knudson,	  2001).	  Due	  to	  this	   defect,	   DNA	   damage	   caused	   by	   ultraviolet	   light	   cannot	   be	   repaired	   and	   an	  accumulation	  of	  mutations	  occurs	  which	  finally	  leads	  to	  the	  development	  of	  carcinomas	  (Cleaver,	   1968;	   Dell,	   2006;	   Knudson,	   2001).	   But	   alterations	   in	   gene	   expression	   and	  function	   are	   not	   only	   due	   to	   mutations	   within	   the	   gene	   itself.	   In	   the	   case	   of	   chronic	  myelogenous	   leukaemia	   for	   example,	   onset	   of	   disease	   results	   from	   a	   reciprocal	  translocation	   between	   chromosomes	   9	   and	   22	   (Knudson,	   2001;	   Rowley,	   1973).	   The	  newly	  formed	  chromosome	  22	  is	  shorter	  and	  was	  named	  Philadelphia	  Chromosome.	  As	  a	  result	  of	  the	  translocation,	  the	  Abelson	  murine	  leukaemia	  viral	  oncogene	  (ABL)	  gene,	  which	   was	   located	   on	   chromosome	   9,	   is	   now	   fused	   to	   the	   breakpoint	   cluster	   region	  (BCR)	   gene	   on	   chromosome	   22.	   This	   resulting	   BCR-­‐ABL	   fusion	   gene	   encodes	   for	   a	  constitutively	   active	   tyrosine	   kinase,	  which	   leads	   to	   a	   higher	   rate	   of	   cell	   proliferation	  (Knudson,	  2001;	  Shtivelman	  et	  al.,	  1985;	  Stam	  et	  al.,	  1985).	  Other	  genes	  acting	  like	  ABL,	  which	   promote	   tumour	   development	   upon	   excessive	   activation	   were	   discovered	   and	  called	   proto-­‐oncogens	   (Stehelin	   et	   al.,	   1976).	   	   Later	   on	   genes	   suppressing	   tumour	  development	  were	   analysed	   in	  more	   detail	   (Balmain,	   2001).	   One	   of	   the	   first	   of	   these	  tumour-­‐suppressor	   genes	   identified	   was	   the	   retinoblastoma	   (RB)	   gene	   (Friend	   et	   al.,	  1986;	   Knudson,	   2001)	   which	   controls	   progression	   through	   the	   cell	   cycle	   (Weinberg,	  1995).	  Deletion	  of	  the	  RB	  gene	  often	  leads	  to	  the	  development	  of	  cancer	  of	  the	  eye	  called	  retinoblastoma.	   In	   1971,	   Knudson	   analysed	   onset,	   severity	   and	   development	   of	  retinoblastoma	   in	   a	   group	   of	   patients.	   He	   set	   up	   his	   ‘two-­‐hit	   hypothesis’	   in	  which	   he	  points	   out	   that	   not	   only	   one	   but	   both	   copies	   of	   the	   tumour	   suppressor	   gene	  must	   be	  inactivated	   in	   one	   cell	   before	   a	   tumour	   develops.	   Thus	   retinoblastoma	   occurs	   with	   a	  higher	   frequency	   and	   in	   younger	   age	   in	   patients,	  which	   already	   inherited	   an	   inactive	  gene	  from	  one	  of	  their	  parents	  (Knudson,	  2001,	  1971).	  	   Later	   on,	   Vogelstein	   named	   tumour	   suppressor	   genes	   like	   the	   RB	   gene	  ‘gatekeepers’.	   They	   directly	   regulate	   the	   growth	   of	   tumours	   by	   inhibiting	   growth	   or	  promoting	   cell	   death	   (Kinzler	   and	   Vogelstein,	   1997).	   During	   his	   analyses	   of	   sporadic	  and	   inherited	   colorectal	   cancer,	   he	   pointed	   out	   that	   the	   adenomatous	   polyposis	   coli	  (APC)	  gene,	  which	  is	  mutated	  in	  patients	  with	  familial	  adenomatous	  polyposis	  (FAP),	  is	  another	  of	  these	  gatekeeper	  genes	  (Kinzler	  and	  Vogelstein,	  1996).	  APC	  interacts	  with	  β-­‐catenin,	   which	   in	   turn	   is	   responsible	   for	   the	   regulation	   of	   various	   processes	   like	   cell	  proliferation,	  differentiation,	  motility,	   adhesion	  and	  apoptosis	   (Fodde	  et	  al.,	  2001).	   	   In	  contrast	  to	  FAP,	  hereditary	  nonpolyposis	  colorectal	  cancer	  (HNPCC)	  is	  based	  on	  defects	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in	   enzymes,	  which	  are	  necessary	   for	   the	  mismatch	   repair	  of	  DNA.	  Genes	   encoding	   for	  such	   repair	   enzymes	   are	   called	   ‘caretakers’	   (Kinzler	   and	   Vogelstein,	   1997).	   The	  initiation	  of	  cancer	  development	   is	  much	  more	   likely	  via	   the	  mutation	  of	  a	  gatekeeper	  like	  APC.	   Once	   both	   copies	   of	   the	   gatekeeper	   loose	   their	   proper	   function,	   the	   loss	   of	  caretakers	  subsequently	  leads	  to	  genomic	  instability	  and	  facilitates	  tumour	  progression	  (Kinzler	  and	  Vogelstein,	  1996).	  	   Today,	  we	  know	  that	  the	  process	  of	  cell	  transformation	  is	  a	  multi-­‐step	  process	  and	  involves	   several	   genetic	  alterations	   in	   the	  genome	  of	   a	   cell.	   	  These	  alterations	   include	  both,	   mutations	   in	   oncogenes	   leading	   to	   a	   gain	   of	   function	   and	  mutations	   in	   tumour	  suppressor	  genes	   leading	  to	  a	   loss	  of	   function	  of	  the	  respective	  proteins.	  Because	  they	  provide	   gain	   of	   function,	   oncogenes	   are	   typically	   dominant	   (Cooper,	   1990).	   Tumour	  suppressor	   genes	   are	   recessive	   (Hansen	   and	   Cavenee,	   1988).	   The	   action	   of	   an	   active	  oncogene	  (gain	  of	   function)	   leads	  to	  the	  activation	  of	   tumour	  suppressor	  genes.	  These	  tumour	  suppressor	  genes	  first	  need	  to	  be	  bypassed	  (loss	  of	  function)	  before	  the	  effect	  of	  the	   oncogene	   becomes	   visible	   (Boehm	   and	   Hahn,	   2005).	   Genetic	   alterations	   also	  contribute	   to	   the	  essential	  changes	   in	  cell	  physiology	  necessary	   for	   the	  progression	  of	  tumour	  formation,	  including:	  self-­‐sufficiency	  in	  growth	  signals,	  insensitivity	  to	  growth-­‐inhibitory	   signals,	   evasion	   of	   programmed	   cell	   death,	   limitless	   replicative	   potential,	  sustained	  angiogenesis,	  tissue	  invasion	  and	  metastasis	  (Hanahan	  and	  Weinberg,	  2000).	  To	   sustain	   proliferative	   signalling	   and	   thus	   chronic	   proliferation,	   cancer	   cells	   might	  acquire	  the	  ability	  to	  produce	  their	  own	  growth	  factor	  ligands.	  Alternatively,	  they	  might	  get	   other	   cells	   within	   the	   tumour-­‐associated	   stroma	   to	   release	   more	   growth	   factors.	  There	  could	  be	  an	  up-­‐regulation	  of	  growth	   factor	  receptors	  on	  the	  cancer	  cell	  surface,	  firing	  via	  cell	  surface	  receptors	  could	  be	  facilitated	  or	  other	  components	  of	  the	  pathway	  could	   be	   constitutively	   active.	   Another	   way	   of	   tumour	   cells	   to	   enhance	   proliferative	  signalling	   is	   to	   disrupt	   negative	   feedback	  mechanisms.	   To	   evade	   growth	   suppression	  and/or	   cell	   death,	   tumour	   cells	   must	   circumvent	   pathways,	   which	   are	   regulated	   by	  tumour	   suppressor	   genes	   like	   RB	   and	   p53	   (Hanahan	   and	   Weinberg,	   2000,	   2011).	  Furthermore,	  cells	  achieve	  immortality	  by	  sustaining	  the	  protective	  ends	  of	  DNA,	  called	  telomeres	  (Belgiovine	  et	  al.,	  2008).	   In	  order	  to	  achieve	  a	  good	  supply	  of	  nutrients	  and	  oxygen,	  tumour	  tissue	  must	  be	  infiltrated	  by	  new	  vessels	  and	  thus	  angiogenesis	  must	  be	  induced	  (Hanahan	  and	  Weinberg,	  2011).	  This	  is	  possible	  by	  vascular	  endothelial	  growth	  factor	   (VEGF)	  signalling	  which	  might	  be	  up-­‐regulated	  by	  hypoxia	  or	  oncogenes.	  To	  be	  finally	  able	   to	   leave	   their	  own	  tissue	  and	  metastasise,	   cancer	  cells	  undergo	  a	  program	  called	   epithelial-­‐mesenchymal	   transition	   (EMT).	   EMT	   is	   regulated	   by	   a	   change	   in	   the	  expression	  of	   transcription	  factors,	  which	  are	  responsible	   for	  the	  expression	  of	  matrix	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degrading	  enzymes,	   increased	  motility,	  heightened	   resistance	   to	  apoptosis	   and	   loss	  of	  adherent	  junctions	  (Hanahan	  and	  Weinberg,	  2011).	  	  
1.1.2 Tumour	  suppressor	  genes	  In	  1969,	  Henry	  Harris	  made	  the	  observation	  that	  upon	  fusion	  of	  a	  malignant	  cell	  with	  a	  normal	   somatic	   cell,	   tumour	   growth	   could	  be	   suppressed.	  After	   elimination	  of	   certain	  chromosomes	   from	   the	   hybrid,	   these	   suppressing	   characteristics	   are	   lost	   again	   (Dell,	  2006;	  Harris	   et	   al.,	   1969).	   The	   first	   gene,	  which	   could	   be	   identified	   of	   having	   tumour	  suppressing	   abilities	   was	   retinoblastoma	   (RB)	   (Burkhart	   and	   Sage,	   2008;	   Knudson,	  2001).	   After	   RB,	   many	   other	   tumour	   suppressor	   genes	   have	   been	   identified	   and	  analysed.	   To	   prevent	   tumour	   development,	   tumour	   suppressors,	   like	   the	  well	   studied	  RB	  and	  p53	  proteins,	  inhibit	  enhanced	  cell	  proliferation,	  regulate	  an	  apoptotic	  response	  and	  initiate	  the	  DNA	  damage	  response	  upon	  the	  activation	  of	  oncogenic	  stress.	  In	  later	  stages	  of	  carcinogenesis,	  tumour	  suppressor	  genes	  also	  block	  loss	  of	  contact	  inhibition	  and	  metastasis	  (Sherr,	  2004).	  	  	  
1.1.2.1	  RB	  The	  RB	  family	  of	  proteins	  consists	  of	  RB	  (p105),	  p130	  and	  p107.	  The	  best-­‐characterised	  tumour	   suppressor	   function	   of	   RB	   is	   its	   ability	   to	   arrest	   cells	   in	   G1.	   To	   achieve	   this	  arrest,	   different	  members	   of	   the	  RB	   family	   bind	   in	   their	   hypophosphorylated	   form	   to	  members	  of	  the	  E2F	  family	  of	  transcription	  factors	  and	  either	  antagonise	  or	  potentiate	  their	   function.	   RB	   itself	   binds	   to	   the	   transcriptional	   activators	   E2F1,	   2	   and	   3a	   and	  prevents	  them	  from	  binding	  to	  the	  promoter	  of	  genes	  required	  for	  S-­‐phase	  entry.	  p130	  and	  p107	  on	  the	  other	  hand	  bind	  to	  repressors	  like	  E2F4	  and	  5.	  These	  complexes	  then	  bind	  to	  promoters	  of	  S-­‐phase	  genes	  and	  recruit	  chromatin	  remodelling	  factors	  to	  silence	  the	   genes.	   Phosphorylation	   of	   the	   RB	   proteins	   is	   performed	   by	   the	   cyclin	   D-­‐cyclin-­‐dependent	   kinase	   (CDK)	   4/CDK6	   and	   cyclin	   E-­‐CDK2	   complexes	   and	   leads	   to	   its	  inactivation	  (Macaluso	  et	  al.,	  2006;	  Sun	  et	  al.,	  2007;	  Woo	  et	  al.,	  1997).	  	   In	  addition	  to	  their	  ability	  to	  bind	  E2F	  4	  and	  5,	  p107	  and	  p130	  were	  also	  reported	  to	   form	   stable	   complexes	   with	   cyclin	   A-­‐CDK2	   and	   cyclin	   E-­‐CDK2	   complexes.	   They	  contain	   a	   cyclin	   binding	   domain	   as	   well	   as	   a	   CDK	   inhibitor	   domain,	   which	   has	   been	  shown	  to	   inhibit	  CDK2	  activity	  (De	  Luca	  et	  al.,	  1997;	  Macaluso	  et	  al.,	  2006;	  Woo	  et	  al.,	  1997)	  	   Due	  to	  mutations	  in	  RB	  itself	  or	  in	  transforming	  growth	  factor	  beta	  (TGF	  β),	  one	  of	  the	  anti-­‐proliferative	  factor	  sensing	  receptors	  upstream	  of	  RB,	  the	  RB	  pathway	  is	  often	  disrupted	   in	   tumour	   cells.	   RB	   is	   also	   down-­‐regulated	   by	   the	   E7	   protein	   of	   human	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papillomavirus.	   This	   disruption	   in	   the	   RB	   pathway	   makes	   the	   cells	   insensitive	   to	  growth-­‐inhibitory	   signals	   and	   allows	   the	   progression	   of	   the	   cells	   through	   cell	   cycle	  (Burkhart	  and	  Sage,	  2008;	  Sun	  et	  al.,	  2007).	  	   Apart	  from	  cell	  cycle	  arrest,	  more	  functions	  of	  RB	  in	  tumour	  suppression	  emerged.	  These	   include	   genomic	   stability,	   apoptosis	   and	   differentiation	   (Burkhart	   and	   Sage,	  2008).	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Figure	   1.1	   Function	   of	   the	   RB	   tumour	   suppressor	   family.	   Proteins	   of	   the	   RB	   family	   regulate	   the	  transcription	   of	   E2F	   responsive	   S-­‐phase	   genes	   by	   targeting	  members	   of	   the	   E2F	   family	   of	   transcription	  factors.	  p130	   is	   the	  member	  of	   the	  RB	   family,	  which	   is	  predominantly	  expressed	   in	  quiescent	   cells	   in	  G0	  (Sun	  et	  al.,	  2007).	  It	  binds	  to	  the	  transcriptional	  repressors	  E2F4	  and	  E2F5,	  which	  lack	  a	  nuclear	  localisation	  sequence	  and	  transports	  them	  to	  E2F	  responsive	  promoters	  in	  the	  nucleus.	  RB	  proteins	  like	  p130	  mediate	  the	  repression	  of	  E2F	  target	  genes	  by	  recruitment	  of	  chromatin	  remodelling	  factors	  such	  as	  switch/sucrose	  nonfermentable	   (SWI/SNF)	  and	   the	  hisone	  deacetylase	  HDAC	  (Macaluso	  et	  al.,	  2006).	   In	  middle	  G1	  p130	  levels	  begin	  to	  decrease	  (Sun	  et	  al.,	  2007).	  Additionally	  initial	  growth	  factor	  signalling	  leads	  to	  transcription	  of	  cyclin	  D,	  subsequent	  activation	  of	  CDK4/6	  and	  hypophosphorylation	  of	  RB	  (Haberichter	  et	  al.,	  2007).	  In	  its	   hypophosphorylated	   form	   RB,	   which	   is	   expressed	   during	   the	   whole	   cell	   cycle,	   binds	   to	   the	  transcriptional	  activators	  E2F1,	  E2F2	  and	  E2F3a.	  This	  binding	  prevents	  the	  E2F	  activators	  from	  stimulating	  transcriptional	  activity	  of	   the	  promoters	  (Macaluso	  et	  al.,	  2006).	  By	   further	  phosphorylation	  of	  RB	  by	  the	  cyclin	  D	  CDK4/6	  complex	  and	  due	  to	  increasing	  levels	  of	  the	  transcriptional	  activators,	  RB	  proteins	  are	  not	  able	   to	   supress	   certain	   genes	   like	   cyclin	   E	   anymore	   (Cobrinik,	   2005;	   Macaluso	   et	   al.,	   2006).	   Cyclin	   E	  expression	   leads	   to	   CDK2	   activation	   and	   further	   phosphorylation	   of	   the	   RB	   proteins.	   Now	   genes	   for	   the	  further	  progression	  through	  the	  cell	  cycle	  are	  transcribed	  (Blomen	  and	  Boonstra,	  2007;	  Haberichter	  et	  al.,	  2007).	  
	  
	  
1.1.2.2	  p53	  p53	  is	  crucial	  in	  preventing	  transformation	  of	  cells.	  p53	  itself	  or	  one	  of	  the	  members	  of	  the	   pathways	   upstream	   or	   downstream	   of	   p53	   is	   inactivated	   in	   almost	   every	   cancer	  (Junttila	  and	  Evan,	  2009).	  	  Like	  RB,	  p53	  is	  a	  target	  of	  viral	  oncoproteins	  like	  E6	  from	  the	  human	  papillomavirus	  (Scheffner	  et	  al.,	  1990).	  	   p53	  is	  well	  known	  for	  its	  function	  as	  transcription	  factor.	  It	  possesses	  a	  functional	  transactivation	   domain	   and	   activates	   nearby	   genes	   after	   binding	   to	   specific	   DNA	  sequences	   (Levine	   and	   Oren,	   2009).	   Target	   genes	   of	   p53	   are	   involved	   in	   metabolic	  homeostasis,	   anti-­‐oxidant	   defence,	   DNA	   repair,	   Growth	   arrest	   and	   senescence	   and	  apoptosis.	  	  	   More	  recently,	  p53	  was	  shown	  to	  regulate	  the	  transcription	  of	  various	  microRNAs	  as	   well	   (He	   et	   al.,	   2007).	   	   Besides	   transcriptional	   activation,	   p53	   has	   other	   functions	  including	  the	   interaction	  with	  members	  of	   the	  B-­‐cell	   lymphoma	  2	  (BCL-­‐2)	   family.	  This	  leads	  to	  mitochondrial	  outer	  membrane	  permeabilisation,	  release	  of	  cytochrome	  c	  and	  apoptosis	  (Levine	  and	  Oren,	  2009).	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1.1.3	  The	  cell	  cycle	  A	   regulated	   transition	   of	   the	   cell	   through	   cell	   cycle	   is	   important	   to	   allow	   the	   precise	  replication	  of	  the	  cell’s	  genome	  and	  division	  of	  the	  cell	  with	  the	  correct	  partition	  of	  the	  chromosomes	  onto	  the	  resulting	  daughter	  cells	  (Vermeulen	  et	  al.,	  2003).	  	   Cells	   divide	   during	   mitosis	   (M-­‐phase).	   Before	   cells	   are	   able	   to	   replicate	   their	  genome	  again	  in	  S-­‐phase,	  proteins,	  which	  are	  required	  for	  entry	  and	  completion	  of	  the	  replication	   process,	   are	   synthesised	   in	   G1-­‐phase	   (gap	   1-­‐phase).	   After	   successful	  replication,	  cells	  prepare	  for	  mitosis	  by	  producing	  proteins	  such	  as	  microtubules	  in	  G2	  (gap	   2-­‐phase).	   Cells	   in	   G1	  which	   are	   not	   ready	   for	  DNA	   replication	   enter	   into	   a	   state	  called	  G0	  (gap	  0-­‐phase)	  (Vermeulen	  et	  al.,	  2003).	  	  
1.1.3.1	  Cell	  cycle	  transition	  Transition	   through	   the	  cell	   cycle	   is	   regulated	  by	  cyclin	  dependent	  kinases	   (CDK).	  CDK	  are	  serine	  threonine	  protein	  kinases	  and	  are	  activated	  during	  specific	  stages	  of	  the	  cell	  cycle.	   CDK4	   and	   6	   are	   active	   during	   early	   G1.	   Later	   CDK2	   is	   activated,	   which	   is	  responsible	  for	  a	  proper	  DNA	  replication	  in	  S-­‐phase	  and	  CDK1	  is	  active	  during	  M-­‐phase.	  For	  CDK	  to	  be	  active	   the	  binding	  of	  a	  specific	  cyclin	   to	   the	  CDK	   is	  necessary.	  Whereas	  CDK	  are	   stably	   expressed	  during	   the	   cell	   cycle,	   the	   levels	   of	   cyclins	   oscillate.	   Cyclin	  D	  activates	  CDK4/6	  early	  in	  G1.	  CDK2	  interacts	  with	  cyclin	  E	  in	  late	  G1	  and	  with	  cyclin	  A	  predominantly	  in	  S-­‐phase.	  Cyclin	  B	  is	  present	  in	  the	  nucleus	  in	  M-­‐phase	  to	  interact	  with	  CDK1	  (Vermeulen	  et	  al.,	  2003).	  	  	   Upon	  completion	  of	  one	  cell	  cycle,	  cyclin	  levels	  are	  low	  and	  cells	  would	  exit	  the	  cell	  cycle	   and	   enter	   the	   G0	   state,	   which	   is	   called	   quiescence.	   Only	  when	   cells	   receive	   the	  right	  stimulation	  they	  will	  progress	  further	  through	  the	  cell	  cycle.	  This	  stimulation	  can	  arise	   from	  growth	   factor	  signalling	  via	   the	  mitogen-­‐activated	  kinase	  (MAPK)	  pathway.	  This	  pathway	  results	  in	  the	  transcription	  of	  cyclin	  D	  in	  G1.	  Now	  cyclin	  D	  is	  able	  to	  bind	  and	   activate	   CDK	   4	   or	   6	   (Blomen	   and	   Boonstra,	   2007).	   Active	   CDK	   complexes	  phosphorylate	   target	   proteins	   on	   CDK	   consensus	   sites	   (Vermeulen	   et	   al.,	   2003).	   The	  CDK4/6-­‐cyclin	   D	   complex	   phosphorylates	   the	   proteins	   of	   the	   RB	   family	   in	   G1.	   As	  mentioned	   above	   this	   initial	   phosphorylation	   is	   important	   for	   the	   release	   of	   E2F	  transcription	  factors	  and	  the	  transcription	  of	  cyclin	  E.	  The	  CDK2-­‐cyclin	  E	  complex	  then	  helps	  to	  further	  phosphorylate	  RB	  leading	  to	  further	  transcription	  of	  proteins	  necessary	  for	   S-­‐phase	   entry.	   When	   the	   phosphorylation	   of	   RB	   has	   reached	   a	   certain	   threshold,	  cells	  are	  independent	  of	  mitogenic	  signalling	  and	  commit	  to	  the	  progression	  from	  G1-­‐	  to	  S-­‐phase	  and	  through	  the	  whole	  cell	  cycle	  (Blomen	  and	  Boonstra,	  2007).	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   The	  CDK2-­‐cyclin	  E	  complex	  further	  promotes	  S-­‐phase	  entry	  by	  the	  phosphorylation	  of	   its	   inhibitors	   p21Cip1	   and	   p27Kip1,	   which	   are	   degraded	   by	   the	   proteasome	   later	   on.	  Another	   target	   protein	   of	   CDK2-­‐cyclin	   E	   is	   the	   histone	   1	   (H1).	   At	   lower	   levels	   this	  phosphorylation	   was	   suggested	   to	   help	   decondensation	   of	   chromosomes	   and	   thus	  enables	  DNA	  replication	  (Happel	  and	  Doenecke,	  2009;	  Vermeulen	  et	  al.,	  2003).	  	  	   For	  DNA	  replication	   to	  occur,	  origin	   licensing	  has	   to	   take	  place	  already	   in	   late	  M-­‐phase	  and	  early	  G1	  when	  CDK	  are	  still	  inactive	  (Depamphilis	  et	  al.,	  2012).	  Here	  the	  pre-­‐replication	  complex	  (pre-­‐RC)	  is	  loaded	  onto	  the	  origins	  of	  DNA	  replication.	  The	  pre-­‐RC	  consists	   of	   the	   DNA	   helicase	   loader,	   which	   is	  made	   up	   of	   origin	   recognition	   complex	  (ORC)	   1-­‐6,	   cell	   division	   cycle	   (CDC)	   6	   and	   DNA	   replication	   factor	   Cdt1	   and	   the	  mini-­‐chromosome	  maintenance	  (MCM)	  helicase,	  which	  is	  important	  for	  the	  unwinding	  of	  the	  DNA	  double	  helix.	  For	  activation	  of	  the	  helicase	  as	  well	  as	  for	  further	  loading	  of	  proteins	  essential	   for	  replication	   in	   late	  G1	  and	  S-­‐Phase,	  phosphorylation	  events	  are	  necessary,	  which	  are	  conducted	  by	  kinases,	  including	  CDK2-­‐cyclin	  E	  (Depamphilis	  et	  al.,	  2012).	  	  	   Targets	  of	  CDK2-­‐cyclin	  A	  also	  include	  CDC	  6	  and	  MCM	  proteins.	  Phosphorylation	  of	  these	   replication	  proteins	   in	   S-­‐phase	  by	  CDK2-­‐cyclin	  A	   leads	   to	   their	   relocalisation	   to	  the	  cytoplasm	  and	  thus	  prevention	  of	  re-­‐replication	  (Depamphilis	  et	  al.,	  2012;	  Ishimi	  et	  al.,	  2000;	  Paolinelli	  et	  al.,	  2009;	  Petersen	  et	  al.,	  1999).	  	  	   Cyclin	   A	   also	   binds	   to	   CDK1.	   The	   complex	   further	   prevents	   pre-­‐RC	   assembly	   by	  phosphorylation	  of	  CDC6	  (Depamphilis	  et	  al.,	  2012).	  	   The	  complex	  made	  up	  of	  CDK1	  and	  cyclin	  B	  is	  called	  maturation-­‐promoting	  factor	  (MPF).	  MPF	  promotes	  the	  condensation	  of	  chromosomes	  probably	  via	  phosphorylation	  of	   condensins	   and	   further	   phosphorylation	   of	   H1	   (Hagstrom	   et	   al.,	   2002;	   Happel	   and	  Doenecke,	  2009;	  Kimura	  et	  al.,	  1998;	  Vermeulen	  et	  al.,	  2003).	  MPF	  also	  phosphorylates	  lamins,	   which	   induces	   nuclear	   lamin	   disassembly	   and	   nuclear	   envelope	   breakdown	  during	  mitosis	   (Ward	  and	  Kirschner,	  1990).	  Other	   targets	  of	   the	  MPF	  are	   for	  example	  microtubule-­‐associated	  proteins,	  which	  are	   important	   for	   the	   formation	  of	   the	  mitotic	  spindle	  (Shiina	  et	  al.,	  1992;	  Tsukahara	  et	  al.,	  2010).	  	   The	  CDK	  activating	  cyclins	  themselves	  are	  degraded	  via	  the	  proteasome.	  G1	  cyclins	  are	  ubiquitinated	  by	  the	  S-­‐phase	  kinase-­‐associated	  protein	  (SKP),	  Cullin,	  F-­‐box	  (SCF)	  E3	  ligase.	  Mitotic	  cyclins	  are	  ubiquitinated	  by	  the	  anaphase	  promoting	  complex	  (APC).	  APC	  is	  not	  activated	  until	  Anaphase.	  Activation	  is	  regulated	  by	  CDC20	  which	  in	  turn	  needs	  to	  be	  activated	  by	  CDK1	  (Murray,	  2004).	  	   In	   addition	   to	   cyclin	   binding,	   CDK	   also	   need	   to	   be	   phosphorylated	   on	   conserved	  threonin	   and	   tyrosine	   residues	   to	   be	   active.	   The	   cyclin-­‐dependent-­‐activating	   kinase	  (CAK),	   which	   is	   the	   complex	   between	   CDK7	   and	   cyclin	   H,	   performs	   these	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phosphorylations.	  They	  lead	  to	  a	  conformational	  change	  of	  CDK,	  which	  allows	  enhanced	  cyclin	  binding	  (Clarke,	  1995;	  Solomon	  et	  al.,	  1992;	  Vermeulen	  et	  al.,	  2003).	  	   Inhibitory	   phosphorylations	   of	   CDK1	   performed	   by	   WEE1	   and	   the	   membrane	  associated	   tyrosine/threonine1	   protein	   kinase	   (MYT1)	   need	   to	   be	   eliminated	   by	   the	  phosphatase	  CDC25	  (Coleman	  and	  Dunphy,	  1994;	  Fattaey	  and	  Booher,	  1997;	  Vermeulen	  et	  al.,	  2003).	  	  
	  Figure	  1.2	  Cell	  cycle	  regulation.	  In	  proliferating	  cells	  the	  cell	  cycle	  consists	  of	  four	  phases:	  G1,	  S-­‐phase,	  in	  which	  the	  chromosomes	  of	  the	  cells	  are	  duplicated,	  G2	  and	  M-­‐phase,	  in	  which	  the	  replicated	  chromosomes	  are	  divided	  onto	  daughter	  cells	  (Vermeulen	  et	  al.,	  2003).	  Transition	  through	  the	  phases	  of	  the	  cell	  cycle	  is	  regulated	  by	  CDK.	  CDK	  in	  turn	  are	  regulated	  by	  the	  presence	  of	  their	  appropriate	  cyclin,	  phosphorylation	  status	  as	  well	  as	  CDK	  inhibitors.	  Upon	  activation	  of	  the	  CDK4-­‐	  and	  CDK6-­‐cyclin	  D	  complex	  by	  the	  CAK,	  these	  complexes	  phosphorylate	  RB	  proteins.	  Phosphorylation	  of	  RB	  is	  continued	  by	  the	  CDK2-­‐cyclin	  E	  complex.	  Phosphorylation	  of	  RB	  proteins	  results	  in	  the	  release	  of	  the	  E2F	  transcription	  factors	  and	  subsequently	  the	  transcription	   of	   genes	   coding	   for	   proteins	   essential	   during	   replication.	   During	   S-­‐phase,	   cyclin	   E	   gets	  degraded	   and	   is	   exchanged	   for	   cyclin	   A.	   The	   CDK2-­‐cyclin	   A	   complex	  maintains	   RB	   phosphorylation	   and	  regulates	   S-­‐phase	   proteins.	   CDK4,	   6	   and	   2	   are	   inhibited	   by	   p21Cip1	   as	   well	   as	   p27Kip1	   upon	   checkpoint	  activation.	   Another,	   less	   well	   studied,	   CDK	   inhibitor,	   p57Kip2	   is	   especially	   known	   for	   its	   function	   in	  embryogenesis	   (Borriello	   et	   al.,	   2011).	   In	   G2	   a	   premature	   entry	   into	   Mitosis	   is	   prevented	   by	   inhibitory	  phosphorylations	  of	  CDK1	  by	  WEE1	  and	  MYT1.	  The	  phosphatase	  CDC25	  reverses	  these	  phosphorylations.	  The	   active	   CDK1-­‐cyclin	   B	   complex	   phosphorylates	   proteins	   like	   condensin	   and	   lamin,	   which	   leads	   to	  chromatin	  condensation	  and	  nuclear	  envelope	  break	  down	  (Vermeulen	  et	  al.,	  2003).	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1.1.3.2	  Cell	  cycle	  checkpoints	  To	  ensure	   that	   cells	   replicate	   and	  divide	   in	   a	   correct	  way,	   cell	   cycle	   checkpoints	   exist	  which	   stall	   the	   transition	   from	  one	  phase	   of	   the	   cell	   cycle	   to	   another	   (Elledge,	   1996).	  The	  checkpoints	  which	  are	  most	  studied	  are	  DNA	  damage	  checkpoints	  and	  the	  spindle	  checkpoint.	  DNA	  damage	  leads	  to	  arrest	  of	  the	  cell	  cycle	  either	  in	  transition	  from	  G1	  to	  S	  or	  in	  S	  to	  G2	  to	  allow	  DNA	  repair	  to	  take	  place	  (O'Connor,	  1997;	  Taylor	  and	  Stark,	  2001).	  Arrest	  induced	  at	  the	  G1/S	  transition	  is	  p53-­‐dependent	  (Vermeulen	  et	  al.,	  2003).	  There	  are	   several	   ways	   in	   which	   aberrant	   replication	   structures	   or	   DNA	   damage	   is	   sensed.	  Single	  stranded	  DNA	  for	  example,	  which	  might	  be	  a	  result	  of	  nicks	  during	  replication	  or	  of	   stalled	   replication	   forks,	   is	   coated	   by	   replication	   protein	   A	   (RPA)	   (Jones	   and	  Petermann,	   2012).	   The	   RPA	   coated	   single	   stranded	   DNA	   acts	   as	   trigger	   for	   ataxia	  telangiectasia	   and	   Rad3	   related	   (ATR)	   activation	   via	   binding	   of	   the	   ATR	   interacting	  protein/ATR	   complex.	   ATR	   activation	   leads	   further	   downstream	   to	   the	   activation	   of	  checkpoint	   kinase	   1	   (CHK1).	   CHK1	   in	   turn	   inhibits	   the	   CDK	   activating	   phosphatase	  CDC25	  and	  activates	  p53	  (Branzei	  and	  Foiani,	  2008;	  Jones	  and	  Petermann,	  2012;	  Lopez-­‐Contreras	   and	   Fernandez-­‐Capetillo,	   2010).	   Double-­‐strand	   breaks,	   which	   occur	   for	  example	  after	  replication	  fork	  collapse,	  are	  sensed	  by	  the	  MRN	  (meiotic	  recombination	  11	  (MRE11),	  RAD50,	  Nijmegen	  breakage	  syndrome	  1	  (NBS1))	  complex	  (Lamarche	  et	  al.,	  2010).	  Ataxia	  telangiectasia	  mutated	  (ATM)	  is	  recruited	  to	  the	  double	  strand	  break	  and	  activated	   by	   autophosphorylation.	   ATM	   then	   phosphorylates	   several	   downstream	  proteins	  including	  histone	  H2A	  (H2AX)	  and	  checkpoint	  kinase	  2	  (CHK2).	  CHK2	  leads	  to	  the	   phosphorylation	   of	   CDC25A,	   which	   is	   then	   degraded.	   CHK2	   also	   activates	   p53	  (Derheimer	   and	  Kastan,	   2010;	   Jones	   and	   Petermann,	   2012).	   p53	   in	   turn	   activates	   for	  example	   the	   transcription	  of	   the	  CDK	   inhibitor	   (CKI)	  p21Cip1,	  which	   leads	   to	   cell	   cycle	  arrest	  (el-­‐Deiry	  et	  al.,	  1993).	  	  	   CDK	   inhibitors	  are	  one	  way	  of	  down-­‐regulating	  CDK	  activity.	   	   In	  mammalian	  cells	  these	  are	  divided	  into	  members	  of	  the	  INK4	  family	  and	  members	  of	  the	  Cip/Kip	  family	  of	   CDK	   inhibitors.	  Members	   of	   the	   INK4	   family	   include	  p16INK4a,	   p15INK4b,	   p18INK4c	   and	  p19INK4d	   (Besson	   et	   al.,	   2008).	   The	   INK4	   protein	   family	   members	   specifically	   inhibit	  CDK4	   and	   CDK6	   activity	   by	   interacting	   directly	   with	   these	   kinases.	   In	   this	   way	   the	  association	  of	  the	  kinases	  with	  their	  activating	  D-­‐type	  cyclins	  is	  impaired	  (Besson	  et	  al.,	  2008;	  Canepa	  et	  al.,	  2007).	  	  	   Members	   of	   the	   Cip/Kip	   family	   are	   p21Cip1,	   p27Kip1	   and	   p57Kip2.	   p57Kip2	   plays	   an	  important	   role	   in	   cell	   cycle	   regulation	   during	   embryonic	   development.	   As	  mentioned	  above,	  p21Cip1	  transcription	  is	  initiated	  by	  p53	  upon	  DNA	  damage	  signalling	  (Besson	  et	  al.,	  2008).	  p27Kip1	   is	  activated	  via	  different	  stimuli	   like	  mitogen	  starvation,	  cell	  density,	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differentiation	   signals,	   loss	   of	   adhesion	   to	   the	   extracelluar	  matrix	   or	   TGF	  ß	   signalling	  (Chu	  et	  al.,	  2008).	  Cip/Kip	  proteins	  are	  known	   for	   their	   inhibitory	  effect	  on	  all	   cyclin-­‐CDK.	  As	   they	   interact	  directly	  with	   the	  cyclin	  and	  CDK	  subunit,	  Cip/Kip	  proteins	  were	  also	   reported	   to	   facilitate	   the	   formation	   of	   the	   cyclin	   D-­‐CDK4/6	   complex.	   In	   the	  presence	  of	  high	  INK4	  protein	  levels	  however,	   INK4	  proteins	  will	  displace	  the	  Cip/Kip	  proteins	   from	   CDK4/6	   and	   the	   newly	   available	   Cip/Kip	   proteins	   will	   intensify	   the	  inhibition	  of	  the	  cyclin	  E-­‐CDK2	  complex.	  Similarly	  the	  up-­‐regulation	  of	  Cip/Kip	  proteins	  themselves	  can	  have	  the	  same	  effect	  (Blomen	  and	  Boonstra,	  2007).	  	  	   The	  spindle	  checkpoint	  ensures	  during	  mitosis	  that	  all	  duplicated	  sister	  chromatids	  are	  attached	  to	   the	  mitotic	  spindle	  before	   the	  onset	  of	  anaphase.	  The	  kinetochore	  of	  a	  chromatid,	  which	   is	  not	  captured	  by	  microtubules	  of	   the	  mitotic	  spindle,	   is	  recognised	  by	   mitotic	   arrest	   deficient	   2	   (MAD2).	   Together	   with	   budding	   uninhibited	   by	  benzimidazoles	  1	  homologue	  beta	  (BUBR1)	  and	  budding	  uninhibited	  by	  benimidazoles	  3	   homologue	   (BUB3)	   it	   forms	   the	   mitotic	   checkpoint	   complex,	   which	   binds	   CDC20.	  CDC20	  is	  the	  activator	  of	  the	  ubiquitin	  ligase	  APC.	  Thus	  APC	  stays	  inactive	  and	  can	  not	  promote	   transition	  of	   the	  cell	   into	  anaphase	  via	  ubiquitination	  of	  securin	  and	  cyclin	  B	  (Ciliberto	  and	  Shah,	  2009).	  	   	  	  
1.1.3.3	  Telomere	  shortening	  Although	   these	   cell	   cycle	   checkpoints	  might	   be	   interrupted	   in	   a	   certain	   population	   of	  cells,	  which	  can	  now	  proliferate	  independently	  from	  their	  surroundings,	  this	  population	  is	  still	  limited	  in	  its	  number	  of	  successive	  divisions.	  After	  a	  certain	  number	  of	  population	  doublings,	  untransformed	  human	  cells	  would	  enter	  a	  senescent	  state	  and	  stop	  growing	  due	   to	   telomere	  shortening	   (Collado	  et	  al.,	  2007;	  Zakian,	  1995).	  Telomeres,	  which	  are	  located	  at	  the	  end	  of	  chromosomes,	  consist	  of	  repetitive	  G-­‐rich	  DNA,	  which	  is	  bound	  by	  various	   telomere	   proteins	   (Stewart	   et	   al.,	   2012).	   Telomeres	   protect	   the	   end	   of	   the	  chromosomes	   from	   destruction.	   During	   each	   cell	   cycle	   however	   several	   base	   pairs	   of	  telomeric	   DNA	   are	   lost	   due	   to	   an	   insufficiency	   to	   complete	   replication	   of	   5’	   ends	   of	  chromosomal	  DNA	  during	  S-­‐phase.	  Only	  cells,	  which	  obtain	  a	   telomerase	   function	  and	  are	   able	   to	   maintain	   the	   length	   of	   their	   telomeres	   are	   able	   to	   survive	   and	   expand	  (Zakian,	  1995).	  The	  main	  components	  of	  human	  telomerase,	  which	  are	  important	  for	  its	  catalytic	  activity	  are	  the	  Telomerase	  Reverse	  Transcriptase	  (hTERT),	  the	  RNA	  molecule	  which	  serves	  as	  template	  for	  the	  synthesis	  of	  the	  telomeric	  repeats	  and	  the	  RNA	  binding	  protein	   dyskerin	   (Belgiovine	   et	   al.,	   2008).	   The	   hTERT	   expression	   is	   down-­‐regulated	  early	   in	   human	   development	   and	   introduction	   of	   the	   cDNA	   for	   hTERT	   is	   sufficient	   to	  restore	  telomerase	  activity	  in	  cultured	  human	  cell	  lines	  (Belgiovine	  et	  al.,	  2008;	  Harley,	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2002).	   In	   contrast	   to	  humans,	  mice	   constitutively	   express	   telomerase	   in	  many	   tissues	  (Smith	  and	  Kipling,	  2004).	  	  
1.1.4	  Senescence	  as	  a	  mechanism	  to	  suppress	  tumour	  development	  Cellular	  senescence	  was	  first	  observed	  in	  cultured	  human	  fibroblasts	  (Hayflick,	  1965).	  It	  is	   characterised	   by	   an	   irreversible	   growth	   arrest.	   There	   are	   two	   types	   of	   senescence.	  Replicative	   senescence	   is	   induced	   in	   aging	   human	   cells	   mainly	   due	   to	   telomere	  shortening	  (Collado	  et	  al.,	  2007).	  Senescence	  is	  also	  induced	  by	  checkpoint	  pathways	  in	  response	  to	  oncogene	  activation	  (Serrano	  et	  al.,	  1997).	  This	  so-­‐called	  oncogene-­‐induced	  senescence	   is,	   like	   apoptosis,	   seen	   as	   one	   of	   the	   strategies	   to	   prevent	   cancer	  development.	   Whether	   the	   cell	   undergoes	   apoptosis	   or	   enters	   senescence	   upon	  oncogenic	  stress	  is	  dependent	  on	  cell	  type	  and	  type	  of	  oncogenic	  stress	  (Erol,	  2011).	  	  
1.1.4.1	  Characteristics	  In	  contrast	  to	  the	  non-­‐proliferative	  state	  of	  quiescent	  cells	  (G0),	  which	  is	  responsive	  to	  mitogenic	  stimulation,	  the	  growth	  arrest	  of	  senescent	  cells	  is	  irreversible.	  Senescence	  is	  well	  studied	  in	  fibroblasts,	  which	  arrest	  in	  G1,	  but	  depending	  on	  cell	  type	  and	  activated	  oncogene,	  cells	  can	  also	  arrest	  in	  other	  phases	  of	  the	  cell	  cycle	  (Campisi	  and	  d'Adda	  di	  Fagagna,	  2007;	  Di	  Leonardo	  et	  al.,	  1994;	  Wada	  et	  al.,	  2004).	  Proliferating	  cells	  are	  able	  to	   incorporate	   the	   uridine	   derivate	   5-­‐bromo-­‐2’-­‐deoxyuridine	   (BrdU)	   into	   the	   newly	  replicated	  DNA	   strand	   during	   S-­‐Phase.	   Since	   senescent	   cells	   are	   unable	   to	   proliferate	  and	  thus	  do	  not	   take	  up	  BrdU,	  a	  decrease	   in	  BrdU	   incorporation	   indicates	  a	  senescent	  cell	  population	  (Campisi	  and	  d'Adda	  di	  Fagagna,	  2007).	  	   Senescent	   cells	   also	   undergo	   morphological	   changes.	   A	   reorganisation	   in	   the	  cytoskeleton	   leads	   to	   a	   flattened	   and	   enlarged	   appearance.	   The	   reorganisation	   is	  thought	   to	   be	   due	   to	   a	   down-­‐regulation	   of	   actin	   and	   an	   overproduction	   of	   vimentin	  (Nishio	  et	  al.,	  2001).	  	   Another	  marker,	  which	   is	  more	  specific	   for	   the	   identification	  of	  senescent	  cells,	   is	  an	   elevated	   beta-­‐galactosidase	   (ß-­‐gal)	   activity	   detectable	   at	   a	   pH	   of	   6	   (Campisi	   and	  d'Adda	  di	  Fagagna,	  2007;	  Dimri	  et	  al.,	  1995).	  SA-­‐ß-­‐gal	  activity	   is	  due	   to	  an	   increase	   in	  galactosidase	  beta	  1	  (GLB1)	  expression,	  the	  gene	  encoding	  lysosomal	  ß-­‐D-­‐galactosidase	  (Lee	  et	  al.,	  2006).	  As	  a	  lysosomal	  enzyme,	  it	  reaches	  its	  maximal	  activity	  at	  a	  pH	  of	  4.0	  -­‐	  4.5.	  In	  senescent	  cells	  lysosomal	  biogenisis	  is	  increased.	  Therefor	  a	  ß-­‐gal	  activity	  can	  be	  detected	  even	  at	  a	  suboptimal	  pH	  of	  6	  (Kurz	  et	  al.,	  2000).	  For	  the	  detection,	  X-­‐gal	  can	  be	  used	   as	   a	   chromogenic	   substrate	   for	   the	   galactosidase	   (Dimri	   et	   al.,	   1995).	   As	   ß-­‐gal	  activity	  at	  a	  pH	  of	  6	  is	  a	  general	  marker	  for	  increased	  lysosome	  number	  or	  activity	  it	  is	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not	  exclusively	  observed	  in	  senescent	  cells	  (Kurz	  et	  al.,	  2000;	  Lee	  et	  al.,	  2006;	  Severino	  et	  al.,	  2000).	   	   Often,	  a	  reorganisation	  of	  chromatin	   is	  observed	  upon	  the	  activation	  of	  oncogenic	  stress.	   These	   heterochromatic	   structures	   that	   are	   formed	   are	   called	   senescence	  associated	  heterochromatic	  foci	  (SAHF)	  (Campisi	  and	  d'Adda	  di	  Fagagna,	  2007).	  Histone	  modifications	   found	   in	  euchromatin,	   like	  acetylated	   lysine	  9	  or	   tri-­‐methylated	   lysine	  4	  on	   histone	   3	   (H3K9Ac	   and	   H3K4me3),	   are	   excluded	   from	   SAHF.	   Instead	  heterochromatin-­‐associated	   proteins	   like	   heterochromatin	   protein	   1	   (HP1)	   and	   Lys9	  tri-­‐methyl	   on	   histone	   H3	   (H3K9me3)	   are	   enriched	   (Kuilman	   et	   al.,	   2010).	   These	  proteins	   as	  well	   as	   the	  RB	   tumour	   suppressor	   proteins	   are	   thought	   to	   accumulate	   on	  E2F-­‐responsive	   promoters,	   which	   results	   in	   a	   stable	   repression	   of	   E2F	   target	   genes	  (Narita	  et	  al.,	  2003).	  Genes	  like	  cyclin	  A,	  cyclin	  B	  and	  proliferating	  cell	  nuclear	  antigen	  (PCNA)	   are	   down-­‐regulated	   (Pang	   and	   Chen,	   1994;	   Stein	   et	   al.,	   1991).	   Therefore	   the	  formation	   of	   SAHF	   is	   thought	   to	   be	   one	   of	   the	   ways,	   how	   senescent	   cells	   alter	   their	  profile	   of	   gene	   expression.	   It	   is	   of	   note	   that	   SAHF	   formation	   is	   a	   common	   feature	   of	  senescence,	   which	   is	   a	   result	   of	   oncogene	   induced	   DNA	   replication	   stress.	   Oncogenic	  events	   in	   proliferating	   transformed	   cells	   and	   cancer	   cells	   in	   vivo	   still	   lead	   to	   SAHF	  resembling	  heterochromatin	  formation.	  In	  contrast	  the	  appearance	  of	  SAHF	  seems	  to	  be	  cell	   type	   dependent	   in	   replicative	   senescence	   and	   other	   forms	   of	   stress	   induced	  senescence	  (Di	  Micco	  et	  al.,	  2011;	  Kosar	  et	  al.,	  2011).	  	  	   Senescent	   cells	   also	   express	   secreted	   factors.	   This	   phenomenon	   is	   described	   as	  senescence	   associated	   secretory	   phenotype	   (SASP).	   Secreted	   factors	   include	  interleukins,	   chemokines,	   growth	   factors	   and	   proteases	   (Rodier	   and	   Campisi,	   2011).	  The	  secretory	  proteins	  are	  thought	  to	  regulate	  the	  secreting	  senescent	  cells	  themselves	  as	   well	   as	   neighbouring	   cells	   and	   extracellular	   environment	   (Acosta	   et	   al.,	   2008;	  Campisi	  and	  d'Adda	  di	  Fagagna,	  2007).	   	  Several	  implications	  for	  the	  formation	  of	  SASP	  were	  reported.	  Thus	  factors	  such	  as	  PAI-­‐1,	  IGFBP7,	  IL6	  and	  IL8,	  which	  are	  secreted	  by	  senescent	  cells,	  were	  shown	  to	  reinforce	  cell	  cycle	  arrest	  and	  senescence	  especially	   in	  primary	  cells	  (Acosta	  et	  al.,	  2008;	  Rodier	  and	  Campisi,	  2011;	  Young	  and	  Narita,	  2009).	  On	   the	   other	   hand	   IL6	   and	   IL8	   for	   example	   are	   known	   for	   their	   positive	   effect	   on	  angiogenesis	   and	   epithelial-­‐mesenchymal	   transition	   of	   premalignant	   cells.	   Using	   a	  Boyden	   chamber	   it	   was	   shown	   that	   both	   cytokines	   enhance	   the	   invasion	   ability	   of	  premalignant	  epithelial	  cells	  (Coppe	  et	  al.,	  2008;	  Rodier	  and	  Campisi,	  2011;	  Young	  and	  Narita,	   2009).	   Secretion	   of	   other	   factors	  which	   can	   facilitate	   tumour	   cell	   invasiveness	  like	  matrix	  metalloproteinases	  or	  VEGF	  have	  been	  reported	  (Rodier	  and	  Campisi,	  2011).	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By	   the	   secretion	  of	   inflammatory	   cytokines,	   SASP	   formation	   can	  also	  help	   to	  promote	  the	  clearance	  of	  senescent	  cells	  (Young	  and	  Narita,	  2009).	  	  
1.1.4.2	  Pathways	  to	  senescence	  The	  main	  reason	  for	  replicative	  senescence	  in	  primary	  human	  cells	  is	  the	  shortening	  of	  telomeres.	   The	   ends	   of	   short	   telomeres	   are	   recognised	   as	   double	   strand	   breaks.	   This	  leads	  to	  a	  generation	  of	  a	  persistent	  DNA	  damage	  response	  (DDR)	  and	  ultimately	  to	  the	  activation	   of	   p53	   and	   consequently	   RB	   (Belgiovine	   et	   al.,	   2008;	   Rodier	   and	   Campisi,	  2011).	   Active	   p53	   induces	   transcription	   of	   p21Cip1.	   p21Cip1	   mainly	   acts	   as	   cell	   cycle	  inhibitor	   via	   its	   interaction	  with	   CDK2	   although	   its	   interaction	  with	   CDK4/6-­‐cyclin	   D	  complex	  is	  also	  known.	  Inactive	  CDK	  are	  unable	  to	  phosphorylate	  RB	  proteins.	  Thus	  RB	  proteins	  can	  sequester	  E2F	  transcription	  factors	  and	  cell	  cycle	  progression	  is	  inhibited	  (Campisi	  and	  d'Adda	  di	  Fagagna,	  2007;	  Sherr	  and	  Roberts,	  1999).	  	   To	  avoid	  telomere	  shortening	  and	  the	  associated	  DNA	  damage	  response	  in	  cultured	  human	  cells,	   telomerase	  activity	   is	  often	  restored	  by	   introducing	  hTERT	   into	   the	  cells.	  Telomerase	   reactivation	   is	   often	   sufficient	   to	   prolong	   the	   cellular	   life	   span	   of	   human	  fibroblasts	   indefinitely	   (Belgiovine	   et	   al.,	   2008).	   In	   some	   immortalised	   fibroblast	   cell	  lines	  the	  loss	  of	  p16INK4a	  expression	  was	  found.	  For	  other	  cells	  like	  keratinocytes,	  down-­‐regulation	  of	  p16INK4a	  expression	  is	  obligatory	  for	  immortalisation.	  It	  was	  suggested	  that	  p16INK4a	  activation	   in	   these	  cells	   is	  due	   to	  cell	   culture	  conditions,	  which	   lead	   to	  stress,	  the	  induction	  of	  p16INK4a	  and	  cell	  cycle	  arrest	  (Belgiovine	  et	  al.,	  2008).	  	   Although	  murine	   embryonic	   fibroblasts	   (MEF)	   obtain	   telomerase	   activity	   and	   do	  not	  suffer	  from	  telomere	  shortening,	  they	  senesce	  after	  a	  short	  period	  of	  time	  in	  culture	  (vom	  Brocke	  et	  al.,	  2006).	  This	  is	  due	  to	  a	  high	  susceptibility	  of	  MEFs	  for	  stress	  caused	  by	  reactive	  oxygen	  species	  (ROS),	  which	  result	  from	  the	  unphysiologically	  high	  oxygen	  levels	   (ca.	  20%),	   cells	   are	   frequently	   cultured	   in.	  ROS	   leads	   to	  DNA	  modifications	  and	  subsequently	   to	   the	   activation	   of	   the	   p53	   pathway.	   Therefor	   senescence	   can	   be	  bypassed	   in	   these	   cells	   by	   a	   spontaneous	   acquisition	   of	   a	   p53	   mutation.	   It	   was	   also	  reported	   that	   MEFs	   with	   intact	   p53	   pathways,	   which	   are	   cultured	   at	   physiological	  oxygen	  levels	  (3%)	  do	  not	  senesce	  (vom	  Brocke	  et	  al.,	  2006).	  	  	   Premature	  senescence,	  which	  is	  a	  result	  of	  the	  activation	  of	  oncogenic	  stress,	  is	  also	  often	   triggered	   by	   DNA	   damage	   pathways.	   As	   mentioned	   above,	   DNA	   damage	   like	  double	  strand	  breaks	  as	  well	  as	  single-­‐strand	  breaks	  induce	  a	  signalling	  cascade,	  which	  leads	  to	  the	  activation	  of	  p53.	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   Another	   consequence	   of	   oncogenic	   signalling	   is	   the	   activation	   of	   the	  
INK4b/ARF/INK4a	   locus.	   In	   cancers,	   this	   locus	   is	   often	   altered	   for	   example	   by	   point	  mutations	   or	   epigenetic	   changes.	   The	   INK4b/ARF/INK4a	   locus	   encodes	   for	   the	   CDK	  inhibitors	   p15INK4b	   and	   p16INK4a	   as	   well	   as	   ARF	   (Canepa	   et	   al.,	   2007).	   P15INK4b	   and	  p16INK4a	  activate	  RB	  via	   inhibition	  of	  CDK.	  ARF	  inhibits	  the	  p53	  inhibitor	  HDM2.	  When	  HDM2	  is	  active	  it	  can	  either	  bind	  to	  p53	  and	  sterically	  block	  its	  transactivation	  domain	  or	   function	   as	   p53	   specific	   ubiquitin	   ligase	   (Levine	   and	   Oren,	   2009).	   For	   HDM2	  inhibition,	   ARF	   binds	   to	   HDM2,	   which	   promotes	   its	   rapid	   degradation	   (Zhang	   et	   al.,	  1998).	  	  	   Usually	   polycomb	   repressive	   complexes	   repress	   the	   transcription	   of	   the	  
INK4b/ARF/INK4a	   locus	   (Bracken	   et	   al.,	   2007;	  Gil	   et	   al.,	   2004).	   Induction	   of	   the	   locus	  upon	  oncogene	  activation	  might	  be	  possible	  due	   to	  decreased	  expression	  of	  polycomb	  proteins	   or	   dissociation	   of	   the	   complexes	   from	   the	   locus.	   Polycomb	   proteins	   bind	   to	  histone	   H3	   trimethylated	   on	   Lysine	   27	   (H3K27me3).	   The	  RAS	   oncogene	   for	   example	  was	  reported	  to	  increase	  expression	  of	  the	  H3K27me3	  demethylase	  JMJD3,	  which	  led	  to	  an	  increase	  in	  p16INK4a	  expression	  (Barradas	  et	  al.,	  2009).	  	  	   In	  a	  variety	  of	   cancer	  cells	   the	  p53	  and	  RB	  pathways	  are	   inhibited	   (Burkhart	  and	  Sage,	   2008;	   Levine	   and	  Oren,	   2009).	  Thus	  oncogene	   activation	   in	   these	   cells	   does	  not	  lead	  to	  cell	  cycle	  arrest	  and	  senescence.	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Figure	   1.3	   Induction	   of	   oncogene-­‐induced	   senescence.	   In	   unperturbed	   cells	   CDK	   activity	   leads	   to	  hyperphosphorylation	   of	   RB	   proteins.	   Hyperphosphorylated	   RB	   proteins	   release	   the	   E2F	   transcription	  factors	  and	  E2F	  responsive	  genes	  can	  be	  described.	  Transcription	  of	  these	  genes,	  which	  are	  essential	  for	  S-­‐phase,	  results	  in	  entry	  and	  progression	  through	  S-­‐phase.	  Senescence-­‐inducing	  signals	  lead	  to	  the	  inhibition	  of	  E2F	  regulated	  transcription.	  Therefore	  one	  of	  two	  tumour	  suppressor	  pathways	  are	  activated,	  the	  p53	  or	  p16INK4a-­‐RB	  pathways.	  The	  p53-­‐pathway	  is	  activated	  as	  a	  result	  of	  DNA-­‐damage	  signalling.	  Down-­‐regulation	  of	  the	  p53	  inhibitor	  HDM2	  by	  ARF	  also	  results	  in	  increased	  p53	  activity.	  Active	  p53	  establishes	  senescence	  in	   part	   by	   inducing	   the	   expression	   of	   p21Cip1.	   p21Cip1	   inhibits	   CDK	   activity	   and	   thus	   perturbs	   RB	  hyperphosphorylation.	   p16INK4a	   directly	   inhibits	   CDK4/6,	   which	   also	   results	   in	   inhibition	   of	   RB	  phosphorylation.	   Hypophosphorylated	  RB	   is	   therefore	   able	   to	   interact	  with	   E2F	   and	   thereby	   suppresses	  expression	  of	  genes	   required	   for	   cell	   cycle	  progression.	  Cells	  arrest	   in	  G1	  and	  enter	   senescence	   (Campisi	  and	   d'Adda	   di	   Fagagna,	   2007).	   Apart	   from	   the	   inability	   to	   proliferate,	   senescent	   cells	   display	   a	   typical	  phenotype.	  Characteristics	  include	  a	  flattened	  and	  enlarged	  cell	  morphology,	  chromatin	  remodelling,	  which	  is	  visible	  as	  senescence-­‐associated	  heterochromatic	  foci,	  a	  higher	  β-­‐galactosidase	  activity	  and	  the	  secretion	  of	  senescence-­‐associated	  secretory	  phenotype	  factors	  (Campisi	  and	  d'Adda	  di	  Fagagna,	  2007).	  	  	  	  	  	  
1.2	  CKS	  (Cyclin-­‐dependent	  kinase	  subunit)	  The	  human	  CKS1	  and	  2	  are	  members	  of	  the	  Suc1/Cks	  family	  of	  proteins.	  The	  members	  of	  this	  family	  are	  conserved	  in	  all	  eukaryotes	  (Harper,	  2001)	  and	  were	  first	  discovered	  in	   fission	   yeast	   as	   Suc1	   (Hayles	   et	   al.,	   1986;	   Pines,	   1996)	   and	   budding	   yeast	   as	   Cks1	  (Hadwiger	  et	  al.,	  1989).	  Since	  its	  discovery,	   this	   family	  of	  proteins	  has	  been	  studied	  in	  several	   model	   organisms	   such	   as	   fission	   and	   budding	   yeast,	   Xenopus,	   C.	   elegans	   and	  mice,	  as	  well	  as	  in	  human-­‐derived	  cultured	  cells.	  Whereas	  in	  yeast	  and	  Xenopus	  only	  one	  Cks	   protein	   has	   been	   identified,	   two	   homologues	   have	   been	   found	   in	  C.	  elegans,	  mice	  and	  humans.	  	  	   The	  human	  CKS1	  and	  2	  consist	  of	  a	  four-­‐stranded	  ß-­‐sheet	  with	  two	  α-­‐helices	  on	  top	  of	   one	   side	   (Seeliger	   et	   al.,	   2002).	   The	   Cks	   proteins	   in	   yeast	   contain	   additionally	   two	  large	   insertions	  of	   a	   long	  α-­‐helix	  at	   the	  N-­‐terminus	  and	  a	   large	   loop	  between	   the	   two	  other	  α-­‐helices	  (Endicott	  et	  al.,	  1995).	  	  	  
1.2.1	  Non-­‐mammalian	  CKS	  proteins	  CKS	  proteins	  (Suc1	  in	  fission	  yeast)	  were	  first	  identified	  to	  be	  a	  binding	  partner	  of	  Cdc2,	  which	  is	  the	  fission	  yeast	  homologue	  of	  CDK1.	  The	  function	  of	  CKS	  proteins	  within	  this	  complex	   is	  still	  not	  well	  defined	  although	  some	  progress	  has	  been	  made	  using	   in	  vitro	  systems.	  For	  example,	  in	  Xenopus	  interphase	  egg	  extracts,	  the	  CKS	  homologue	  xe-­‐p9	  has	  been	  shown	  to	  prevent	  the	  dephosphorylation	  of	  the	  Xenopus	  CDK1	  homologue	  Cdc2	  	  on	  Tyrosine	  15.	  Thus	   the	  kinase	   stays	   inactive	  and	   cells	   arrest	   in	  G2	   (Patra	  and	  Dunphy,	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1996).	  It	  is	  thought	  that	  this	  effect	  is	  due	  to	  phosphorylation	  of	  Cdc25	  by	  the	  Cdc2/xe-­‐p9	  complex.	  The	  Cdc25	  phosphatase	  is	  then	  no	  longer	  able	  to	  dephosphorylate	  Cdc2	  on	  Tyrosine	   15	   resulting	   in	   an	   inactive	   kinase,	   which	   is	   not	   able	   to	   promote	   important	  mitotic	  events	  like	  spindle	  formation.	  	  	   In	  addition	  to	  cell	  cycle	   inhibitory	  effects,	  many	  cell	  cycle	  promoting	  functions	  for	  the	   CKS	   binding	   to	   CDK	   have	   been	   postulated	   as	   well.	   In	   Xenopus	   egg	   extracts	   for	  example	   xe-­‐p9	   enhances	   the	   hyperphosphorylation	   of	   an	   APC	   component	   by	  recombinant	   Cdc2-­‐cyclin	   B	   complex.	   This	   hyperphosphorylation	   is	   important	   for	   the	  activation	   of	   the	   APC.	   The	   activated	   APC	   can	   then	   act	   as	   ubiquitin	   ligase	   and	   target	  proteins	  inhibiting	  progression	  through	  mitosis	  (Patra	  and	  Dunphy,	  1998).	  	  	   A	   potential	   role	   for	   CKS	   proteins	   in	   the	   activation	   of	   the	   APC	   has	   not	   only	   been	  observed	   in	  mitosis.	   Studies	   in	  C.	   elegans,	  Drosophila	   and	  murine	   germ	   cells	   revealed	  problems	   in	   spindle	   formation	   and	   progression	   past	  Metaphase	  when	   CKS	   is	  missing	  (Pearson	   et	   al.,	   2005;	   Polinko	   and	   Strome,	   2000;	   Spruck	   et	   al.,	   2003).	   	   Besides	   these	  studies	   in	   multicellular	   eukaryotes,	   showing	   cell	   cycle	   promoting	   functions	   for	   CKS,	  which	   are	   likely	   to	   be	   associated	   with	   higher	   CDK	   activity,	   this	   was	   also	   shown	   in	  
Saccharomyces	  cerevisiae	  where	   Cks	   is	   important	   for	   the	   kinase	   activity	   of	   several	   G1	  Cyclins-­‐Cdc28	  (CDK1)	  complexes	  (Reynard	  et	  al.,	  2000).	  	   Assuming	   that	   CKS	   proteins	   promote	   CDK	   activity	   in	   a	   direct	   way,	   CKS	   proteins	  need	  to	  be	  able	  to	  interact	  with	  the	  kinase	  itself.	  CKS	  proteins	  are	  able	  to	  interact	  to	  a	  certain	  extent	  with	  CDK	  themselves.	  A	  study	  in	  Xenopus	  egg	  extracts	  however	  showed,	  that	   cyclin	   binding	   and	   subsequent	   phosphorylation	   of	   the	   Xenopus	   CDK	   homologue,	  Cdc2,	   on	   Threonine	   161	   is	   required	   for	   CKS	   binding	   (Egan	   and	   Solomon,	   1998).	   This	  kind	  of	   cyclin	   stimulated	  binding	   is	   also	  believed	   to	  be	   the	   case	   for	   the	  human	  CDK2-­‐cyclin	   A-­‐CKS	   complex.	   A	   structural	   analysis	   revealed	   that	   cyclins	   and	   CKS1	   bind	   to	  opposite	   sides	   of	   CDK2	   (Bourne	   et	   al.,	   1996).	   It	  was	   presumed	   that	   cyclin	   binding	   to	  CDK2	  induces	  conformational	  changes,	  which	  facilitate	  the	  phosphorylation	  of	  CDK2	  on	  Thr-­‐160	   by	   CAK	   and	   subsequent	   CKS	   binding.	   The	   study	   also	   showed,	   that	   CKS	   is	  positioned	  in	  a	  way	  that	   it	  extends	  the	  site	  of	   interaction	  for	  a	  substrate	  of	  the	  kinase.	  Additionally,	   the	   adenosine	   tri-­‐phosphate	   (ATP)	   binding	   site	   of	   the	   kinase	   is	   on	   the	  same	   site	   as	   a	   positively	   charged	   region	   on	   the	   CKS	   protein.	   In	   a	   crystal	   structure	  analysis	   of	   CKS1,	   this	   region	   bound	   the	   phosphate	   analogue,	   vanadate	   (Arvai	   et	   al.,	  1995).	  These	  structural	  analyses	  would	  support	  a	  role	  of	  CKS	  proteins	  in	  targeting	  the	  cyclin-­‐CDK	   complex	   to	  phospho-­‐proteins	   and	   facilitating	   their	  phosphorylation	   in	   this	  way.	  In	  structural	  analysis,	  CKS	  proteins	  were	  also	  found	  to	  form	  dimers	  (Endicott	  et	  al.,	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1995;	   Parge	   et	   al.,	   1993;	  Watson	   et	   al.,	   1996).	   Dimer	   formation	   of	   excess	   CKS	  might	  counteract	  its	  function	  within	  the	  cyclin-­‐CDK	  complex.	  	   Apart	  from	  regulating	  the	  cell	  cycle	  via	  direct	  interactions	  with	  cell	  cycle	  proteins,	  an	  effect	  of	  CKS	  proteins	  on	  transcription	  was	  observed	  in	  yeast.	  It	  recruits	  CDK	  and	  the	  proteasome	  to	  the	  promoters	  of	  various	  genes	  and	  thus	  helps	  to	  remodel	  the	  chromatin	  to	   facilitate	  transcription.	  Genes	  reported	  to	  be	  regulated	  in	  this	  manner	   include	  GAL1	  and	  the	  APC	  activator	  CDC20	  (Chaves	  et	  al.,	  2010;	  Morris	  et	  al.,	  2003;	  Yu	  et	  al.,	  2005).	  	  	  
1.2.2	  Mammalian	  CKS	  proteins	  In	  mammals,	  CKS	  binds	  to	  three	  CDK,	  CDK1,	  CDK2	  and	  CDK3	  (Harper,	  2001).	  CDK3	  was	  suggested	   to	   be	   important	   in	   the	   exit	   from	   G0	   (Ren	   and	   Rollins,	   2004)	   but	   further	  functions	   remain	   poorly	   understood.	   In	   contrast	   CDK1	   and	   2	   have	   been	   extensively	  studied	   and	   play	   important	   roles	   within	   the	   cell	   cycle.	   Besides	   their	   still	   not	   well-­‐defined	   function	   within	   the	   CDK-­‐cyclin	   complex,	   the	   mammalian	   CKS	   proteins	   were	  shown	  to	  take	  part	  in	  the	  ubiquitination	  of	  certain	  cell	  cycle	  regulators.	  	   In	  2001,	  Spruck	  et	  al.,	  as	  well	  as	  Ganoth	  et	  al.,	  reported	  a	  function	  for	  CKS1	  within	  the	  SCFSkp2	  ubiquitin	  ligase	  (Ganoth	  et	  al.,	  2001;	  Spruck	  et	  al.,	  2001).	  The	  ubiquitination	  of	  the	  CDK2	  inhibitor	  p27Kip1	  could	  be	  reconstituted	  by	  human	  CKS1	  in	  a	  purified	  system	  (Ganoth	  et	  al.,	  2001;	  Spruck	  et	  al.,	  2001)	  and	  was	  impaired	  in	  Cks1-­‐/-­‐	  mice	  (Spruck	  et	  al.,	  2001).	  SCFSkp2	   is	  an	  E3	  ubiquitin	   ligase,	  which	  consists	  of	  SKP1,	  Cullin1	  (CUL1),	  RING-­‐box	   protein	   (RBX)	   1	   and	   SKP2.	   RBX1	   and	   SKP1	   are	   placed	   on	   CUL1,	  which	   serves	   as	  scaffold.	   RBX1	   binds	   the	   ubiquitin	   transferase	   (E2)	   and	   SKP1	   binds	   SKP2	   (Deshaies,	  1999;	  Jackson	  and	  Eldridge,	  2002).	  SKP2	  is	  the	  F	  box	  protein,	  which	  binds	  the	  substrate.	  For	   the	   ubiquitination	   of	   p27Kip1,	   CKS1	   interacts	   with	   SKP2.	   CKS1	   recognises	  phosphorylated	  p27Kip1.	  p27Kip1	  then	  binds	  to	  both	  CKS1	  and	  SKP2	  to	  be	  ubiquitinated.	  CDK2-­‐cyclin	  A	  complexes	  stimulate	  this	  process	  possibly	  by	  the	  ability	  of	  CDK2	  to	  bind	  CKS1	  and	  the	  ability	  of	  cyclin	  A	  to	  bind	  SKP2	  (Hao	  et	  al.,	  2005).	  Ubiquitination	  of	  p21Cip1	  by	  the	  SCFSkp2	  ubiquitin	  ligase	  was	  also	  enhanced	  in	  the	  presence	  of	  CKS1	  (Bornstein	  et	  al.,	  2003).	  Further	   targets	  of	   the	  SCFSkp2	  ubiquitin	   ligase,	  which	  might	  require	  CKS1	  as	  linker	  protein	  are	  p57Kip2	  and	  p130	  (Bornstein	  et	  al.,	  2003;	  Kamura	  et	  al.,	  2003;	  Tedesco	  et	  al.,	  2002).	  p130	  is	  the	  pocket	  protein	  and	  CDK	  inhibitor,	  which	  is	  active	  primarily	  in	  G0	  and	  degraded	  thereafter	  (see	  chapter	  1.1.2.1).	  p57Kip2	  has	  been	  shown	  to	  be	  essential	  during	   embryogenesis	   (Borriello	   et	   al.,	   2011).	   It	   shares	  CDK	   inhibitory	   functions	  with	  p21Cip1	  and	  p27Kip1	  and	  levels	  decrease	  at	  the	  end	  of	  G1.	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  Figure	   1.4	   p27Kip1	   ubiquitination	   by	   the	   SCFSkp2	   ubiquitin	   ligase.	   The	   SCFSkp2	   ubiquitin	   ligase	   is	  composed	  of	   the	  subunits	  SKP1,	  Cullin1,	  RBX1	  and	   the	  F-­‐box	  protein	  SKP2	  (Jackson	  and	  Eldridge,	  2002).	  The	   scaffold	   protein	   Cullin1	   forms	   the	   backbone	   of	   the	   ligase	   and	   separates	   the	   substrate	   binding	   and	  catalytic	  components.	  It	  binds	  SKP1	  at	  its	  N-­‐terminal	  and	  RBX1	  at	  its	  C-­‐terminal	  end.	  The	  adaptor	  protein	  SKP1	  binds	  SKP2,	  which	  functions	  as	  a	  substrate	  specificity	  factor.	  It	  recognises	  and	  binds	  phosphorylated	  p27Kip1.	   p27Kip1	   binding	   is	   enhanced	  by	  CKS1	   (Spruck	   et	   al.,	   2001).	  The	  E2	  ubiquitin-­‐conjugating	   enzyme	  UBC3	   is	   recruited	   to	   the	   Cullin1	   backbone	   via	   RBX1.	   UBC3	   can	   now	   ubiquitinate	   the	   substrate	   p27Kip1.	  Polyubiquitinated	  p27Kip1	  is	  then	  degraded	  by	  the	  26S	  proteasome.	  (Adapted	  from	  (Wang	  et	  al.,	  2012))	  	  	  	  	   Later	   it	   was	   discovered	   that	   CKS	   proteins	   are	   also	   involved	   in	   the	   function	   of	  another	  ubiquitin	  ligase,	  which	  plays	  a	  crucial	  role	  in	  cell	  cycle	  progression,	  the	  APC/C.	  It	  was	   shown	   that	   CKS	   facilitates	   the	   binding	   of	   cyclin	  A	   to	   the	  APC/C.	  Here	   cyclin	  A,	  which	  is	  in	  complex	  with	  CDK2	  and	  CKS,	  binds	  to	  the	  APC/C	  cofactor	  CDC20.	  Cyclin	  A	  is	  then	   recruited	   to	   the	  APC/C	   through	   the	   CKS	   interaction	  with	   phosphorylated	  APC/C	  (Di	  Fiore	  and	  Pines,	  2010).	  	   Expression	   of	   CKS	   proteins	   in	   mammals	   is	   regulated	   by	   transcription	   as	   well	   as	  protein	  degradation.	  mRNA	  levels	  for	  CKS1	  are	  low	  in	  G0,	  increase	  at	  the	  end	  of	  G1	  and	  peak	   in	  S/G2.	  The	  responsible	  region	   in	   the	  promoter	  of	  CKS1,	  which	   is	   leading	   to	   the	  repression	   in	  G0	  and	  early	  G1	  was	   identified	  as	  a	   cell	   cycle	  dependent	  element	   (CDE)	  and	   cell	   cycle	   genes	   homology	   region	   (CHR)	   tandem	   site	   (Rother	   et	   al.,	   2007b).	   The	  transcription	   of	   both,	   CKS1	   and	   2,	   is	   down-­‐regulated	   by	   p53	   (Rother	   et	   al.,	   2007a;	  Rother	  et	  al.,	  2007b).	  	   CKS1	  protein	  levels	  were	  observed	  to	  decrease	  in	  G1	  and	  again	  in	  M	  phase.	  Down-­‐regulation	  in	  G1	  was	  shown	  to	  be	  dependent	  on	  the	  APC/CCdh1	  ubiquitin	  ligase	  (Bashir	  et	  al.,	  2004).	  Low	  levels	  of	  CKS1	  in	  G1	  lead	  to	  the	  stabilisation	  of	  the	  CDK	  inhibitor	  p27Kip1	  preventing	  premature	  entry	  into	  S-­‐phase.	  It	  was	  suggested	  that	  CKS	  down-­‐regulation	  in	  M-­‐phase	  is	  also	  dependent	  on	  the	  ubiquitin	  proteasome	  pathway	  (Hattori	  et	  al.,	  2003).	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1.2.3	  CKS	  as	  oncogenes	  Both	  proteins,	  CKS1	  and	  2,	  are	  over-­‐expressed	  in	  various	  types	  of	  cancer	  and	  are	  often	  associated	  with	  aggressive	  forms	  characterised	  by	  high	  proliferation	  and	  a	  tendency	  to	  metastasise.	   For	   example,	  CKS1	  was	   found	   to	   be	   over-­‐expressed	   in	  multiple	  myeloma	  (Chang	   et	   al.,	   2010;	   Fonseca	   et	   al.,	   2006;	   Zhan	   et	   al.,	   2007),	   renal	   cancer	   (Liu	   et	   al.,	  2008),	  gastric	  cancer	  (Masuda	  et	  al.,	  2003),	  colorectal	  cancer	  (Shapira	  et	  al.,	  2005),	  lung	  cancer	   (Inui	   et	   al.,	   2003),	   breast	   cancer	   (Slotky	   et	   al.,	   2005;	   Wang	   et	   al.,	   2009;	  Westbrook	   et	   al.,	   2009),	   prostate	   cancer	   (Lan	   et	   al.,	   2008)	   and	   hepatocellular	   cancer	  (Calvisi	  et	  al.,	  2009;	  Lee	  et	  al.,	  2011;	  Shen	  et	  al.,	  2010).	  CKS1	  over-­‐expression	  was	  also	  observed	  in	  cancer	  cell	  lines	  and	  animal	  models	  (Kitajima	  et	  al.,	  2004;	  Lan	  et	  al.,	  2008;	  Lee	   et	   al.,	   2011;	  Wang	  et	   al.,	   2009).	   In	   cell	   cultures	  derived	   from	  carcinomas	  of	   these	  animal	  models	  or	  patients,	   the	  role	  of	  CKS	   as	  an	  oncogene	  has	  been	  studied	  by	  down-­‐regulation	  of	  CKS.	   The	   loss	   of	  CKS	   in	   these	   cells,	  which	   otherwise	   show	  high	   levels	   of	  CKS,	   led	   to	   a	   decrease	   in	   proliferation	   and	   tumorigenicity.	   CKS1	   knock-­‐down	   is	  frequently	   accompanied	   by	   the	   accumulation	   of	   p27Kip1.	   Furthermore	   high	   levels	   of	  CKS1	  are	  often	  correlated	  to	   low	  levels	  of	  p27Kip1	  in	  cancer	  tissue	  samples	  (Kitajima	  et	  al.,	  2004;	  Lee	  et	  al.,	  2011;	  Wang	  et	  al.,	  2009).	  Thus	  the	   function	  of	  CKS1	  as	  part	  of	   the	  SCFSkp2	   ubiquitin	   ligase	   in	   p27Kip1	   degradation	   is	   believed	   to	   promote	   tumorigenesis.	  High	   levels	   of	   CKS1	   are	   not	   always	   associated	  with	   a	   reduction	   in	   p27Kip1	   (Tsai	   et	   al.,	  2005;	  Westbrook	   et	   al.,	   2009).	   Additional	   SKP2	   and	   p27Kip1	   independent	  mechanisms	  such	   as	   inhibition	   of	   apoptosis,	   G2/M	   transition,	   up-­‐regulation	   of	   interleukin	   8	   and	  promoting	   anchorage	   independent	   growth	   and	   migration	   activities	   were	   associated	  with	  CKS1	  expression	  in	  cancer	  cell	  lines	  as	  well	  (Lan	  et	  al.,	  2008;	  Lee	  et	  al.,	  2011;	  Tsai	  et	  al.,	  2005;	  Wang	  et	  al.,	  2009).	  	  	   A	   possible	   tumour	   promoting	   function	   of	   CKS2,	   which	   is	   also	   over-­‐expressed	   in	  various	  cancer	  types	  like	  breast	  cancer	  (van	  't	  Veer	  et	  al.,	  2002),	  colon	  cancer	  (Li	  et	  al.,	  2004),	   skin	   cancer	   (de	  Wit	   et	   al.,	   2005),	   cervical	   cancer	   (Lyng	   et	   al.,	   2006),	   prostate	  cancer	  (Lan	  et	  al.,	  2008),	  liver	  cancer	  (Chen	  et	  al.,	  2011)	  and	  bladder	  cancer	  (Chen	  et	  al.,	  2011)	  is	  not	  well	  studied.	  	   More	   recently	   Liberal	   et	   al.	   proposed,	   that	   CKS	   over-­‐expression	   in	   cancer	   might	  cause	   override	   of	   the	   intra	   S-­‐phase	   checkpoint	   (Liberal	   et	   al.,	   2011).	   To	   demonstrate	  this	   point	   they	   treated	   cancer	   cell	   lines	   as	   well	   as	   immortalised	   human	   mammary	  epithelial	  cells	  with	  thymidine,	  which	  would	  typically	  lead	  to	  S-­‐phase	  arrest	  induced	  by	  replication	  stress.	  CKS1-­‐	  and	  2	  over-­‐expressing	  cells	  could	  not	  be	  fully	  arrested.	  By	  using	  
CKS2	  over-­‐expressing	  cells	  over	  CKS1	  over-­‐expressing	  cells	  for	  subsequent	  experiments	  they	   ensured	   that	   an	   observed	   effect	   is	   not	   due	   to	   the	  well-­‐studied	   function	   of	   CKS1	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within	   the	   SCFSkp2	   ubiquitin	   ligase.	   The	   authors	   showed	   that	   the	   intra	   S-­‐phase	  checkpoint	   in	   these	   cells	  was	  working	  properly	   by	  monitoring	  CHK1	  phosphorylation	  status,	  the	  amount	  of	  CDC25A	  and	  CDK	  phosphorylation	  on	  Tyr15.	  They	  claimed	  that	  no	  difference	   in	   the	  CHK1	  pathway	  was	  visible	   in	  control	  and	  CKS2	  over-­‐expressing	  cells.	  Thus	  they	  concluded,	  that	  the	  ability	  of	  CKS	  over-­‐expressing	  cells	  to	  override	  the	  intra	  S-­‐phase	  checkpoint	  is	  due	  to	  an	  unknown	  function	  of	  CKS.	  CKS	  proteins	  might	  be	  able	  to	  maintain	   Tyr15-­‐phosphorylated	   CDK2	   in	   an	   active	   state.	   To	   confirm	   their	   hypothesis	  they	  showed	  that	  immunoprecipitated	  CDK2	  from	  CKS2	  over-­‐expressing	  HEK293A	  cells	  had	   an	   increased	   kinase	   activity	   towards	   RB.	   In	   an	   assay	  with	   recombinant	   proteins,	  addition	   of	   wtCKS1	   enhanced	   CDK2	   activity	   as	   well.	   A	   mutant	   form	   of	   CKS1,	   which	  shows	  a	  reduced	  ability	  to	  bind	  CDK	  (CKS1E63Q),	  does	  not	  have	  a	  positive	  influence	  on	  CDK2	   activity.	   In	   contrast	   to	   this,	   addition	   of	   a	   CKS1	  mutant,	  which	   is	   unable	   to	   bind	  phospho-­‐proteins	   (CKS1AM),	   leads	   as	  well	   to	   a	   higher	   CDK2	   activity	   albeit	   not	   to	   the	  same	  degree	   as	   the	  wild-­‐type	  protein.	   These	   results	  would	   support	   the	   idea	   that	   CKS	  keeps	  CDK2	  in	  an	  active	  conformation	  regardless	  of	  the	  inhibitory	  phosphorylation	  on	  Tyr15.	   This	   CKS	   function	   would	   not	   require	   the	   ability	   of	   CKS	   proteins	   to	   bind	   to	  phospho-­‐proteins	  (Liberal	  et	  al.,	  2011).	  	  
1.3	  Aim	  of	  this	  study	  Both	   CKS	   proteins	   have	   been	   shown	   to	   be	   over-­‐expressed	   in	   a	   variety	   of	   advanced	  metastatic	  cancers.	  Studies	  on	  animal	  models	  (Lan	  et	  al.,	  2008;	  Westbrook	  et	  al.,	  2009)	  and	   cell	   culture	   have	   further	   suggested	   a	   role	   of	   CKS	   proteins	   as	   oncogenes.	   These	  studies	  showed	  an	  impaired	  proliferative	  capacity	  of	  cancer	  cells	  upon	  down-­‐regulation	  of	  CKS	  proteins	  (Lee	  2011,	  Wang	  2009,	  Lan	  2008,	  Kitajima	  2004).	  Whether	  CKS	  acts	  as	  a	  real	   oncogene	   and	   has	   the	   ability	   to	   promote	   the	   transformation	   process	   of	   primary	  cells	   to	   cancer	   cells	   remains	   unclear.	   Known	   oncogenes	   lead	   to	   checkpoint	   activation	  upon	  their	  over-­‐expression	  in	  primary	  cells.	  Therefore	  the	  response	  of	  primary	  cells	  to	  
CKS	  over-­‐expression	  should	  be	  studied.	  In	  case	  of	  checkpoint	  activation	  upon	  CKS	  over-­‐expression	   the	   nature	   of	   this	   activation	   should	   be	   analysed.	   Furthermore	   a	   tumour	  promoting	  function	  of	  CKS	  in	  checkpoint	  inhibited	  cells	  should	  be	  investigated.	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Chapter	  2	  –	  Material	  and	  Methods	  	  
2.1	  Cell	  lines	  and	  tissue	  culture	  methods	  IMR90	  human	  foetal	   lung	   fibroblasts	  and	  human	  embroyonic	  kidney	  (HEK)	  293T	  cells	  were	  obtained	   from	   the	  American	  Type	  Culture	  Collection	   (ATCC).	  The	  packaging	   cell	  line	   Takara	   (GP2-­‐293)	   was	   obtained	   from	   Takara	   Bio.	   Unless	   otherwise	   stated	   cells	  were	  maintained	  in	  Dulbecco’s	  modified	  Eagle’s	  medium	  (DMEM,	  PAA)	  with	  10%	  (v/v)	  foetal	   bovine	   serum	   (PAA),	   1%	   (v/v)	   non	   essential	   amino	   acids	   (PAA),	   1%	   (v/v)	   L-­‐glutamine	   and	   1%	   (v/v)	   Penicillin/Streptomycin	   (PAA),	   50	   µg/ml	   Normocin	  (Invivogen)	  and	  1%	  (v/v)	  antibiotic-­‐antimycotic	  (Gibco).	  Cells	  were	  grown	  at	  37˚C	  with	  5%	  CO2.	  	  
2.2	  Retrovirus	  production	  and	  transduction	  of	  target	  cells	  Amphotropic	   retroviral	   stocks	  were	   prepared	   by	   transient	   transfection	   of	   the	   Takara	  packaging	   cell	   line.	   Confluent	  Takara	   cells	  were	   split	   one	   to	   four	   and	  plated	   in	  10	   cm	  culture	  dishes	  one	  day	  prior	  transfection.	  A	  solution	  consisting	  of	  1	  ml	  DMEM,	  75	  µl	  of	  the	   transfection	   reagent	   polyethylenimine	   (PEI,	   Sigma	   Aldrich),	   2	   µg	   of	   a	   VSV-­‐G	   viral	  coding	   helper	   plasmid	   and	   14	   µg	   of	   the	   desired	   expression	   plasmid	   was	   prepared,	  incubated	  for	  20	  minutes	  and	  added	  drop	  wise	  to	  each	  plate	  of	  Takara	  cells.	  On	  the	  day	  following	   transfection,	   culture	   medium	   was	   replaced	   with	   5	   to	   7	   ml	   of	   fresh	   culture	  medium	   and	   the	   fibroblasts,	   to	   be	   infected	   the	   following	   day	   were	   plated	   at	   40%	  confluence	   in	   a	   10	   cm	   plate.	   Two	   days	   after	   transfection,	   the	   virus-­‐containing	  supernatants	   from	   the	  Takara	   cells	  were	   collected	   and	   filtered	   through	  0.45	   µm	  pore	  sized	  acetate	  filters	  (Anachem).	  Polybrene	  (Sigma	  Aldrich)	  was	  added	  at	  a	  1	  to	  2	  µg/ml	  concentration	  to	  boost	  the	  interactions	  between	  cells	  and	  viral	  particles.	  After	  24	  hours,	  cells	  were	  aspirated	  and	   incubated	   in	  regular	  culture	  media	  with	  selection	   in	  medium	  containing	  the	  appropriate	  amount	  of	  the	  required	  antibiotic	  initiated	  three	  days	  post-­‐infection	  (Table	  1).	  	   	   For	  the	  infection	  with	  the	  lentiviral	  vector	  TetO-­‐FUW	  ZEOCIN,	  293T	  cells	  were	  used	  as	   packaging	   cell	   line.	   DMEM	   and	   PEI	   were	   mixed	   with	   20	   µg	   of	   TetO-­‐FUW,	   5	   µg	   of	  pRSV-­‐Rev	   (a	   vector	   expressing	   the	   regulator	   of	   virion	   expression	   protein	   (Rev)	   for	  transporting	   the	   viral	  mRNA	   from	   the	   nucleus	   to	   the	   cytoplasm),	   10	   µg	   of	   pMDLg	   (a	  vector	   expressing	   the	   group-­‐specific	   antigen	   (Gag)	   and	   polymerase	   (Pol)	   for	   the	  assembly	  of	  the	  retroviral	  particles	  and	  the	  synthesis	  of	  viral	  DNA	  and	  integration	  of	  the	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DNA	   into	   the	   host	   genome)	   and	   6	   µg	   of	   pMD2.G	   (a	   vector	   expressing	   VSV-­‐G	   for	   the	  interaction	   with	   target	   cells).	   Transfection	   of	   293T	   cells	   was	   then	   performed	   as	  described	  for	  the	  transfection	  of	  Takara	  cells	  with	  retroviral	  vectors.	  	  Table	  1	  Retroviral	  constructs	  used	  and	  selection	  conditions	  
	  	  
2.3	  Growth	  assays	  
2.3.1	  Colony	  formation	  assay	  and	  growth	  curves	  For	   colony	   formation	   assays	   5	   x	   104	   cells	   were	   seeded	   in	   duplicates	   in	   6	   cm	   dishes.	  Medium	  was	  replaced	  every	  3	  to	  4	  days.	  After	  approximately	  14	  days	  cells	  were	  washed	  once	   with	   1	   x	   phosphate	   buffered	   saline	   (PBS)	   fixed	   for	   10	   minutes	   with	   0.5%	  glutaraldehyde	   (Sigma	   Aldrich)	   and	  washed	   twice	  with	   PBS.	   Fixed	   cells	  were	   stained	  with	  0.1%	  crystal	  violet	  (Sigma	  Aldrich)	  for	  30	  minutes	  followed	  by	  extensive	  washing	  with	  water.	  




selection	  pMaRX	   c-­‐MYC	  
puromycin	   0.5	  to	  1	  µg	  per	  ml	   7	  days	  
pBABE	   HRAS	  G12V	  
pBABE	  
CKS1	  wt	   	  CKS1	  E63Q	  CKS1	  K11E	  S51E	  K71A	  CKS2	  wt	  CKS2	  E63Q	  CKS2	  K11E	  S51E	  K71A	  
pBABE-­‐sin-­‐tet	  
CKS1	  wt	  CKS1	  E63Q	  CKS1	  K11E	  S51E	  K71A	  CKS2	  wt	  	  CKS2	  E63Q	  CKS2	  K11E	  S51E	  K71A	  pWZL	   hTERT	   blasticidin	   2	  µg	  per	  ml	   2	  weeks	  TetO-­‐FUW	   CKS1	  wt	   zeocin	   25	  µg	  per	  ml	  10	  µg	  per	  ml	  for	  further	  culturing	   2	  weeks	  CKS2	  wt	  MSCV	   M2rtTA	   hygromycin	   20	  µg	  per	  ml	   2	  weeks	  pLV	   tTRKRAB	   neomycin	   400	  µg	  per	  ml	   3	  weeks	  LXSN	   E6/E7	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   For	  growth	  curves	  7	  x	  103	  cells	  were	  seeded	   in	  duplicates	   in	  24	  well	  plates.	  Cells	  from	  two	  wells	  were	  fixed	  the	  day	  after	  plating	  (day	  0)	  and	  every	  second	  day	  thereafter	  for	   a	   period	   of	   12	   days.	   Fixed	   cells	   were	   stained	   as	   described	   above.	   Stainings	   were	  quantitatively	   analysed	   by	   extracting	   the	   crystal	   violet	   with	   10%	   acetic	   acid	   (Fisher	  Scientific)	   and	   measuring	   the	   absorbance	   of	   the	   acetic	   acid	   crystal	   violet	   solution	   at	  	  	  595	  nm	  (A595)	  using	  a	  Bio-­‐Rad	  680XR	  microplate	  reader.	  To	  obtain	  the	  growth	  curves,	  the	  absorbance,	  representing	  cell	  density,	  was	  plotted	  against	  elapsed	  time.	  	  
2.3.2	  BrdU	  (5-­‐Bromo-­‐2’-­‐deoxyuridine)	  incorporation	  assay	  	  3.5	  x	  103	  Cells	  were	  plated	  in	  duplicates	  into	  96	  well	  plates	  and	  pulsed	  with	  50	  µM	  BrdU	  	  (Sigma	   Aldrich)	   for	   16	   hours	   the	   following	   day	   (Gratzner,	   1982).	   Cells	   were	   then	  washed	   with	   PBS	   and	   fixed	   for	   10	   minutes	   with	   4%	   (w/v)	   paraformaldehyde	   (PFA,	  Sigma	  Aldrich)	  at	  room	  temperature.	  	  	   For	   immunofluorescence	   staining	   the	   following	   steps	   were	   performed	   at	   room	  temperature.	   Cells	   were	   permeabilised	   with	   0.2%	   (v/v)	   Triton	   X-­‐100	   in	   PBS	   (Sigma	  Aldrich)	   for	   10	   minutes	   and	   incubated	   in	   1	   x	   blocking	   solution	   (0.5%	   (w/v)	   BSA	  (Calbiochem),	   0.2%	   (w/v)	   fish	   skin	   gelatin	   (Sigma	   Aldrich))	   for	   30	  minutes.	   Staining	  with	   rat	   anti-­‐BrdU	   antibody,	   clone	   3H579	   (1:100,	   Santa	   Cruz)	   was	   performed	   in	   the	  presence	  of	  DNase	  I	  (0.5	  U/µl;	  Sigma	  Aldrich)	  and	  MgCl2	  (3	  mM,	  Sigma	  Aldrich)	   in	  1	  x	  blocking	   solution	   for	   1	   hour.	   Cells	  were	  washed	   three	   times	  with	   PBS	   and	   incubated	  with	  the	  secondary	  Alexa	  Fluor	  488	  goat	  anti-­‐rat	  antibody	  (1:1000	  in	  PBS,	  Invitrogen)	  for	  30	  minutes.	  Finally,	  cells	  were	  washed	  with	  PBS	  and	  incubated	  with	  DAPI	  (1.5	  µM,	  Invitrogen	   (Schnedl	   et	   al.,	   1977)).	   Plates	  were	   read	   by	   the	   IN	   Cell	   Analyzer	   and	  High	  Content	  Analysis	  was	  performed	   to	  discriminate	  positive	  BrdU	  nuclei	   and	   total	   nuclei	  (see	  below	  for	  the	  description	  of	  High	  Content	  Analysis).	  	  	  	  
2.3.3	  Senescence	  associated	  ß-­‐galactosidase	  (SA-­‐ß-­‐gal)	  assay	  To	  analyse	  enhanced	  SA-­‐ß-­‐gal	  activity	  cells	  were	  washed	  once	  with	  PBS,	  fixed	  with	  0.5%	  (w/v)	  glutaraldehyde	  for	  10	  minutes	  at	  room	  temperature	  and	  washed	  twice	  with	  PBS	  (pH6)	  supplemented	  with	  1	  mM	  MgCl2	  	  (PBS/MgCl2).	  Fixed	  cells	  were	  stained	  overnight	  at	   37°C	  with	   an	   X-­‐gal	   staining	   solution	   containing	   1	  mg/ml	   X-­‐Gal	   (Invitrogen),	   5	  mM	  K3Fe(CN)6	   (Sigma	  Aldrich)	   and	  5	  mM	  K4Fe(CN)6	  3H2O	   (Sigma	  Aldrich)	   in	  PBS/MgCl2.	  Staining	  was	  stopped	  by	  washing	  the	  cells	  with	  distilled	  water	  when	  sufficient	  staining	  was	  visible	   in	   IMR90	  H-­‐RASG12V	  control	   cells.	  Pictures	  were	   taken	  on	  an	  Olympus	   IX	  inverted	  microscope	  and	  the	  percentage	  of	  SA-­‐ß-­‐gal	  positive	  cells	  was	  scored.	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2.4	  Immunofluorescence	  (IF)	  staining	  and	  antibodies	  Cells	  were	  plated	  in	  96	  well	  plates	  at	  a	  density	  of	  3.5	  x	  103	  cells	  per	  well.	  Two	  days	  later	  cells	  were	  fixed	  with	  PFA	  and	  permeabilised	  as	  described	  above.	  Incubation	  of	  primary	  antibodies	  was	  performed	  in	  1	  x	  blocking	  buffer	  (see	  section	  2.3.2)	  at	  room	  temperature	  for	   1	   hour.	   After	   consecutive	   rinses	   in	   PBS,	   cells	   were	   incubated	   with	   secondary	  antibody	  for	  30	  minutes.	  Nuclei	  were	  stained	  as	  previously	  described.	  	  	   The	   following	  primary	   antibodies	  were	  used:	  mouse	   anti-­‐p16INK4a	   antibody,	   clone	  JC8	   (1:500,	   Santa	   Cruz);	   mouse	   anti-­‐p21Cip1,	   clone	   P1484	   (1:100,	   Sigma	   Aldrich)	   and	  mouse	  anti-­‐p53,	  clone	  DO-­‐1	  (1:100,	  Santa	  Cruz).	  Goat	  anti-­‐mouse	  Alexa488-­‐conjugated	  antibody	  (1:1000,	  Invitrogen)	  was	  used	  as	  secondary	  antibody.	  	  	   Images	  of	   stained	  cells	  were	  acquired	  using	   the	   IN	  Cell	  Analyzer	  1000	  automated	  high-­‐throughput	  microscope	   (GE	  Healthcare)	  with	  10x	   (for	  BrdU	  staining)	  or	  20x	   (for	  p16INK4a,	   p21Cip1	   and	   p53	   staining).	   For	   each	   condition	   images	   were	   acquired	   at	   an	  excitation	  wavelength	  of	  360	  nm	  and	  emission	  wavelength	  of	  460	  nm	  (corresponding	  to	  DAPI)	  and	  at	  an	  excitation	  wavelength	  of	  480	  nm	  and	  emission	  wavelength	  of	  535	  nm	  (corresponding	   to	   primary	   antibody/Alexa	   Fluor®	   488	   secondary	   antibody)	  respectively.	   For	   analyses	   of	   p21Cip1	   and	   p53	   levels	   in	   CKS	   positive	   cell	   subsets,	  additional	   incubation	   steps	  with	   a	   rabbit	   anti-­‐CKS1/2	  FL79	   antibody	   and	   a	   goat	   anti-­‐rabbit	   Alexa	   Fluor®	   594-­‐conjugated	   antibody	   (1:1000,	   Invitrogen)	   were	   necessary.	  Alexa	  Fluor®	  594	  was	  detected	  using	  an	  excitation	  filter	  of	  565	  nm	  and	  emission	  filter	  of	  620	  nm	  wavelength.	  	   Images	   were	   analysed	   and	   quantified	   via	   High	   Content	   Analysis	   (HCA)	   with	   the	  help	  of	  the	  IN	  Cell	  Investigator	  (v1.7)	  software	  (GE	  Healthcare).	  First,	  DAPI	  images	  were	  used	  to	  identify	  the	  nuclear	  area	  of	  each	  cell	  and	  thus	  the	  cell	  itself	  and	  the	  number	  of	  all	  cells	  in	  one	  image.	  A	  nucleus	  was	  defined	  as	  region	  with	  a	  defined	  DAPI	  intensity	  and	  an	  area	  of	  at	  least	  100	  µm2.	  To	  identify	  the	  single	  cells,	  a	  collar	  segmentation	  routine	  was	  used	  with	  a	  diameter	  of	  1	  µm	  around	  the	  nucleus.	  Then	  the	  average	  intensity	  of	  pixels	  in	  the	  second	  channel	  (AlexFluor®488)	  for	  the	  nuclear	  region	  was	  determined.	  A	  negative	  control,	   usually	   the	   empty	   vector	   control,	   and	   a	   positive	   control,	   which	   express	   low	  levels	   and	   high	   levels	   of	   the	   visualised	   protein	   respectively,	   were	   first	   analysed.	   The	  nuclear	   intensity	   values	   for	   the	   specific	   protein	   of	   all	   cells	   were	   mapped	   into	   a	  histogram.	   Using	   the	   histogram,	   a	   threshold	   filter	   was	   set	   up,	   which	   allowed	   for	  distinguishing	  between	  cells	  with	  high	   levels	   (positive)	  or	   low	   levels	   (negative)	  of	   the	  specific	   protein.	   After	   the	   analysis	   of	   all	   images	   in	   one	   experiment	   the	   software	  generated	   a	   mean	   percentage	   for	   both	   cell	   populations	   (positive	   and	   negative)	   in	   all	  images	   acquired	   per	   well.	   This	   procedure	   was	   repeated	   for	   the	   third	   channel	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(AlexFluor®594)	   where	   applicable.	   In	   the	   case	   of	   double	   stainings	   with	   an	   antibody	  against	   CKS	   and	   against	   p21Cip1	   or	   p53,	   a	   decision	   tree	   was	   set	   up	   to	   identify	   the	  percentage	   of	   cells	   negative	   for	   CKS	   but	   positive	   for	   checkpoint	   protein	   as	   well	   as	  double	  positive	  and	  double	  negative	  cells.	  	  	   For	   the	  quantification	  of	   cells	  positive	   for	  Senescence	  associated	  heterochromatic	  foci	  (SAHF),	  20x	  images	  of	  DAPI	  stained	  cells	  were	  acquired	  at	  two	  different	  intensities	  using	   two	   different	   exposure	   times.	   The	   nucleus	   was	   defined	   in	   the	   image	   with	   the	  lower	   intensity.	   In	   the	   image	  with	   the	  higher	   intensity	   SAHF	  were	   identified	  by	  using	  the	   organelle	   parameter	   in	   the	   IN	   Cell	   Investigator	   Software.	   SAHF	   were	   defined	   as	  spots	   with	   a	   high	   fluorescence	   intensity	   and	   an	   area	   of	   1	   to	   3	   µm.	   After	   comparing	  empty	  vector	  control	  cells	  and	  RAS	  oncogene	  control	  cells,	  a	  threshold	  number	  of	  SAHF	  for	  the	  cells	  to	  be	  counted	  as	  positive	  for	  SAHF	  formation	  was	  defined.	  	  	  
2.5	  Generation	  of	  viral	  vectors	  for	  the	  transduction	  of	  fibroblasts	  
2.5.1	  Retroviral	  vectors	  used	  for	  continuous	  protein	  expression	  Constructs	   for	   the	   stable	   expression	   of	   human	   CKS1wt,	   CKS1E63Q,	   CKS2wt	   and	  
CKS2E63Q	   were	   prepared	   by	   Mattia	   Frontini.	   Briefly,	   cDNA	   was	   prepared	   and	   the	  sequence	   coding	   for	   CKS1wt	   and	   CKS2wt	   was	   PCR-­‐amplified	   and	   cloned	   into	   pSP72.	  
CKS1E63Q	   and	   CKS2E63Q	   were	   obtained	   by	   PCR	   site-­‐directed	   mutagenesis	   of	   the	   wt	  counterparts.	   FLAG	   and	  HIS	   tags	  were	   introduced.	   The	   sequence	   encoding	   for	   all	  CKS	  variants	   coupled	   to	   the	   FLAG	   and	   HIS	   tag	   were	   then	   PCR-­‐amplified	   from	   pSP72	  plasmids	  with	  primers	  containing	  BamHI	  and	  SalI	  sites	  for	  cloning	  into	  the	  pBABE	  PURO	  retroviral	  vector	  (Figure	  4.1	  A).	  	  	   Using	  the	  pBABE	  CKS1wt	  and	  CKS2wt	  PURO	  as	  template,	  pBABE	  CKS1	  K11E	  S51E	  K71A	   and	   CKS2	   K11E	   S51E	   K71A	   PURO	   were	   generated	   by	   PCR	   site	   directed	  mutagenesis	  by	  Roman	  Holic.	  pBABE	  HRASG12V	  PURO,	  pMaRX	  c-­‐MYC	  PURO,	  LXSN	  E6	  and	  E7	  NEO	  have	  been	  available	  in	  the	  lab	  and	  were	  described	  previously	  (Banito	  et	  al.,	  2009).	   pWZL	  hTERT	  BLAST	  was	   kindly	  provided	  by	  Martin	  Teichmann	   (University	   of	  Bordeaux,	  France).	  Constructs	  for	  inducible	  CKS	  expression	  are	  described	  below.	  The	  accuracy	  of	  CKS	  sequences	  in	  pBABE	  as	  well	  as	  the	  inducible	  vectors	  was	  verified	  by	  sequencing	  (Figure	  2.1):	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  Figure	  2.1	  Verification	  of	  CKS	   sequences	   in	  pBABE	  PURO	  vectors.	  Sequences	  obtained	  from	  pBABE	  CKS	  PURO	  analyses	  were	  aligned	  with	  the	  respective	  CKS	  c-­‐DNA	  sequences	  to	  verify	  their	  accuracy.	   The	   alignments	   show	   the	   published	   cDNA	   sequences	   for	   the	   CKS	   variants	   (upper	  sequence)	   aligned	  with	   that	   obtained	   from	   the	   sequencing	   of	   the	   produced	   pBABE	   CKS	   PURO	  DNA	  constructs	  (lower	  sequence).	  Red	  boxes	  highlight	   the	  mutational	  changes	   in	   the	  sequence	  leading	  to	  the	  insufficiency	  of	  CDK	  (E63Q)	  or	  phospho-­‐protein	  (AM)	  binding	  in	  the	  CKS	  variants.	  
CKS1	  K11E	  S51E	  K71A	  (CKS1AM)	   CKS2	  K11E	  S51E	  K71A	  (CKS2AM)	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2.5.2	  Generation	  of	  viral	  vectors	  used	  for	  induced	  protein	  expression	  
2.5.2.1	  TetO-­‐FUW	  CKS	  ZEOCIN	  constructs	  The	  TetO-­‐FUW	  ZEOCIN	  vector	  was	  obtained	  from	  Addgene	  (Boston,	  MA).	  CKS	  FLAG	  Tag	  constructs	  were	  used	  as	  templates	   in	  a	  PCR	  reaction	  to	  obtain	  the	  CKS	   fragments	  with	  EcoRI	  restriction	  sites	  on	  both	  ends.	  Sequences	  of	  the	  primers	  used	  were	  as	  follow:	  	  FLAG_EcoRI	  Reverse:	  TGTAGAATTCTCAGTGATGGTGATGGTGAT	  CKS2_EcoRI	  Forward:	  AACTGAATTCATGGCCCACAAGCAGAT	  CKS1_EcoRI	  Forward:	  CGACGAATTCATGTCGCACAAACAAATTTACTAT	  	  PCR	  conditions	  used:	  Initial	  denaturing:	  95°C	  5	  min	  Denaturing:	  98°C	  45	  s	  Annealing:	  55°C	  45	  s	  	  	  	  	  	  	  	  	  	  	   5	  times	  Elongation:	  72°C	  30	  s	  	  Denaturing:	  98°C	  45	  s	  Annealing:	  60°C	  45	  s	  	  	  	  	  	  	  	  	  	  	   25	  times	  Elongation:	  72°C	  30	  s	  Final	  elongation:	  72°C	  5	  min	  	  PCR	  products	  and	  TetO-­‐FUW	  vector	  were	  both	  cut	  on	   their	  EcoRI	   sites	   (Figure	  3.1	  B).	  For	  ligations	  the	  T4	  ligase	  and	  buffer	  (NEB)	  were	  used	  according	  to	  the	  recommended	  conditions.	  	  
2.5.2.2	  pBABE	  sin	  tet	  CKS	  PURO	  constructs	  The	  pBABE	  sin	  tet	  PURO	  vector	  was	  provided	  by	  Ana	  Banito	  (Cell	  Proliferation	  Group,	  CSC	  MRC).	  The	  CKS	  FLAG	  Tag	   sequences	  were	   cut	  out	   from	   the	  pSP72	  CKS	  FLAG	  Tag	  constructs	   using	   EcoRI	   and	   XhoI	   restriction	   enzymes	   and	   cloned	   into	   the	   EcoRI/XhoI	  restriction	  site	  of	  the	  pBABE	  sin	  tet	  PURO	  vector	  (Figure	  3.2	  B).	  	  
2.5.2.3	  Additional	  constructs	  for	  induced	  protein	  expression	  The	  tetracycline	  inducible	  activator	  was	  expressed	  via	  the	  MSCV	  M2rtTA	  HYGRO,	  which	  was	   provided	   by	   Ana	   Banito	   (Cell	   Proliferation	   Group,	   CSC	   MRC).	   The	   pLV-­‐tTRKRAB	  NEO	   was	   coding	   for	   the	   tetracycline	   responsive	   repressor	   and	   was	   provided	   by	   the	  Didier	  Trono	  laboratory	  (École	  polytechnique	  fédérale	  de	  Lausanne).	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2.5.3	  Transformation	  of	  Escherichia	  Coli	  For	  cloning	  and	  plasmid	  recovery,	  chemically	  competent	  Escherichia	  coli	  (E.	  coli)	  strain	  DH5α	  was	  used.	  A	  stock	  of	  competent	  cells	  was	  obtained	  as	  follow:	  E.	  coli	  were	  picked	  and	  a	  starter	  culture	  was	  grown	  in	  5	  ml	  lysogeny	  broth	  (LB)	  overnight	  at	  37˚C.	  1	  ml	  of	  starter	  culture	  was	  added	  to	  500	  ml	  LB	  and	  the	  culture	  was	  grown	  until	  an	  OD595	  nm	  of	  0.375	   to	   0.5	   was	   reached.	   Cells	   were	   centrifuged	   at	   4˚C	   for	   5	   minutes	   at	   4000	   g.	  Resulting	  pellets	  were	  resuspended	  in	  ice	  cold	  0.1	  M	  CaCl2	  and	  incubated	  on	  ice	  for	  20	  minutes.	   Cells	  were	   centrifuged	   again,	   resuspended	   in	   10.5	  ml	   ice	   cold	   	   0.1	  M	   CaCl2	  ,	  22%	  (v/v)	  glycerol	  and	  dispensed	  in	  100	  µl	  aliquots.	  Aliquots	  were	  snap	  frozen	  on	  dry	  ice	  and	  stored	  at	  -­‐80˚C.	  	  	   For	   transformation,	   competent	   cells	   were	   thawed	   on	   ice	   and	   mixed	   with	   the	  ligation	  product	  (see	  below)	  or	  10	  ng	  of	  plasmid	  DNA	  by	  gently	  flicking	  the	  tube.	  Cells	  were	   then	   incubated	  30	  min	  on	   ice,	  heat	  shocked	   for	  40	  seconds	   in	  a	  42˚C	  water	  bath	  and	  returned	  to	  ice	  for	  another	  5	  minutes.	  500	  µl	  of	  LB	  medium	  without	  antibiotics	  was	  added	   and	   the	   transformation	  mixture	  was	   grown	   for	   1	   hour	   at	   37˚C.	   Approximately	  100	  µl	  of	  each	  transformation	  was	  spread	  on	  LB	  agar	  plates	  containing	  the	  appropriate	  antibiotic.	   Plates	   were	   incubated	   overnight	   at	   37˚C	   and	   several	   colonies	   were	   picked	  and	  grown	  in	  2	  ml	  of	  LB	  medium	  containing	  antibiotics	  overnight.	  Ampicillin	  was	  used	  for	   all	   vectors	   described	   at	   a	   concentration	   of	   100	   µg/ml.	   To	   verify	   cloning,	   plasmid	  DNA	   was	   extracted,	   digested	   with	   appropriate	   restriction	   enzymes	   to	   check	   for	   the	  correct	   insert	   and	   sequenced.	   To	   obtain	   a	   sufficient	   amount	   of	   plasmid	   for	   retroviral	  infections	  of	   IMR90,	  2	  ml	  cultures	  were	  added	  to	  250	  ml	  LB	  broth	  medium	  containing	  the	   appropriate	   amount	   of	   antibiotics	   and	   grown	   at	   37˚C	   with	   shaking	   at	   150	   rpm	  overnight.	  	  
2.5.4	  Plasmid	  DNA	  Extraction	  from	  Escherichia	  coli	  From	  2	  ml	  overnight	  cultures	  1	  ml	  was	  pelleted	  in	  1.5	  ml	  eppendorf	  tubes	  and	  plasmid	  DNA	   was	   extracted	   using	   the	   YORBIO	   Plasmid	   DNA	   Purification	   Kit.	   Buffers	   and	  Columns	   provided	   with	   the	   kit	   were	   used	   and	   DNA	   was	   isolated	   according	   to	  manufacturer’s	  instructions,	  based	  on	  a	  modified	  alkaline	  lysis	  procedure.	  	   250	  ml	  overnight	  cultures	  were	  pelleted	  by	  centrifugation	  at	  6000	  g	  for	  15	  min	  at	  4˚C.	  Plasmid	  DNA	  was	  then	  purified	  using	  the	  Qiagen	  HiSpeed®	  Plasmid	  Purification	  kit.	  The	  purification	  protocol	   is	   also	  based	  on	  a	  modified	  alkaline	   lysis	  procedure.	  Briefly,	  cell	   pellets	   were	   resuspended	   in	   buffer	   P1	   containing	   EDTA	   to	   protect	   DNA	   from	  degrading	   enzymes	   and	   RNase	   to	   remove	   contaminating	   RNA.	   Lysis	   of	   the	   cells	   was	  achieved	  by	  adding	  an	  alkaline	  lysis	  buffer	  P2	  containing	  SDS.	  Pre-­‐chilled	  neutralisation	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buffer	   P3	   was	   added	   to	   renature	   plasmid	   DNA	   and	   precipitate	   genomic	   DNA	   and	  proteins.	   The	   soluble	   fraction	   containing	   the	   plasmid	   DNA	   was	   applied	   to	   an	   anion-­‐exchange	   resin.	   Impurities	   were	   removed	   by	   washing	   the	   resin	   with	   isopropanol-­‐containing	  buffer	  QC.	  Plasmid	  DNA	  was	  eluted	  from	  the	  column	  using	  a	  high	  salt	  buffer	  QF	   with	   a	   pH	   of	   8.5.	   The	   DNA	   was	   precipitated	   from	   the	   high	   salt	   solution	   with	  Isopropanol,	  collected	  using	  the	  QIAprecipitator	  and	  eluted	  from	  the	  precipitator	  with	  a	  Tris-­‐EDTA	  buffer.	  DNA	  concentration	  was	  determined	  by	  measuring	  the	  absorbance	  at	  260	  nm	  (A260)	  with	  a	  NanoDrop®	  ND-­‐1000	  UV-­‐Vis	  spectrophotometer.	  	  
2.5.5	  PCR	  PCR	   was	   performed	   in	   25	   µl	   of	   1x	   Phusion	   HF	   buffer	   using	   0.4	   units	   of	   Phusion	  polymerase	   (New	   England	   Biolabs),	   0.5	   µM	   primers	   and	   200	   µM	   dNTPs	   (Roche)	   and	  	  	  	  20	  ng	  of	  the	  desired	  plasmid	  as	  template	  DNA.	  	  The	  reaction	  took	  place	  in	  a	  DNA	  Engine	  Dyad	  Peltier	  Thermal	  Cycler	  (Bio	  Rad)	  using	  the	  appropriate	  program	  (see	  above).	  For	  cloning	  purposes	  the	  PCR	  reactions	  of	  6	  reaction	  tubes	  were	  combined	  and	  cleaned	  using	  the	  QIAquick	  PCR	  Purification	  Kit	  (Qiagen).	  The	  kit	  contains	  silica-­‐gel-­‐membrane	  columns,	  which	  bind	  DNA	  in	  the	  presence	  of	  a	  high	  salt	  binding	  buffer.	  First,	  5	  volumes	  of	   the	  binding	  buffer	  PB	  were	  added	  to	   the	  combined	  PCR	  products.	  The	  solution	  was	  mixed	  by	   inverting	   the	   tube	  and	   transferred	   to	   the	   silica-­‐gel-­‐membrane	  column.	  After	  spinning	  the	  column	  for	  15	  seconds	  at	  high	  speed	  the	  flow-­‐through	  was	  discarded	  and	  700	  µl	  of	  washing	  buffer	  PE	  was	  added	  then	  centrifuged	  for	  1	  minute.	  The	  flow	  through	  was	   discarded	   and	   the	   column	  was	   centrifuged	   again	   for	   1	  minute.	   The	   purified	  DNA	  was	  eluted	  with	  42	  µl	  of	  buffer	  EP.	  	  
2.5.6	  Restriction	  enzyme	  digest	  PCR	  products	  and	  target	  vectors	  were	  digested	  with	  restriction	  enzymes	  to	  receive	  the	  desired	   overhanging	   basepairs.	   All	   enzymes	   used	   were	   obtained	   from	   New	   England	  Biolabs	   (NEB)	   and	   the	   appropriate	   reaction	   buffer	   was	   chosen	   according	   to	   the	  recommendation	   provided	   by	  NEB.	   Digestion	   of	   5	   µg	   of	   vector	   DNA	   or	   PCR	   products	  were	  performed	  in	  50	  µl	  of	  the	  appropriate	  buffer	  supplemented	  with	  40	  units	  of	  each	  enzyme	  for	  the	  recommended	  time	  at	  37˚C.	  	   To	  avoid	  self-­‐ligation	  of	  the	  resulting	  ends	  of	  the	  vector,	  the	  phosphate	  group	  of	  the	  5’	  end	  of	  the	  vector	  was	  removed	  by	  adding	  6.5	  units	  of	  antarctic	  phosphatase	  with	  the	  corresponding	  buffer	  (NEB),	  incubated	  for	  30	  minutes	  at	  37˚C.	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2.5.7	  Agarose	  gel	  electrophoresis	  To	  analyse	  PCR	  product	  size	  and	  separate	  the	  products	  of	  a	  restriction	  enzyme	  digest,	  DNA	   was	   subjected	   to	   electrophoresis	   using	   1%	   agarose	   gels.	   Electrophoresis	   was	  performed	  in	  1xTAE	  (diluted	  from	  50x	  stock:	  2	  M	  Tris-­‐acetate,	  50	  mM	  EDTA,	  pH8.0)	  at	  a	  constant	   100	   volts	   in	  Mini	   Sub	  GT	   tanks	   (Biorad).	  DNA	  was	   visualised	  using	   the	  DNA	  intercalator,	  ethidium	  bromide,	  and	  a	  Geldoc	  transilluminator	  (Biorad).	  	  
2.5.8	  DNA	  recovery	  following	  agarose	  gel	  electrophoresis	  Resolved	   DNA	   fragments	  were	   visualised	   using	   UV	   light.	   The	   desired	   DNA	   fragments	  were	  excised	  from	  the	  Gel	  and	  the	  DNA	  extracted	  from	  the	  Gel	  using	  the	  QIAquick	  Gel	  Extraction	  Kit	  (Qiagen).	  This	  involves	  first	  dissolving	  the	  agarose	  gel	  in	  three	  volumes	  of	  buffer	   QG	   at	   50˚C	   for	   10	   minutes	   followed	   by	   binding	   of	   the	   DNA	   to	   a	   silica-­‐gel-­‐membrane	  similar	  to	  the	  membranes	  used	  in	  the	  PCR	  purification	  kit.	  Further	  clean	  up	  of	  the	  DNA	  was	  performed	  as	  described	  for	  the	  purification	  of	  PCR	  products.	  	  
2.6	  Analysis	  of	  gene	  expression	  
2.6.1	  RNA	  extraction	  from	  IMR90	  fibroblasts	  RNA	   extraction	   was	   performed	   using	   TRIzol	   reagent	   (Ambion).	   The	   method	   used	   is	  based	   on	   the	   guanidium	   thiocyanate-­‐phenol-­‐chloroform	   extraction	   first	   described	   by	  Piotr	  Chomczynski	  (Chomczynski	  and	  Sacchi,	  1987).	  TRIzol	  is	  an	  acidic	  phenol	  solution	  containing	  guanidinium	   isothiocyanate.	  Guanidinium	   isothiocyante	  denatures	  proteins	  including	  RNases.	  After	  adding	  chloroform	  to	  the	  acidic	  phenol	  and	  a	  centrifugation	  step	  RNA	  resides	  in	  the	  resulting	  upper	  aqueous	  phase.	  	  	   For	   RNA	   isolation,	   cells	   were	   plated	   on	   6	   cm	   culture	   dishes	   and	   grown	   until	  approximately	  70%	  confluent.	  Cells	  were	  homogenised	  by	  adding	  1	  ml	  of	  TRIzol	  and	  the	  resulting	  suspension	  was	  transferred	  to	  an	  eppendorf	  tube.	  Chloroform	  was	  added	  and	  the	  mixture	   vortexed,	   incubated	   for	   3	  minutes	   and	   centrifuged	   for	   15	  minutes	   at	   4°C	  and	  highest	  speed.	  The	  RNA-­‐containing	  aqueous	  phase	  was	  transferred	  into	  a	  new	  tube	  and	   precipitated	   by	   adding	   400	   µl	   of	   isopropanol	   and	   incubating	   at	   -­‐20°C	   overnight.	  RNA	  was	  pelleted	  by	  centrifugation	  for	  30	  minutes	  at	  highest	  speed	  and	  4°C.	  The	  pellet	  was	  washed	  with	  75%	  ethanol	  and	  resuspended	  in	  RNase	  free	  water.	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2.6.2	  Quantitative	  RT	  PCR	  	  Quantitative	  PCR	  was	  carried	  out	  using	  SensiMix	  One-­‐Step	  (Quantace)	  as	  directed	  in	  the	  accompanying	   manual.	   The	   SensiMix	   buffer	   contains	   the	   reverse	   transcriptase	   for	  cDNA-­‐synthesis	   from	   mRNA,	   the	   DNA-­‐polymerase,	   nucleotides	   and	   magnesium.	  Additionally	  provided	  were	  SYBR	  Green	   I	   solution,	  which	   is	   incorporated	  during	  DNA	  synthesis	   and	   a	   RNase	   inhibitor.	   In	   a	   20	   µl	   reaction,	   10	   ng	   of	   RNA	   was	   added	   plus	  primers	  at	  a	  final	  concentration	  of	  200nM.	  The	  primers	  used	  for	  determination	  of	  CKS	  expression	  were:	  	  CKS1	  Forward:	  CTAGCAAACCGAGCGATCAT	  CKS1	  Reverse:	  TTTAGGGACCAGCTTGGCTA	  CKS2	  Forward:	  CCCAAAACTCATCTGATGTCC	  CKS2	  Reverse:	  TGGAAGAGGTCGTCTAAAGAGAA	  	  Thermocycling	   was	   performed	   using	   the	   BioRad	   CFX	   96	   Real	   Time	   system	   C1000	  Thermal	  Cycler	  and	  the	  following	  conditions:	  	  cDNA	  synthesis:	  50°C	  30	  min	  	  Initial	  denaturing:	  95°C	  15	  s	  Denaturing:	  94°C	  15	  s	  	  Annealing:	  60°C	  30	  s	  Elongation:	  72°C	  30	  s	  Plate	  read	  Melting	  curve	  	  	  
2.6.3	  Protein	  extraction	  Cells	  were	  washed	  once	  with	  ice	  cold	  PBS,	  scraped	  from	  the	  culture	  dish	  by	  using	  1	  ml	  of	   PBS	   per	   10	   cm	   dish	   and	   briefly	   centrifuged.	   	   Lysis	   of	   the	   resulting	   cell	   pellet	   was	  performed	  using	  lysis	  buffer	  (50	  mM	  Tris-­‐Cl	  pH	  8.0	  (Sigma	  Aldrich),	  0.5%	  Nonidet	  P-­‐40	  (NP-­‐40,	   Roche),	   0.1%	   EDTA	   (Sigma	   Aldrich),	   10%	   glycerol	   (BDH)	   and	   protease	  inhibitors	  (Complete	  EDTA-­‐free,	  Roche).	  Protein	  concentrations	  were	  determined	  using	  the	  RC	  DC	  Protein	  Assay	  kit	  (Bio	  rad),	  which	  is	  based	  on	  the	  Lowry	  protocol	  (Lowry	  et	  
40	  times	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al.,	  1951)	  and	  measured	  with	  the	  Nanodrop	  1000	  Spectrophotometer	  using	  the	  Lowry	  protocol	  of	  the	  ND-­‐1000	  V3.3.1	  Software.	  	  
2.6.4	  SDS-­‐PAGE	  Electrophoresis	   was	   performed	   using	   the	   discontinuous	   buffer	   system	   introduced	   by	  Laemmli	  (Laemmli,	  1970).	  Samples	  corresponding	  to	  40	  µg	  of	  proteins	  were	  prepared	  by	  adding	  5x	  Laemmli	  buffer	  (1x	  Laemmli	  buffer	  final	  concentration:	  60	  mM	  Tris-­‐Cl	  	  pH	  6.8,	  2%	  SDS	  (Sigma	  Aldrich),	  10%	  glycerol,	  5%	  2-­‐Mercaptoethanol	  (Sigma	  Aldrich)	  and	  0.01%	  bromophenol	  blue	  (Sigma	  Aldrich))	  and	  boiling	  it	  for	  5	  minutes.	  The	  samples	  were	   loaded	   into	   the	  wells	   of	   the	   gel	   and	  proteins	  were	   separated	  using	   100	   volts	   to	  allow	  stacking	  of	  proteins	  and	  constant	  130	  volts	  thereafter	  until	  appropriate	  resolution	  was	   achieved.	   All	   SDS-­‐PAGE	  was	   performed	   using	   the	  Mini-­‐Protean®	   electrophoresis	  system	  from	  Bio-­‐Rad.	  	  
2.6.5	  Western	  blot	  analysis	  The	   protocol	   used	   for	   transfer	   and	   blotting	   was	   based	   on	   the	   original	   technique	  described	  by	  Towbin	  and	  Burnette	  (Burnette,	  1981;	  Towbin	  et	  al.,	  1979).	  The	  transfer	  was	   performed	   using	   the	   Mini-­‐PROTEAN®	   transfer	   system	   from	   Bio-­‐Rad	   with	  Tris/Glycine	   transfer	   buffer	   (25	   mM	   Tris,	   192	   mM	   glycine	   (Sigma	   Aldrich),	   10%	  methanol	   (Fisher	   Scientific),	   0.1%	  SDS).	   Proteins	  were	   electrophoretically	   transferred	  for	   1.5	   hours	   to	   a	   Hybond-­‐P	   PVDF	   membrane	   (GE	   Healthcare)	   using	   a	   constant	   100	  volts.	  Membranes	  were	  blocked	  for	  1	  to	  2	  hours	  in	  blocking	  solution	  (5%	  skimmed	  milk	  and	  0.1%	  Tween-­‐20	  (Sigma	  Aldrich)	  in	  PBS)	  and	  probed	  with	  primary	  antibodies	  (Table	  2a)	  overnight	  at	  4˚C	  in	  blocking	  solution.	  After	  4	  washes	  with	  PBS-­‐tween	  (0.1%	  Tween	  in	  PBS)	  for	  5	  minutes	  at	  room	  temperature	  HRP-­‐conjugated	  secondary	  antibody	  (Table	  2b)	   incubation	   was	   conducted	   for	   1	   hour	   at	   room	   temperature	   in	   blocking	   solution.	  Following	  a	  further	  4x5	  minute	  washes	  in	  PBS,	  antibody	  bound	  proteins	  were	  detected	  using	  ECL	  Plus	  reagents	  and	  exposed	  to	  Hyperfilm-­‐ECL	  from	  GE	  Healthcare.	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Table	  2a	  Primary	  antibodies	  for	  Westen	  blot	  and	  immunofluorescence	  analysis	  	  
Antibody	   Clone	   Source	   Company	   Concentra-­‐tion	  in	  WB	  anti-­‐CKS1/2	  (FL79)	   poly	   rabbit	   Santa	  Cruz	   1:250	  anti-­‐γ-­‐tubulin	  (T3559)	   poly	   rabbit	   Sigma	  Aldrich	   1:2000	  anti-­‐Flag	   M2	   mouse	   Sigma	  Aldrich	   1:500	  anti-­‐Telomerase	  reverse	   poly	   rabbit	   Abcam	   1:250	  anti-­‐p21Cip1	   P1484	   mouse	   Sigma	  Aldrich	   1:500	  anti-­‐p53	   DO-­‐1	   mouse	   Santa	  Cruz	   1:250	  anti-­‐p16INK4a	   JC8	   mouse	   Santa	  Cruz	   -­‐	  Anti-­‐BrdU	   3H579	   rat	   Santa	  Cruz	   -­‐	  anti-­‐PCNA	   PC10	   mouse	   Cell	  Signalling	   1:1000	  anti-­‐cyclin	  A	  (H-­‐432)	   poly	   rabbit	   Santa	  Cruz	   1:250	  anti-­‐cyclin	  B1	   GNS1	   mouse	   Santa	  Cruz	   1:250	  anti-­‐cyclin	  D1	  (H-­‐295)	   poly	   rabbit	   Santa	  Cruz	   1:250	  anti-­‐cyclin	  E	   E-­‐4	   mouse	   Santa	  Cruz	   1:250	  anti-­‐CDK2	   poly	   rabbit	   Santa	  Cruz	   1:500	  anti-­‐RPA32/RPA2	   9H8	   mouse	   Abcam	   1:500	  anti-­‐MCM2	  (d7g11)	   poly	   rabbit	   Cell	  Signalling	   1:1000	  anti-­‐γH2AX	   JBW301	   mouse	   Milipore	   1:250	  anti-­‐p27Kip1	  (C-­‐19)	   poly	   rabbit	   Santa-­‐Cruz	   1:500	  	  	  	  	  Table	  2b	  Secondary	  antibodies	  for	  Westen	  blot	  
	  
Antibody	   Source	   Company	   Concentra-­‐tion	  in	  WB	  HRP	  conjugated	  anti-­‐mouse	   goat	   Santa	  Cruz	   1:250	  HRP	  conjugated	  anti-­‐rabbit	   goat	   Sigma	  Aldrich	   1:2000	  HRP	  conjugated	  anti-­‐goat	   donkey	   Sigma	  Aldrich	   1:500	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2.7	  Analysis	  of	  CDK2	  activity	  
2.7.1	  Transfection	  of	  HEK	  293T	  cells	  293T	   cells	   were	   transiently	   transfected	   using	   polyethylenimine	   (PEI).	   Here	   the	   poly-­‐cation	   PEI	   forms	   positively	   charged	   complexes	   with	   the	   DNA,	   which	   should	   be	  integrated	   into	   the	   cell	   (Boussif	   et	   al.,	   1995).	   These	   complexes	   bind	   to	   anionic	   cell	  surface	  components	  and	  are	   taken	  up	  by	   the	  cell	  via	  endocytosis.	  For	   the	   transfection	  confluent	   293T	   cells	  were	   split	   1:4	   in	   10	   cm	   culture	  dishes.	   The	   transfection	   solution	  was	   prepared	   by	  mixing	   20	   µg	   of	   vector	   (pBABE	   CKS1	   PURO,	   pBABE	   CKS2	   PURO	   or	  empty	  pBABE	  PURO)	  with	  1	  ml	  of	  serum-­‐free	  DMEM	  and	  75	  µl	  of	  PEI	  and	  incubating	  it	  for	  20	  minutes.	  The	  PEI-­‐DNA	  solution	  was	  added	  drop	  wise	  to	  the	  cells.	  Cells	  were	  then	  kept	   as	   usual	   at	   37°C,	   5%	   CO2	   overnight	   before	   the	   medium	   was	   changed	   and	   cells	  harvested	  for	  protein	  isolation,	  immune	  precipitation	  and	  kinase	  assay	  the	  same	  day.	  	  
2.7.2	  Transduction	  of	  IMR90	  cells	  IMR90	   cells	   used	   for	   kinase	   assay	   experiments	   were	   virally	   transduced	   with	   pBABE	  CKS1	  PURO,	  pBABE	  CKS2	  PURO	  and	  empty	  pBABE	  PURO	  as	  described	  before.	  The	  day	  after	  infection	  with	  the	  retroviral	  supernatant,	  cells	  were	  either	  harvested	  immediately	  for	   further	   processing	   or	   kept	   in	   puromycin	   containing	  medium	   for	   additional	   seven	  days.	  	  
2.7.3	  Immunoprecipitation	  
CKS1,	   CKS2	   or	   empty	   vector	   pBABE	   PURO	   transduced	   IMR90	   and	   293Tcells	   were	  cultured	   in	   10	   cm	  dishes	   and	   harvested	   at	   different	   time	   points	   after	   transformation.	  Therefore	  cells	  from	  one	  plate	  were	  washed	  with	  5	  ml	  ice-­‐cold	  PBS	  and	  collected	  with	  	  	  1	  ml	  PBS	  using	  a	  cell	   scraper.	  Cells	  were	   then	  pelleted	  by	  centrifugation	  at	  2000	  g	   for	  	  	  	  	  1	   minute.	   Cells	   were	   resuspended	   in	   approximately	   2	   to	   5	   times	   the	   volume	   of	   the	  resulting	   cell	   pellet	   of	   ice	   cold	  RIPA	  buffer	   (50	  mM	  Tris-­‐HCl	   pH	  8,	   150	  mM	  NaCl,	   1%	  Triton	   X	   100,	   0.5%	   sodium	   deoxycholate,	   0.1%	   SDS,	   1	  mM	   EDTA,	   complete	   protease	  inhibitor	   tablets	   (Roche,	   1	   tablet/50	   ml)).	   Cells	   were	   lysed	   in	   RIPA	   buffer	   for	  approximately	  15	  minutes	  on	  ice	  and	  subsequently	  centrifuged	  at	  4˚C	  at	  16	  000	  g	  for	  10	  minutes.	  The	  total	  cell	  extract,	  which	  was	  present	  in	  the	  supernatant,	  was	  collected	  and	  an	  aliquot	  was	  frozen	  down	  for	  further	  analysis	  by	  Western	  blotting	  (WB).	  The	  protein	  concentration	  was	  measured	  using	   the	  RC	  DC	  Protein	  Assay	  kit	   (Bio	  Rad).	  1	  µg	  of	   the	  desired	  antibody	  was	  added	  to	  1	  µg	  of	  cell	  lysate	  (for	  cyclin	  A-­‐CDK2	  CoIP:	  Anti-­‐cyclin	  A;	  for	  cyclin	  E-­‐CDK2	  CoIP:	  Anti-­‐cyclinE).	  The	  mixture	  was	  rotated	  slowly	  for	  2	  hours	  at	  4˚C.	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30	  µl	  of	  protein	  G	  coated	  magnetic	  beads	  (Dynabeads,	  Invitrogen)	  were	  added	  and	  the	  mixture	  was	  rotated	  again	  for	  1h	  at	  4˚C	  to	  allow	  the	  conjugation	  of	  the	  antibodies	  to	  the	  beads.	   The	   protein-­‐bound	   beads	  were	  washed	   three	   times	   in	   RIPA	   buffer	   and	   finally	  resuspended	  in	  30	  µl	  of	  1	  x	  reaction	  buffer	  A	  (provided	  with	  the	  CDK2-­‐cyclin	  A	  Kinase	  Enzyme	  System;	  Promega).	  Kinase	   assays	  were	  performed	   immediately	   after	   immune	  precipitation	  and	  an	  aliquot	  was	  frozen	  down	  to	  determine	  the	  amount	  of	  CDK2	  bound	  to	  the	  cyclins	  via	  Western	  blot.	  	  
2.7.4	  Kinase	  assay	  Kinase	  assays	  were	  performed	  using	  the	  ADP-­‐GloTM	  Kinase	  Assay	  Kit	  (Promega).	  Here,	  the	   kinase	   activity	   is	   measured	   by	   the	   amount	   of	   ADP,	   which	   is	   produced	   during	   a	  kinase	   reaction.	   Histone	   H1	   is	   used	   as	   a	   substrate	   for	   the	   immunoprecipitated	   CDK2	  complex.	   In	   the	   assay	   the	   kinase	   converts	   added	   ATP	   into	   ADP.	   After	   the	   reaction	   is	  stopped,	   remaining	   ATP	   is	   depleted.	   Then	   the	   ADP	   is	   converted	   into	   ATP,	   which	   is	  measured	  using	  a	  luciferase/luciferin	  reaction	  in	  which	  ATP	  is	  necessary	  as	  cofactor.	  	  	   The	   assay	   was	   performed	   by	   following	   the	   instructions	   provided	   with	   the	   kit.	  Briefly,	  reactions	  were	  set	  up	  in	  a	  white	  96	  well	  plate.	  In	  a	  first	  step	  the	  components	  for	  the	  kinase	  reaction	  were	  added	  to	  the	  plate	  consisting	  of	  the	  following	  in	  a	  final	  volume	  of	  25	  µl:	  10	  µl	  of	   the	   immunoprecipitated	  kinase	  complex	  or	  10	  µl	  of	  1	  ng/µl	  purified	  active	   CDK2-­‐cyclin	   A	   as	   positive	   control	   (CDK2-­‐cyclin	   A2	   Kinase	   Enzyme	   System,	  Promega),	   5	   µl	   of	   1	   mg/ml	   Histone	   H1	   (CDK2-­‐cyclin	   A2	   Kinase	   Enzyme	   System,	  Promega),	  5	  µl	  of	  2xbuffer	  (CDK2-­‐cyclin	  A2	  Kinase	  Enzyme	  System,	  Promega)	  and	  5	  µl	  of	  250	  µM	  ATP	   in	  1xbuffer.	   	  The	  reaction	  was	   incubated	   for	  15	  minutes	  at	  30˚C	  while	  shaking.	  To	  terminate	  the	  reaction	  and	  deplete	  the	  remaining	  ATP,	  25	  µl	  of	  ADP-­‐GloTM	  Reagent	  was	  added	  and	   incubated	   for	  another	  40	  minutes	  at	  room	  temperature	  while	  shaking.	  For	  the	  luciferase	  reaction	  50	  µl	  of	  kinase	  detection	  reagent	  was	  added	  and	  the	  reaction	  mixture	  was	  incubated	  for	  30	  minutes	  at	  room	  temperature	  while	  shaking.	  The	  Luminescence	   was	   measured	   on	   a	   GloMax®	   Microplate	   Luminometer	   (Promega)	   by	  using	  the	  Kinase-­‐GloTM	  Luminescence	  Protocol.	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Chapter	  3	  -­‐	  Induced	  expression	  of	  CKS	  proteins	  in	  IMR90	  
fibroblasts	  using	  a	  Tet-­‐On	  expression	  system	  	  CKS	  proteins	  were	  to	  be	  over-­‐expressed	  in	  fibroblasts	  to	  study	  the	  role	  of	  CKS	  in	  cancer	  development	   and	   to	   investigate	   the	   molecular	   processes,	   which	   lead	   to	   a	   possible	  advantage	  of	  CKS	  expression	  in	  cancer	  cells.	  Over-­‐expression	  was	  to	  be	  achieved	  by	  viral	  transduction	  using	  retroviral	  vectors	  containing	  CKS.	  	   Vectors	  generally	  used	  for	  the	  stable	  over-­‐expression	  of	  proteins	  carry	  a	  selection	  marker,	  which	  confers	  resistance	  against	  a	  selection	  agent	  in	  a	  successfully	  transfected	  cell.	  	  Cells	   transduced	   with	   the	   desired	   viral	   construct	   need	   to	   be	   selected	   for	   this	  marker.	  When	   using	   regular	   viral	   transfection	   vectors	   the	   protein	   of	   interest	   is	   over-­‐expressed	   during	   this	   selection	   process.	   If	   any	   cellular	   toxicity	   is	   associated	  with	   the	  over-­‐expression	   of	   the	   target	   protein	   this	  will	   effectively	   be	   a	   selection	   disadvantage,	  thereby	  significantly	  complicating	  the	  selection	  of	  stably	  over-­‐expressing	  cells.	  	  	   An	   initial	   test	  using	   the	  retroviral	  vector	  pBABE	   for	   the	  stable	  over-­‐expression	  of	  
CKS	   resulted	   in	   growth	   arrest	   of	   the	   transduced	   IMR90	   fibroblasts	   (see	   Chapter	   4).	  Thus,	  a	  stable	  over-­‐expression	  of	  CKS	  proteins	  and	  a	  possible	  oncogenic	  effect	  on	  cells	  caused	   by	   CKS	   impairs	   the	   study	   of	   the	   early	   events	   upon	   elevation	   of	   CKS	   protein	  levels.	  	  	   An	  inducible	  system	  was	  introduced	  to	  overcome	  the	  complications	  of	  CKS-­‐related	  toxicity	   during	   selection	   of	   transfected	   cells	   and	   to	   facilitate	   the	   study	   of	   the	   early	  events	  upon	  elevation	  of	  CKS	  protein	   levels.	  The	  expression	  of	   the	   target	  protein	  was	  inducible	   via	   the	   addition	   of	   doxycycline.	   This	   allowed	   for	   selection	   to	   take	   place	  without	  immediate	  over-­‐expression	  of	  CKS	  and	  has	  the	  advantage	  that	  CKS	  is	  expressed	  only	  during	  the	  course	  of	  the	  desired	  experiment.	  	  
3.1	  TetO	  FUW	  ZEOCIN	  For	  the	  controlled	  induction	  of	  CKS	  proteins	  a	  Tet-­‐On	  inducible	  system	  was	  generated.	  
CKS1,	  CKS2,	  the	  non	  CDK	  binding	  mutants	  CKS1E63Q	  and	  CKS2E63Q	  as	  well	  as	  the	  anion	  binding	   site	  mutants	  CKS1AM	   and	  CKS2AM	  were	   cloned	   into	   the	   TetO	   FUW	   vector	   as	  described	   in	   Material	   and	   Methods.	   The	   TetO	   FUW	   vector	   contains	   a	   Tetracycline	  responsive	  promoter	  element	  (TRE).	  The	  TRE	  contains	  seven	  direct	  repeats	  of	  the	  tetO	  operator	  sequence,	  upstream	  from	  a	  minimal	  CMV	  promoter.	  This	  sequence	  is	  derived	  from	   Tet-­‐operons	   in	   bacteria,	   which	   confer	   resistance	   against	   antibiotics	   from	   the	  tetracycline	   family,	   such	   as	   doxycycline.	   Only	   in	   the	   presence	   of	   doxycycline	   do	   the	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bacteria	   transcribe	   the	  necessary	   efflux	  protein	   responsible	   for	   the	   resistance.	   This	   is	  due	  to	  Tet	  repressors	  (TetR),	  which	  are	  bound	  as	  homodimers	  to	  the	  tetO	  sequence	  in	  the	  absence	  of	  doxycycline,	  blocking	  the	  function	  of	  the	  promoter	  and	  thus	  suppressing	  expression	   of	   the	   efflux	   protein	   gene	   (Hillen	   and	  Berens,	   1994;	  Welman	   et	   al.,	   2007).	  Binding	  of	  doxycycline	  to	  the	  TetR	  homodimer	  changes	  its	  conformation,	  which	  leads	  to	  a	  lower	  affinity	  of	  the	  repressor	  towards	  tetO	  and	  transcription	  can	  take	  place.	  Another	  Tet	   repressor,	   rTetR,	   whose	   binding	   properties	   were	   the	   reverse	   of	   TetR	   was	  subsequently	   identified	   (Berens	   and	   Hillen,	   2003).	   The	   rTetR	  would	   bind	   to	   the	   tetO	  sequence	   in	   the	   presence	   of	   doxycyline	   but	   not	   in	   its	   absence.	   And	   by	   fusion	   of	   a	  transcription	  activating	  domain	  to	  the	  rTetR,	  a	  reverse	  activator	  (rtTA)	  was	  engineered,	  which	   would	   activate	   gene	   expression	   in	   the	   presence	   of	   doxycycline	   (Gossen	   and	  Bujard,	  1992;	  Gossen	  et	  al.,	  1995).	  	  	   In	  the	  constructed	  CKS-­‐expressing	  TetO	  FUW	  vectors,	  the	  cloned	  CKS	  constructs	  are	  under	  the	  control	  of	  the	  CMV	  promoter,	  which	  is	  in	  turn	  controlled	  by	  the	  Tetracycline	  responsive	  element	  (Figure	  3.1	  A	  and	  B).	  	  	   The	  Vector	  bears	  a	   zeocin	   resistance	   for	   stable	   selection	   in	  mammalian	  cells.	  The	  reverse	   transactivator	   M2rtTA	   is	   used	   to	   induce	   CKS	   expression	   (Figure	   3.1	   A).	   In	  comparison	  to	  rtTA,	  M2rtTA	  is	  more	  sensitive	  to	  doxycycline,	  more	  stable	  in	  eukaryotic	  cells	  and	  shows	  a	  reduced	  basal	  activity	  (Urlinger	  et	  al.,	  2000).	  	  	   Cells	   were	   first	   transduced	   with	   a	   vector	   containing	   M2rtTA	   (MSCV	   M2rtTA	  HYGRO),	  selected	  for	  the	  appropriate	  period	  of	  time	  with	  hygromycin	  and	  subsequently	  transduced	   with	   the	   TetO	   FUW	   CKS	   ZEOCIN	   constructs.	   Due	   to	   the	   high	   number	   of	  cycles	  of	  cell	  growth	  and	  division	  associated	  with	  the	  two	  stable	  selection	  processes	  to	  produce	   the	   inducible	   protein-­‐expressing	   cell	   lines,	   immortalised	   IMR90	   fibroblasts	  with	   an	   introduced	   telomerase	   function,	   IMR90	   TERT,	  were	   used	   as	   the	   parental	   cell	  line.	   After	   the	   transduction	   of	   IMR90	   TERT	   M2rtTA	   cells	   with	   the	   TetO	   FUW	   CKS	  ZEOCIN	   vector,	   cells	   were	   selected	   for	   about	   three	   weeks	   in	   the	   presence	   of	   zeocin.	  Zeocin	  is	  a	  member	  of	  the	  bleomycin/phleomycin	  family	  of	  antibiotics.	   It	   is	  thought	  to	  intercalate	   into	   DNA	   and	   cleave	   it	   (Oliva-­‐Trastoy	   et	   al.,	   2005).	   During	   and	   after	   the	  selection	   process,	   cells,	   which	   were	   successfully	   transduced	   with	   TetO	   FUW	   CKS	  ZEOCIN	  were	  viable.	   	  Nevertheless,	  zeocin	  selection	   led	  to	  a	  remarkable	  change	   in	   the	  appearance	  of	  the	  IMR90	  TERT	  cells	  (Figure	  3.1	  C).	  Cells	  became	  elongated	  and	  formed	  spindle-­‐shaped	   branches	   at	   low	   levels	   of	   zeocin	   (25	   µg/ml).	   This	   phenotype	   became	  more	  profound	  at	  high	  levels	  of	  zeocin.	  The	  toxicity	  of	  zeocin	  despite	  the	  used	  selection	  resistance	   gene	   has	   been	   previously	   described	   in	   human	   cells	   (Oliva-­‐Trastoy	   et	   al.,	  2005).	  To	   test	   the	   functionality	  of	   the	  CKS	   induction	  via	  doxycycline,	   cells,	   selected	   in	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medium	   containing	   low	   levels	   of	   zeocin,	  were	   treated	   for	   48	   hours	  with	   10	   µg/ml	   of	  doxycycline	   (Figure	   3.1	   D).	  Without	   doxycycline	   the	   IMR90	   TERT	  M2rtTA	   TetO	   FUW	  CKS1	  and	  CKS2	  cells	  showed	  already	  a	  basal	  expression	  of	  CKS	  proteins.	  Upon	  induction	  with	  doxycycline,	  CKS1	  expression	  could	  slightly	  be	  increased.	  Cells	  transduced	  with	  the	  CKS2	   construct	   showed	   a	   higher	   level	   of	   induction.	   Due	   to	   the	   high	   sensitivity	   of	   the	  cells	   to	   zeocin	   as	   well	   as	   the	   observed	   background	   expression,	   the	   inducible	   system	  needed	  further	  optimization.	  	  
Figure	  3.1	  Using	  the	  TetO-­‐FUW	  vector	  with	  the	  zeocin	  selection	  marker	  for	  the	  induced	  expression	  of	  
CKS	  proteins	  results	  in	  cell	  stress	  for	  IMR90	  TERT	  cells.	  (A)	  Model	  displaying	  the	  mechanism	  by	  which	  
CKS	   is	   expressed	   using	   a	   Tet-­‐On	   inducible	   expression	   system:	   the	   reverse	   transactivator	   M2rtTA	   is	  transcribed.	  In	  the	  presence	  of	  doxycycline,	  M2rtTA	  binds	  as	  homodimer	  to	  the	  tetO	  sequence	  of	  the	  TetO	  FUW	  vector	  and	  activates	  the	  transcription	  of	  the	  inserted	  CKS	  constructs	  via	  the	  CMV	  promoter.	  (B)	  Map	  depicting	  the	  TetO	  FUW	  ZEOCIN	  vector	  with	   inserted	  CKS	  constructs	  (total	  size:	  8655	  bp).	  (C)	  Brightfield	  images	  showing	  the	  phenotype	  of	  IMR90	  TERT	  cells,	  which	  were	  cultured	  for	  7	  days	  in	  medium	  containing	  different	   concentrations	   of	   Zeocin.	   (D)	   Western	   blot	   showing	   the	   CKS	   expression	   in	   IMR90	   TERT	   cells	  transduced	  with	  TetO	  FUW	  ZEOCIN	  CKS,	   selected	  and	  kept	   in	  medium	  containing	  a	   low	  concentration	  of	  Zeocin.	  CKS	  expression	  was	  assessed	  after	  adding	  doxycyline	  for	  48	  h.	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3.2	  pBABE	  sin	  tet	  PURO	  	   	   	   	   	   	  In	   retroviral	   vectors,	   the	   expression	   cassette	   is	   flanked	   by	   the	   virus’	   long	   terminal	  repeats	  (LTR).	  In	  the	  corresponding	  virus,	  these	  5’	  and	  3’	  LTR	  embed	  the	  viral	  genome.	  They	   are	   necessary	   for	   the	   integration	   of	   the	   dsDNA,	  which	   results	   from	   the	   reverse	  transcription	  of	  viral	  RNA,	  into	  the	  host	  chromosome.	  They	  are	  also	  the	  control	  centre	  for	   viral	   gene	   expression	   and	   contain,	   for	   example,	   the	   viral	   enhancer	   and	   promoter	  sequences	  (Uren	  et	  al.,	  2005).	  	  	   In	  Tet-­‐On	  inducible	  retroviral	  expression	  vectors,	  activation	  of	  transcription	  occurs	  via	   the	   reverse	   activator	   binding	   to	   the	   tetO	   operator	   sequence.	   In	   the	   absence	   of	  doxycycline	   the	   reverse	   activator	   does	   not	   bind	   the	   operator	   sequence.	   Therefore	  transcription	  of	  the	  target	  protein	  is	  not	  activated	  via	  this	  promoter.	  Transcription	  can	  still	   occur	   to	   a	   certain	   degree	   via	   the	   LTR	   flanking	   the	   cassette.	   To	   inhibit	   this	  transcription,	   vectors	  were	   developed	   in	  which	   the	   enhancer	   and	   promoter	   region	   of	  the	  3’-­‐LTR	  are	  deleted.	  Upon	  transcription	  of	  the	  viral	  genome,	  reverse	  transcription	  of	  the	  resulting	  mRNA	  and	  integration	  of	  the	  DNA	  copy	  into	  the	  host	  cell	  genome,	  5’	  and	  3’	  LTR	  do	  not	  contain	  the	  promoter	  sequence	  anymore	  and	  the	  genes	  of	  interest	  have	  to	  be	  expressed	   from	   internal	   promoters.	   This	   deletion	   also	   minimises	   the	   possibility	   that	  cellular	   oncogenes	   in	   proximity	   to	   the	   integrated	   virus	   DNA	   could	   be	   transactivated.	  Vectors,	   in	  which	  the	  expression	  of	  genes	  is	   inactivated	  by	  the	  deletion	  of	  LTR	  regions	  are	  called	  self	  inactivating	  (sin)	  vectors	  (Yu	  et	  al.,	  1986).	  	  	   To	   decrease	   the	   leaky	   expression	   of	   CKS	   proteins	   in	   the	   absence	   of	   doxycycline,	  pBABE	  sin	   tet	  PURO	  was	  chosen	  as	   retroviral	  expression	  vector.	  Here,	   the	  cloned	  CKS	  genes	  are	  under	  the	  control	  of	  the	  CMV	  promoter,	  which	  is	  in	  close	  proximity	  to	  the	  tetO	  operator	  sequence	  (Figure	  3.2	  A	  and	  B).	  A	  reverse	  activator	  activates	  CKS	  expression	  in	  the	   presence	   of	   doxycycline.	   To	   further	   inhibit	   residual	   leaky	   expression	   of	   the	   CKS	  proteins	  in	  the	  absence	  of	  doxycycline,	  cells	  were	  also	  transduced	  with	  a	  vector	  coding	  for	  a	  tetracycline	  controlled	  transcriptional	  silencer	  (tTRKRAB).	  The	  silencer	  is	  a	  fusion	  of	   a	   Tet	   repressor	   and	   the	   potent	   repressor	   domain	   KRAB	   (Krüppel	   associated	   box),	  derived	  from	  the	  human	  kidney	  protein	  Kid-­‐1	  (Freundlieb	  et	  al.,	  1999).	  In	  the	  resulting	  system,	  tTRKRAB	  binds	  to	  tetO	  in	  the	  absence	  of	  doxycycline	  and	  represses	  the	  activity	  of	   the	  adjacent	  CMV	  promoter.	  Conversely,	   in	   the	  presence	  of	  doxycycline	   the	   reverse	  activator	  M2rtTA	  engages	  with	  the	  tetO	  sites	  and	  the	  promoter	  is	  activated	  (Figure	  3.2	  A).	  	   IMR90	   TERT	   cells	   were	   first	   transduced	  with	  MSCV	   Hygro	  M2RtTA,	   followed	   by	  pLV-­‐tTRKRAB	  and	   finally	  with	   the	  pBABE	  sin	   tet	  CKS	  PURO	  constructs.	  Each	  round	  of	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viral	   transduction	   was	   followed	   by	   selection	   of	   stably	   transduced	   cells	   with	   the	  selection	  agent	   to	   the	   transduction	  marker	   from	   the	  most	   recently	  added	  vector.	  This	  took	   place	   over	   a	   time	   period	   shown	   to	   allow	   for	   complete	   selection	   of	   stably	  transduced	   cells	   over	   cells	   that	   are	  not	   (table	   1).	   The	  pBABE	  PURO	  vector	   is	   selected	  using	   puromycin,	   which	   allows	   cells	   to	   be	   selected	   relatively	   quickly	   and	   is	   in	  comparison	  to	  zeocin,	  well	  tolerated	  by	  cells	  bearing	  the	  resistance	  marker.	  	   To	  test	   the	  efficiency	  of	   this	   inducible	  system,	   IMR90	  TERT	  sin	   tet	  CKS	  cells	  were	  treated	   with	   increasing	   concentrations	   of	   doxycycline.	   After	   48	   hours	   cells	   were	  collected	   and	   CKS	   expression	   was	   evaluated	   by	  Western	   blot	   analysis	   (Figure	   3.2	   C).	  Almost	  no	  ectopic	  CKS	  expression	  was	  observed	  in	  the	  absence	  of	  doxycyline.	  In	  CKS1,	  CKS1E63Q	  and	  CKS2	   IMR90	  TERT	   cells	   1	   µg	  per	  ml	   of	   doxycycline	   led	   to	   a	  moderate	  expression	  of	  CKS	  proteins	  with	  CKS1	  cells	   showing	   the	  most	  pronounced	  expression.	  The	   expression	   of	   protein	   increases	   with	   the	   doxycycline	   concentration,	   effectively	  peaking	  at	  a	  concentration	  of	  4	  µg	  per	  ml	  of	  doxycycline	  or	  higher.	  Cells	  transduced	  with	  
CKS2E63Q	   bearing	   constructs	   had	   little	   or	   no	   expression	   of	   the	   protein	   even	   after	  induction	  with	  8	  µg	  of	  doxycycline.	  Thus	  pBABE	  sin	  tet	  CKS2E63Q	  PURO	  was	  not	  used	  for	   further	   analysis.	   As	   4	   µg	   of	   doxycycline	   induced	   peak	   protein	   expression	   all	  subsequent	   experiments	   were	   performed	   using	   this	   concentration	   for	   CKS	   induction.	  Next	  the	  ectopic	  CKS	  expression	  upon	  induction	  was	  observed	  over	  a	  period	  of	  five	  days.	  Doxycycline	  was	  added	  at	  timepoint	  0	  and	  cells	  were	  collected	  for	  protein	  isolation	  and	  analysis	  at	  8	  hour	  timepoints.	  At	  48	  and	  96	  hours	  the	  medium	  was	  changed	  and	  fresh	  medium	  with	  doxycycline	   added.	  Moderate	  CKS	   expression	  was	  observed	   at	   16	  hours	  post	  induction,	  with	  the	  level	  of	  CKS	  expression	  increasing	  with	  time	  until	  peaking	  at	  48	  hours	   (Figure	   3.2	   D).	   At	   the	   point	   that	   new	   media	   with	   doxycycline	   is	   added,	   there	  appeared	   to	   be	   a	   slight	   decrease	   in	   CKS	   expression,	   but	   levels	   were	   generally	   stable	  thereafter.	  	  	   In	  IMR90	  cells	  transduced	  with	  vectors	  for	  stable	  CKS	  expression,	  cell	  growth	  was	  impaired	   to	   a	   high	   degree	   (see	   Chapter	   4).	   Next,	   I	   tested	  whether	   IMR90	   TERT	   cells	  transduced	  with	  the	  pBABE	  sin	  tet	  CKS	  showed	  the	  same	  phenotype	  upon	  CKS	  induction	  as	   observed	   in	   the	   stably	   CKS	   expressing	   IMR90	   cells.	   Therefore	   the	   proliferation	   of	  untreated	   IMR90	  TERT	   cells	  was	   compared	   to	   IMR90	  TERT	   cells,	  which	  were	   treated	  with	  doxycycline	   for	   the	   induction	  of	  CKS	   expression.	  Protein	  expression	  was	   induced	  for	   48	   hours	   and	   cells	   were	   plated	   for	   the	   various	   assays	   performed	   to	   determine	  proliferative	  capacity	  (Figure	  3.2	  E).	  A	  BrdU	  uptake	  assay	  did	  not	  show	  any	  difference	  in	  the	   amount	   of	   cells,	   which	   were	   actively	   proliferating	   after	   the	   induction	   of	   CKS	  expression.	   In	   a	   colony	   formation	   assay	   no	   difference	   in	   the	   proliferative	   potential	   of	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CKS	  induced	  and	  non-­‐induced	  cells	  could	  be	  observed	  as	  well.	  This	  was	  confirmed	  using	  40	   µg/ml	   instead	   of	   4	   µg/ml	   of	   doxycycline	   to	   induce	   CKS	   expression	   (Supplemental	  figure	   7.1).	   Thus	  CKS	   induction	   in	   cells	   transduced	  with	   the	   inducible	   system	  did	   not	  lead	  to	  growth	  arrest.	  	   Growth	  arrest	  is	  induced	  by	  checkpoint	  proteins	  upon	  the	  activation	  of	  oncogenes.	  To	   see	   whether	   checkpoints	   were	   activated	   in	   this	   setting,	   cells	   were	   treated	   with	  doxycycline	   for	   5	   days,	   fixed	   and	   stained	   for	   checkpoint	   proteins.	   Here	   p21Cip1	   was	  chosen	   as	   representative	   growth	   arrest	   inducing	   checkpoint	   protein	   (Figure	   3.2	   F).	   A	  large	   up-­‐regulation	   of	   p21Cip1	   was	   observed	   in	   CKS	   induced	   cells.	   30%	   of	   cells	   over-­‐expressing	  CKS2	  and	  twice	  as	  many	  CKS1	  over-­‐expressing	  cells	  were	  p21Cip1	  positive.	  In	  contrast	  almost	  no	  p21Cip1	  positive	  non-­‐induced	  cells	  were	  observed.	  The	  discrepancy	  of	  induced	   expression	   of	   CKS	   proteins	   up-­‐regulating	   p21Cip1	   checkpoint	   proteins	   but	   not	  resulting	   in	   growth	   arrest	   in	   IMR90	   cells	  might	   be	   due	   to	   the	   process	   in	  which	   these	  cells	  were	  generated.	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  Figure	  3.2	  Using	  pBABE	  sin	  tet	  PURO	  for	  the	  induced	  expression	  of	  CKS	  proteins	  in	  IMR90	  TERT	  cells	  
ensures	  a	  good	  expression	  of	  recombinant	  CKS	  proteins	  and	  results	  in	  p21Cip1	  activation.	  (A)	  Model	  showing	  the	  mechanism	  by	  which	  CKS	  is	  expressed	  using	  a	  Tet-­‐On	  inducible	  expression	  system	  including	  a	  Tet	  reverse	  activator	  and	  a	  Tet	  repressor:	  In	  the	  absence	  of	  doxycycline	  the	  Tet	  repressor	  tTRKRAB	  would	  bind	   as	   homodimer	   to	   the	   tetO	   sequence	   of	   pBABE	   sin	   tet	   PURO	  whereas	   the	   reverse	   activator	  M2rtTA	  would	  not	  be	  able	  to	  bind.	  Thus	  the	  transcription	  of	  the	  tetO-­‐CMV-­‐promoter	  regulated	  gene	  is	  suppressed.	  When	  doxycycline	  binds	  to	  the	  activator	  as	  well	  as	  the	  repressor,	  both	  change	  their	  conformation.	  tTRKRAB	  is	   no	   longer	   able	   to	   bind	   to	   the	   tetO-­‐CMV	   promoter	   of	   pBABE	   sin	   tet	   PURO	   and	   can	   not	   inhibit	   the	  transcription	  of	  the	  inserted	  CKS	  construct.	  Additionally	  binding	  of	  M2rtTA	  to	  the	  tet	  responsive	  promoter	  element	  activates	  the	  expression	  of	  CKS.	  (B)	  Map	  displaying	  the	  pBABE	  sin	  tet	  PURO	  vector	  with	  inserted	  CKS	  constructs	  (Total	  size:	  5867	  bp).	  (C,	  D)	  Western	  blot	  analyses	  showing	  the	  expression	  of	  CKS	  proteins	  in	  IMR90	  TERT	  cells	  transduced	  with	  the	  pBABE	  sin	  tet	  CKS	  constructs.	  CKS	  expression	  was	  induced	  with	  increasing	  concentrations	  of	  doxycycline	  for	  48	  h	  (C).	  Additionally	  the	  CKS	  expression	  was	  monitored	  over	  a	  period	  of	  120	  h	  (D).	  For	  this	  purpose	  the	  medium	  containing	  4	  µg/ml	  of	  doxycycline	  was	  changed	  every	  48	  h.	   (E)	  The	  proliferative	  capacity	  of	   IMR90	  TERT	  CKS	  cells	  was	  assessed	  via	  crystal	  violet	   staining	  and	  BrdU	  incorporation	  assay.	  pBABE	  sin	  tet	  CKS	  PURO	  transduced	  IMR90	  TERT	  cells,	  in	  which	  CKS	  expression	  was	  induced	  and	  non-­‐induced	  control	  cells	  were	  seeded	  at	  a	  low	  density	  and	  stained	  with	  crystal	  violet	  two	  weeks	   later.	   Images	  of	   stained	   cells	   (left)	  were	   acquired	  and	   the	   staining	  was	  quantitatively	   analysed	  by	  dissolving	  the	  crystal	  violet	  dye	  with	  acetic	  acid	  and	  measuring	  the	  absorbance	  as	  indicated	  in	  Material	  and	  Methods.	  The	  absorbance	  representing	  the	  non	  induced	  Empty	  Vector	  control	  was	  set	  as	  one	  (upper	  panel).	  To	   assess	   the	   percentage	   of	   actively	   replicating	   cells,	   IMR90	   TERT	   CKS	   cells	   were	   incubated	  with	   BrdU	  overnight	  and	   stained	  with	  an	  anti	  BrdU	  antibody	   thereafter	   (lower	  panel)	   Images	  of	  BrdU	  positive	   cells	  were	   acquired	   using	   the	   IN	   Cell	   Analyzer	   1000.	   The	   percentage	   of	   positive	   cells	   was	   assessed	   via	   high	  content	  analysis	  as	  described	  in	  Material	  and	  Methods.	  (F)	  To	  test	  for	  checkpoint	  activation	  by	  induced	  CKS	  expression,	   IMR90	  TERT	  CKS	  cells	  were	  subjected	   to	   immunofluorescence	  using	  an	  antibody	  recognizing	  p21Cip1.	  Left	  panels	  show	  representative	  images	  of	  cells	  subjected	  to	  immunofluorescence	  5	  days	  after	  CKS	  protein	   induction	  using	  4	  µg/ml	  of	  doxycycline	  or	   left	  untreated	  respectively.	  Percentage	  of	  positive	  cells	  was	  determined	  by	  high	  content	  analysis	  as	  described	  in	  the	  methods.	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Primary	   IMR90	   cells	  were	   first	   transduced	  with	   pWZL	   hTERT	   BLASTICIDIN,	   selected	  and	   expanded.	   This	   process	  was	   repeated	  with	  MSCV	  M2rtTA	   HYGRO,	   pLV	   tTRKRAB	  NEO	  and	  pBABE	  sin	   tet	  CKS	  PURO	  constructs.	   In	  each	  of	   these	  steps	  alterations	   in	   the	  cellular	  genome	  can	   lead	  to	  changes	   in	   the	  checkpoint	  pathways.	  Abrogation	  of	  a	   fully	  functional	   checkpoint	   pathway	   has	   been	   previously	   shown	   for	   hTERT	   transduced	  human	  fibroblasts.	  In	  one	  example,	  in	  VH25	  hTERT	  fibroblasts	  p53	  was	  shown	  to	  be	  up-­‐regulated	  during	   later	  passages	  without	  cell	   cycle	  arrest	   (van	  Waarde-­‐Verhagen	  et	  al.,	  2006).	  	   To	   avoid	   possible	   alterations	   in	   the	   checkpoint	   pathways,	   the	   long	   process	   of	  consecutive	  rounds	  of	  stable	  transfection	  and	  subsequent	  selection	  was	  shortened	  to	  a	  minimum.	   To	   achieve	   that,	   primary	   IMR90	   cells	   were	   directly	   cotransduced	  with	   the	  minimal	   amount	   of	   constructs	   necessary	   for	   induced	   CKS	   expression,	   namely	   MSCV	  M2rtTA	  HYGRO	   and	   pBABE	   sin	   tet	   CKS	   PURO.	   Following	   a	   selection	   process	   of	   three	  weeks,	  the	  resulting	  cells	  were	  treated	  in	  the	  same	  way	  as	  described	  before	  for	  IMR90	  TERT	  sin	  tet	  CKS	  cells.	  After	  the	  induction	  with	  4	  µg/ml	  of	  doxycycline	  for	  5	  days,	  cells	  were	   subjected	   to	   immunofluorescence	   staining	   to	   determine	   their	   level	   of	   p21Cip1	  expression.	   No	   up-­‐regulation	   of	   p21Cip1	   expression	   was	   observed	   in	   these	   fibroblasts	  following	   induced	   expression	   of	   CKS1	   or	   CKS2,	   contrasting	   with	   the	   induced	   p21Cip1	  expression	   shown	  previously	   in	   the	   IMR90	  TERT	   sin	   tet	   CKS	   cells	   (Figure	   3.3	  A).	  Up-­‐regulation	  of	  the	  checkpoint	  protein	  and	  transcriptional	  activator	  of	  p21Cip1,	  p53	  as	  well	  as	  cell	  cycle	  arrest	  could	  also	  not	  be	  observed	  (Supplemental	   figure	  7.2).	  Western	  blot	  analysis	   showed	   a	   satisfactory	   up-­‐regulation	   of	   CKS1	   proteins	   after	   48	   hours	   of	  incubation	  in	  doxycycline	  containing	  medium	  (Figure	  3.3	  B).	  Up-­‐regulation	  of	  CKS2	  was	  lower	  than	  expected.	  Immunofluorescence	  staining	  with	  an	  anti-­‐CKS	  antibody	  revealed	  however	   that	   only	   45%	   of	  CKS1	   and	   26%	   of	  CKS2	   transduced	   cells	  were	   positive	   for	  high	   CKS	   levels	   (Figure	   3.3	   C).	   It	   therefore	   appears	   that	   transducing	   the	   IMR90	   cells	  with	   the	   various	   vectors	   of	   the	   inducible	   system	   resulted	   in	   a	   heterogeneous	   cell	  population,	   where	   despite	   all	   the	   transduced	   cells	   being	   resistant	   to	   the	   selection	  markers	   not	   all	   of	   the	   resulting	   cells	   could	   express	   CKS	   proteins	   when	   treated	   with	  doxycycline.	  This	  could	  be	  due	  to	  the	  silencing	  of	  the	  inserted	  CKS	  construct	  in	  some	  of	  the	  population.	  Heterogeneous	  induction	  of	  CKS	  expression	  may	  also	  have	  impacted	  on	  the	  cell	  proliferation	  studies	  reported	  here.	  It	  is	  possible	  that	  variable	  expression	  of	  CKS	  proteins	  resulted	  in	  variable	  expression	  of	  checkpoint	  proteins,	  such	  as	  p21Cip1,	  amongst	  the	  whole	  cell	  population.	  In	  some	  cells,	  p21Cip1	  may	  have	  caused	  growth	  arrest,	  but	  this	  could	  have	  been	  masked	  by	  cells	  where	  CKS	  proteins	  were	  not	  expressed	  or	  expressed	  in	  insufficient	  quantities,	  allowing	  them	  to	  continue	  to	  proliferate.	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  Figure	   3.3	   Transduction	   of	   primary	   IMR90	   fibroblasts	   with	   pBABE	   sin	   tet	   CKS	   results	   in	   a	  
heterogeneous	  cell	  population	  regarding	  CKS	  expression.	  (A)	  IMR90	  cells	  transduced	  with	  pBABE	  sin	  tet	   CKS	   PURO	   were	   kept	   in	   medium	   either	   with	   or	   without	   doxycycline,	   fixed	   and	   stained	   for	   p21Cip1	  thereafter.	   (B)	   CKS	   over-­‐expression	   in	   pBABE	   sin	   tet	   CKS	   PURO	   transduced	   IMR90	   was	   confirmed	   by	  Western	   blot	   analysis	   after	  CKS	   expression	  was	   induced	  with	   different	   concentrations	   of	   doxycycline	   for	  	  	  48	   h.	   (C)	   The	   percentage	   of	   IMR90	   CKS	   cells	   expressing	   a	   high	   level	   of	   CKS1	   or	   CKS2	   respectively	   was	  assessed	  by	  immunofluorescence	  staining	  with	  an	  antibody	  against	  both	  human	  paralogs	  of	  CKS.	  (A	  and	  C)	  Representative	   images	  of	   immunofluorescence	  stainings,	  which	  were	  performed	  5	  days	  after	   induction	  of	  the	  cells	  with	  4	  µg/ml	  of	  doxycycline,	  are	  shown	   in	   the	   left	  panel.	   Images	  were	  acquired	  with	   the	   IN	  Cell	  Analyzer	   1000	   and	   quantitatively	   evaluated	   using	   high	   content	   analysis	   as	   described	   in	   Material	   and	  Methods.	  Resulting	  graphs	  are	  shown	  in	  the	  right	  panel.	  Scale	  bar,	  10	  µm.	  	  	  To	  avoid	  a	  heterogeneous	  population	  of	  IMR90	  cells	  regarding	  the	  ability	  to	  express	  CKS	  proteins,	  possible	  genetic	  variations	  of	  the	  cells	  which	  might	  have	  occurred	  during	  the	  infection	   and	   selection	   process	   should	   be	   minimised.	   To	   obtain	   a	   homologues	   cell	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population	   IMR90	  TERT	  sin	   tet	  CKS1	  cells	  were	  produced	  by	   transfecting	   IMR90	  cells	  with	  the	  appropriate	  vectors	  and	  selecting	  for	  successfully	  transfected	  cells	  as	  described	  before.	  After	  the	  selection	  process	  cells	  were	  seeded	  at	  a	  very	  low	  density	  to	  enable	  the	  outgrowth	  of	   single	   clones	   containing	   cells	  with	   the	   same	  genetic	   background.	   Clones	  were	  picked	  and	  cultured	  for	  several	  weeks	  until	  cell	  numbers	  were	  sufficient	  to	  test	  for	  
CKS	   induction.	   Cells	  were	   treated	  with	   doxycycline	   for	   5	   days	   and	  CKS	   induction	  was	  determined	  via	   immunofluorescence	  staining	   (Figure	  3.4	  A).	  None	  of	   the	   isolated	   four	  clones	  tested	  showed	  a	  homogeneous	  up-­‐regulation	  of	  CKS	  proteins	  upon	  induction.	  In	  two	   clones	   no	   up-­‐regulation	   of	   CKS	   proteins	   could	   be	   observed	   at	   all,	   while	   in	   the	  remaining	  two	  clones	  only	  a	  quarter	  or	  a	  third	  of	  the	  cells	  expressed	  high	  levels	  of	  CKS.	  No	  up-­‐regulation	  of	  p21Cip1	  was	  observed	  in	  any	  of	  the	  four	  clones	  (Figure	  3.4	  B).	  	  
	  Figure	  3.4	  Clones	  picked	  from	  pBABE	  sin	  tet	  CKS	  PURO	  transduced	  IMR90	  TERT	  fibroblasts	  also	  give	  
rise	   to	   heterogeneous	   populations.	   IMR90	   TERT	   cells	  were	   virally	   transfected	  with	   the	   CKS1	   bearing	  inducible	  constructs	  and	  selected	  with	  puromycin.	  Clones	  were	  picked	  and	  cultured.	  The	  resulting	  cell	  lines	  (CKS	  I,	   II,	   III	  and	  IV),	  were	  kept	   in	  medium	  containing	  no	  or	  4	  µg/ml	  of	  doxycycline	   for	  5	  days,	   fixed	  and	  objected	   to	   immunofluorescence	   staining	   with	   antibodies	   recognising	   CKS	   (A)	   and	   p21Cip1	   (B).	  Representative	   images	   are	   shown	   in	   the	   left	   panel.	   Graphs	   showing	   the	   percentage	   of	   CKS	   or	   p21Cip1	  positive	  cells	  respectively	  are	  given	  in	  the	  right	  panel.	  Intensity	  thresholds	  determining	  positive	  cells	  were	  set	  and	  percentage	  of	  positive	  cells	  determined	  using	   the	   IN	  Cell	  Analyzer	  1000	  software	  as	  described	   in	  Material	  and	  Methods.	  Scale	  bar,	  10	  µm.	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Previously,	   the	  ability	  of	   induced	  CKS	  proteins	   to	  stimulate	  p21Cip1	   checkpoint	  protein	  expression	  was	  analysed	  as	  a	  percentage	  of	  the	  total	  population	  of	  cells.	  However,	  it	  is	  possible	   that	   the	  relationship	  between	  CKS	  protein	  expression	  and	  checkpoint	  protein	  expression	   might	   be	   stronger	   in	   the	   subset	   of	   the	   heterogeneous	   cells	   that	   strongly	  express	   the	   CKS	   proteins	   when	   induced.	   To	   examine	   this,	   cells	   were	   treated	   with	  doxycycline	   for	   five	  days,	   fixed	  and	  double	   stained	   for	  CKS	  and	  p21Cip1	   (Figure	  3.5	  A).	  Approximately	  one	  third	  of	  fibroblasts	  showed	  an	  up-­‐regulation	  of	  CKS1.	  Whereas	  only	  18%	  of	   the	   cells	   in	   the	   total	   cell	   population	  were	  p21Cip1	  positive	   (upper	   right	  panel),	  32%	  of	   the	   cells	  with	   up-­‐regulated	   CKS1	   levels	  were	   positive	   for	   p21Cip1	   (lower	   right	  panel).	   In	   contrast	  only	  11%	  of	   cells	  were	  p21Cip1	  positive	   in	   the	  CKS	  negative	   subset.	  15%	  of	  all	  IMR90	  TERT	  cells	  transduced	  with	  the	  pBABE	  sin	  tet	  CKS2	  vector	  and	  treated	  with	  doxycycline	  were	  positive	  for	  p21Cip1.	  In	  the	  CKS2	  positive	  subset,	  32%	  of	  the	  cells	  and	   in	   the	   CKS2	   negative	   subset	   only	   10%	   of	   the	   cells	   showed	   an	   up-­‐regulation	   of	  p21Cip1.	  Additionally,	  levels	  of	  p53,	  a	  checkpoint	  protein	  acting	  upstream	  of	  p21Cip1,	  were	  investigated	  (Figure	  3.5	  B).	  After	  CKS	  induction	  in	  IMR90	  TERT	  sin	  tet	  CKS1	  cells,	  37%	  of	  the	  cells	  were	  p53	  positive.	  The	  proportion	  of	  p53	  positive	  cells	  was	  48%	  in	  the	  CKS1	  positive	  subset	  and	  24%	  in	  the	  CKS1	  negative.	  In	  IMR90	  TERT	  sin	  tet	  CKS2	  cells	  30%	  of	  all	   cells	   were	   p53	   positive.	   Almost	   half	   of	   the	   CKS2	   positive	   cells	   were	   p53	   positive	  whereas	   in	   only	   14%	  of	   the	  CKS2	  negative	   cells	   the	  p53	  pathway	  was	   activated.	   This	  result	  indicates	  that	  the	  cells,	  which	  were	  transduced	  with	  the	  vectors	  of	  the	  inducible	  system	  and	  in	  which	  CKS	  is	  strongly	  expressed,	  act	  as	  anticipated	  and	  were	  more	  likely	  to	  express	  both	  p21Cip1	  and	  p53	  checkpoint	  proteins.	  Using	  a	  method,	  which	  enables	  the	  identification	   of	   the	   subset	   of	   cells	   high	   in	   CKS,	   would	  make	   it	   possible	   to	   study	   the	  effect	  of	  high	  levels	  of	  CKS	  proteins	  in	  a	  heterogeneous	  population.	  In	  conclusion,	  high	  levels	  of	  CKS	  expression	  result	   in	  an	  increase	  of	  p21Cip1	  and	  p53	  expression.	  The	  high-­‐content	   image	  analysis	  method	  that	  I	  developed	  and	  describe	  here,	  allows	  for	  the	  first	  time	   to	   assess	   the	   role	   of	   CKS1	   in	   tumour	   progression	   at	   a	   single-­‐cell	   level.	   This	  technique	  overcomes	  problems	  with	  cell	  population	  heterogeneity	  and	  addresses	  these	  questions	  in	  a	  physiological	  context,	  i.e.	  primary	  fibroblasts.	  It	  remains	  to	  be	  shown	  how	  hTERT	  expression	  –	  which	  was	  necessary	  to	  achieve	  the	  described	  inducible	  expression	  –	  contributes	   to	   the	  observed	  phenotypes.	  One	  possibility	   is	   that	  expression	  of	  hTERT	  overcomes	  CKS-­‐induced	  growth	  arrest.	  	  In	   the	   following	   chapters,	   a	   possible	   oncogenic	   effect	   of	   CKS	   proteins	   in	   IMR90	  fibroblasts	   is	   studied	   in	   more	   detail.	   This	   includes	   the	   influence	   of	   CKS	   proteins	   on	  growth	   and	   cell	   cycle	   of	   the	   whole	   cell	   population.	   Therefore	   it	   was	   important	   to	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perform	   growth	   analyses	   using	   a	   homologous	   population	   rather	   than	   a	   subset	   of	   a	  heterogeneous	   population.	   Thus	   the	   formation	   of	   a	   heterogeneous	   cell	   population	  regarding	  CKS	  levels	  should	  be	  avoided.	  The	  approach	  used	  to	  prevent	  this	  was	  the	  use	  of	   IMR90	   fibroblasts	   shortly	   after	   they	   were	   stably	   transfected	   with	   pBABE	   CKS	  constructs	  and	  express	  CKS	  in	  a	  continuous	  manner.	  	  
	  Figure	  3.5	  The	  population	  of	   IMR90	  TERT	  cells	   expressing	  high	   levels	  of	  CKS	   upon	   induction	  with	  
doxycycline	  displays	  a	  higher	  percentage	  of	  cells	  positive	  for	  checkpoint	  proteins.	  After	  the	  induction	  of	  CKS	   expression	   in	   IMR90	  TERT	  CKS	  cells	   for	  5	  days	  with	  4	  µg/ml	  of	  doxycycline,	   cells	  were	   fixed	  and	  stained	   for	   CKS	   (Alexa	   Fluor	   594)	   and	   p21Cip1	   (Alexa	   Fluor	   488)	   (A)	   or	   CKS	   (Alexa	   Fluor	   594)	   and	   p53	  (Alexa	  Fluor	  488)	  respectively	  (B).	  The	  percentage	  of	  CKS	  positive	  cells	  as	  well	  as	  p21Cip1	  or	  p53	  positive	  cells	  was	  identified	  using	  high	  content	  analysis	  as	  described	  in	  Material	  and	  Methods	  and	  presented	  in	  the	  according	  upper	  right	  panel.	  Additionally,	  the	  percentage	  of	  cells	  double	  positive	  for	  CKS	  and	  p21Cip1	  or	  CKS	  and	  p53	  as	  well	   as	  of	   cells	  negative	   for	  CKS	  but	  positive	   for	  p21Cip1	   or	  p53	  was	  determined	   (lower	   right	  panel).	  Scale	  bar,	  10	  µm.	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3.3	  Discussion	  To	   study	   the	   effect	   of	   CKS	   over-­‐expression	   in	   normal	   fibroblasts	   a	   system	   for	   the	  regulated	  expression	  of	  CKS	  proteins	  was	   to	  be	  established.	  The	  aim	  was	   to	  create	  an	  IMR90	   fibroblast	   cell	   line	   in	   which	   the	   expression	   of	   CKS	   proteins	   could	   be	   induced	  within	  a	  short	  period	  of	  time.	  This	  would	  facilitate	  the	  analysis	  of	  immediate	  and	  direct	  effects	  of	  high	   levels	  of	  CKS	  proteins	   in	  primary	   fibroblasts.	   Initial	  analysis	  performed	  with	   fibroblasts	   constitutively	   expressing	   CKS	   proteins	   revealed	   that	   their	   expression	  impairs	  cell	  growth.	  Thus,	  a	  constant	  expression	  might	  not	  be	  tolerated	  and,	  if	  possible,	  evaded	  by	  the	  cells	  (counterselection).	  This	  process	  occurs	  when	  the	  protein	  of	  choice	  is	  expressed	   during	   the	   process	   of	   selection	   after	   viral	   transduction	   with	   the	   vectors	  coding	   for	   the	   respective	   protein	   as	   well	   as	   for	   the	   selection	   marker	   and	   could	   be	  circumvented	  when	   the	  protein	  would	  be	  not	  present	  or	   inactive	  during	   the	   selection	  and	   culturing	  process.	  A	  more	  practical	   advantage	  of	   an	   inducible	   system	   is	   that	   cells	  can	  be	  expanded	  to	  the	  number	  needed	  in	  experiments	  after	  introducing	  the	  inducible	  vector	  and	  transfection	  of	  a	  huge	  number	  of	  cells	  with	  stable	  expression	  vectors	  can	  be	  avoided.	  	  	   Here	   a	   system	  was	   chosen,	   in	   which	   the	   treatment	   of	   cells	   with	   the	   tetracycline	  derivate	   doxycycline	   induces	   the	   expression	   of	   CKS	   proteins.	   This	   Tet-­‐On	   inducible	  system	  is	  based	  on	  the	  activation	  of	  transcription.	  Doxycycline	  binds	  to	  and	  changes	  the	  conformation	  of	  the	  activator	  M2rtTA,	  which	  thereafter	  is	  able	  to	  bind	  the	  tetracycline	  responsive	  element	  within	  the	  promoter	  regulating	  the	  expression	  of	  the	  desired	  gene.	  	  Both,	   M2rtTA	   activator	   and	   the	   actual	   construct	   containing	   the	   CKS	   gene	   under	   the	  control	   of	   the	   tetracycline	   responsive	   element	   containing	   CMV	   promoter	   were	  introduced	   into	   IMR90	   fibroblasts	   by	   transduction.	   This	   had	   the	   advantage	   that	   the	  delivery	  efficiency	   is	  high,	   the	  desired	  gene	   is	  directly	   integrated	   into	   the	  genome	  and	  thus	   long	   outgrowth	  periods	   of	   single	   clones	   are	   not	   necessary.	   The	   inducible	  Tet-­‐On	  vector	   (TetO-­‐FUW)	   used	   initially	   in	   hTERT	   immortalised	   IMR90	   fibroblasts,	   carries	   a	  zeocin	  selection	  marker	  and	  cells	  had	  to	  be	  selected	  for	  approximately	  three	  weeks.	  The	  long	   selection	   process	   is	   a	   probable	   reason	   for	   the	   stressed	   phenotype	   of	   the	   IMR90	  TERT	   cells.	   Zeocin	  binds	   and	   cleaves	  DNA	  and	  has	  been	  described	   to	  be	   toxic	   to	   cells	  even	  when	   they	   do	   express	   the	   resistance	  marker	   Sh	   ble,	   which	   binds	   to	   zeocin	   and	  prevents	   it	   from	   binding	   to	   the	   DNA	   (Oliva-­‐Trastoy	   et	   al.,	   2005).	   The	   suboptimal	  selection	  process	  might	  also	  have	  favoured	  the	  basal	  expression	  of	  ectopic	  CKS	  proteins,	  which	  was	  observed	  in	  IMR90	  TERT	  TetO	  FUW	  CKS	  ZEOCIN	  cells	  before	  the	  induction	  with	  doxycycline.	  A	  rather	   long	  period	  of	  selection	  and	  DNA	  damage	  could	  have	  led	  to	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the	   alteration	   of	   the	   regulatory	   element	   responsible	   for	   transcription	   of	   the	   CKS	  proteins.	  In	  a	  next	  step	  toxicity	  and	  leakiness	  was	  reduced	  by	  replacing	  the	  TetO	  FUW	  CKS	  ZEOCIN	  vector	  by	  the	  pBABE	  sin	  tet	  CKS	  PURO	  vector,	  which	  contains	  a	  puromycin	  selection	  marker.	   	  Puromycin,	  which	   inhibits	  protein	   translation,	   acts	  quicker	  on	   cells	  that	  do	  not	  bear	  the	  selection	  marker	  unlike	  zeocin.	  Thus	  long	  periods	  of	  cells	  in	  culture,	  which	  would	  allow	  ageing	  and	  alterations	  of	  the	  genome,	  are	  avoided.	  Furthermore	  cells	  bearing	  the	  resistance	  gene	  are	  viable	  and	  retain	  intact	  DNA.	  Also	  I	  replaced	  the	  vector	  with	   one	   that	   contains	   self-­‐inactivating	   long	   terminal	   repeats	   (LTR).	   Thus	   the	   LTR	  cannot	   act	   as	   promoter	   after	   the	   integration	   of	   the	   construct	   into	   the	   genome	   of	   the	  transduced	   cells	   reducing	   the	   leakiness	   of	   the	   system.	   To	   further	   inhibit	   basal	  expression	   a	   repressor	   was	   inserted,	   which	   inhibited	   transcription	   of	   the	   introduced	  CKS	   construct	   in	   the	   absence	   of	   doxycycline.	   Using	   these	   constructs	   in	   IMR90	   TERT	  cells,	   background	   expression	   of	   ectopic	   CKS	   proteins	   was	   successfully	   reduced.	   After	  induction	  with	  doxycycline	  CKS	   over-­‐expression	  was	   satisfactory	   in	   all	   but	   the	   IMR90	  TERT	   cells	   transfected	  with	   pBABE	   sin	   tet	   CKS2E63Q	   PURO.	   In	   comparison	   to	   CKS2,	  CKS2E63Q	  has	  a	  reduced	  ability	  to	  bind	  to	  CDK.	  Sequencing	  verified	  the	  accuracy	  of	  the	  CKS2E63Q	   construct	   (Material	   and	   Methods).	   	   A	   possible	   reason	   for	   the	   very	   low	  
CKS2E63Q	  expression	  could	  be	  a	  possible	  toxicity	  of	  the	  protein,	  which	  might	  lead	  to	  its	  down-­‐regulation.	  Quantitative	  real	  time	  PCR	  revealed	  that	  the	  variant	  of	  CKS2	  was	  over-­‐expressed	   but	   at	   lower	   levels	   than	   CKS2	   in	   pBABE	   CKS2	   PURO	   transduced	   cells	   (see	  chapter	   5).	   A	   lower	   transcription	   rate	   might	   be	   due	   to	   epigenetic	   suppression	   of	  CKS2E63Q.	  	   Additionally	   later	  analysis	   revealed	   that	   treatment	  of	   the	  cells	  with	  a	  proteasome	  inhibitor	   led	   to	  a	  moderate	  up-­‐regulation	  of	  CKS2E63Q	  (see	  chapter	  5).	  This	  supports	  the	   idea	   that	  CKS2E63Q	  might	  have	   a	   toxic	   effect	   on	   cells,	  which	   should	  be	  discussed	  later	  in	  this	  thesis.	  Further	  investigations	  into	  the	  suitability	  of	  the	  pBABE	  sin	  tet	  PURO	  vector	  were	  concentrating	  on	  the	  over-­‐expression	  of	  the	  wild-­‐type	  forms	  of	  CKS1	  and	  2.	  Upon	   induction	   of	   CKS	   1	   and	   2	   expression,	   p21Cip1	   was	   up-­‐regulated	   in	   IMR90	   TERT	  cells.	  Unexpectedly	  however	  the	  proliferation	  of	  CKS	  induced	  IMR90	  TERT	  cells	  was	  not	  impaired	   as	   seen	   in	   stably	  CKS	   expressing	   fibroblasts.	   Initially	   the	   immortalisation	   of	  IMR90	   cells	   by	   the	   introduction	   of	   a	   telomerase	   function	   as	   well	   as	   long	   periods	   in	  culture	  and	  selection	  were	  assumed	  to	  be	  the	  underlying	  reasons.	  Each	  transfection	  step	  requires	  a	  selection	  process,	  which	  implicates	  the	  occurrence	  of	  stress	   in	  the	  cells	  and	  endangers	   their	   genomic	   integrity.	   This	  might	   lead	   to	   changes	   in	   tumour	   suppressor	  genes	   and	   insufficient	   checkpoint	   activation	   upon	   the	   activation	   of	   oncogenic	   stress.	  Thus	   the	   transfection	   process	   was	   shortened	   leaving	   out	   hTERT	   and	   the	   repressor	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tTRKRAB.	  Introducing	  this	  minimal	  inducible	  system	  into	  primary	  IMR90	  cells	  however	  did	  not	  even	  lead	  to	  a	  noticeable	  up-­‐regulation	  of	  p21Cip1,	  ruling	  out	  the	  possibility	  that	  solely	   alterations	   in	   checkpoint	  proteins	  might	  have	   led	   to	   the	   inability	  of	   the	   cells	   to	  activate	   pathways	   leading	   to	   growth	   arrest.	   Using	   immunofluorescence	   to	   detect	   CKS	  positive	   cells	   on	   a	   single	   cell	   level,	   a	   probable	   reason	   for	   the	   insufficient	   checkpoint	  activation	  was	   identified.	  Only	  a	   subset	  of	   the	   cells	   transduced	  and	  viable	   in	   selection	  medium,	  do	  express	  CKS	  proteins.	   In	   this	  subset	  however	  p21Cip1	  expression	   is	   indeed	  elevated.	  Since	  it	  is	  assumed	  that	  CKS	  proteins	  act	  as	  oncogenes	  and	  apparently	  lead	  to	  checkpoint	   activation	   in	   non	   cancerous	   fibroblasts	   it	   can	   be	   suspected	   that	   the	  outgrowth	   of	   cells	  with	   lower	   levels	   of	  CKS	   is	   favoured.	   Additionally,	   cells	   expressing	  higher	  levels	  might	  die.	  Another	  possibility	  might	  be	  that	  CKS	  proteins	  are	  degraded	  by	  cellular	   mechanisms.	   	   It	   is	   to	   say	   that	   CKS	   proteins	   are	   regulated	   in	   a	   cell	   cycle	  dependent	   fashion.	   This	   might	   lead	   to	   low	   levels	   of	   CKS	   proteins	   in	   early	   G1	   cells	  although	   CKS	   is	   under	   the	   control	   of	   the	   constitutively	   active	   CMV	   promoter	   in	   the	  inducible	  constructs.	   In	  situ	  hybridization	  could	  show,	  whether	   transcription	  of	  CKS	   is	  already	  impaired	  in	  the	  cells	  lacking	  CKS	  proteins.	  Furthermore	  a	  proteasome	  inhibitor	  could	  be	  used	  to	  see	  whether	  CKS	  proteins	  are	  degraded	  to	  a	  high	  extent.	  	  	   The	  generated	  cell	  line	  for	  the	  induced	  expression	  of	  CKS	  proteins	  will	  be	  valuable	  for	   further	   studies	   on	   early	   and	   late	   effects	   of	   CKS	   over-­‐expression	   despite	   its	  inhomogeneity.	  By	  carefully	  choosing	  the	  expression	  vectors	  regarding	  a	  well	  tolerated	  selection	   marker	   and	   a	   tight	   expression	   control	   mechanism	   the	   cell	   line	   generated	  grows	   normally	   and	   appears	  morphologically	   consistent	  with	   the	   parental	   cell	   in	   the	  absence	   of	   doxycycline.	   Additionally	   the	   inducible	   cell	   line	   shows	   good	   levels	   of	   CKS	  protein	   expression	   upon	   induction	   with	   doxycycline.	   I	   developed	   a	   method,	   which	  makes	  it	  possible	  to	  study	  the	  impact	  of	  CKS	  proteins	  on	  a	  single	  cell	   level.	  To	  analyse	  the	  effect,	  which	  CKS	  over-­‐expression	  has	  on	  a	  particular	  protein	  of	   interest,	  a	  marker	  for	   both,	   the	   target	   proteins	   and	   CKS	   proteins	   can	   be	   used	   simultaneously.	   These	  analyses	  can	  be	  easily	  performed	  using	  imaging	  techniques.	  Additionally	  flow	  cytometry	  and	  cell	  cycle	  analyses	  can	  be	  performed	  in	  a	  similar	  way.	  	  	   For	   techniques	   looking	  at	   the	  behaviour	  of	   the	  overall	   cell	  population	  however,	   a	  homogenous	   cell	   population	   would	   be	   required.	   The	   attempt	   to	   obtain	   such	   a	  population	   by	   picking	   single	   clone	   colonies	   of	   pBABE	   sin	   tet	   CKS1	   PURO	   vector	  transduced	  IMR90	  TERT	  fibroblasts	  was	  not	  successful	  in	  the	  first	  instance.	  To	  further	  optimise	   the	   inducible	   system	   regarding	   homogenous	   levels	   of	   CKS	   protein	   upon	  induction	   of	   expression,	   a	   higher	   number	   of	   clones	   could	   be	   selected	   and	   analysed.	  Other	  systems	  of	  regulated	  expression	  could	  be	  tried	  out	  alternatively.	  Fusion	  of	  CKS	  to	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the	   ligand	   binding	   domain	   of	   the	   estrogen	   receptor	   (ER)	   might	   be	   one	   possibility	  (Littlewood	   et	   al.,	   1995).	   Here	   CKS	   would	   be	   kept	   bound	   to	   the	   chaperone	   in	   the	  cytoplasm	  until	  4-­‐hydroxytamoxifen	  (4OHT)	  is	  added.	  4OHT	  would	  bind	  to	  the	  ER	  part	  of	   the	   fusion	   protein,	   which	   leads	   to	   a	   conformational	   change	   so	   that	   the	   protein	   is	  released.	  Since	  the	  proteins	  are	  already	  expressed	  at	  the	  point	  of	  treatment	  with	  4OHT,	  the	  up-­‐regulation	  of	  available	  CKS	  proteins	  upon	  induction	  is	  assumable	  quicker	  than	  in	  transcription	   regulated	   systems.	   It	   still	   needs	   to	   be	   explored	   whether	   the	   constant	  expression	  of	  CKS	  proteins	  does	  not	  lead	  to	  unwanted	  available	  CKS	  even	  without	  4OHT	  treatment.	   Another	   possibility	   of	   induced	   expression	  would	   be	   the	   use	   of	   the	   Cre-­‐lox	  system.	  Here	  the	  CKS	  gene	  would	  be	  under	  the	  control	  of	  a	  constitutive	  promoter.	  The	  transcription	   however	   is	   inhibited	   by	   the	   insertion	   of	   a	   “stop”	   sequence	   consisting	   of	  several	  stop	  codons.	  This	  sequence	  is	  flanked	  by	  Lox	  P	  sites.	  After	  the	  activation	  of	  a	  Cre	  recombinase	   these	   Lox	   P	   sites	   are	   recombined,	   leading	   to	   the	   excision	   of	   the	   stop	  sequence	   (Dale	   and	   Ow,	   1991).	   Only	   then	   CKS	   would	   be	   transcribed.	   The	   cre-­‐recombinase	  itself	  could	  be	  controlled	  by	  a	  heat	  shock	  factor	  (HSF)	  regulated	  promoter	  (Pelham,	  1982).	  Here	  incubation	  of	  the	  cells	  at	  a	  higher	  temperature	  would	  lead	  to	  the	  trimerisation	  of	  HSF	  and	  its	  binding	  to	  the	  promoter,	  which	  activates	  transcription.	  The	  stop	   sequence	   should	   prevent	   the	   expression	   of	   CKS	   in	   the	   absence	   of	   the	   Cre	  recombinase	   completely.	   How	   tightly	   the	   induction	   of	   the	   recombinase	   can	   be	  controlled	  would	  need	  to	  be	  investigated.	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Chapter	  4	  –	  High	  levels	  of	  CKS	  proteins	  lead	  to	  growth	  arrest,	  
which	  can	  be	  bypassed	  by	  the	  inhibition	  of	  checkpoint	  proteins	  	  
4.1	  Response	  to	  CKS	  over-­‐expression	  in	  primary	  human	  fibroblasts	  Oncogenes	  such	  as	  RAS,	  are	  known	  to	  induce	  different	  checkpoint	  pathways	  in	  the	  cell,	  which	  result	  in	  specific	  cellular	  phenotypes	  (Bihani	  et	  al.,	  2004).	  I	  analysed	  the	  effect	  of	  over-­‐expression	  of	  the	  potential	  oncogene	  CKS	  in	  the	  primary	  fibroblast	  cell	  line	  IMR90.	  It	  was	  tested	  whether	  a	  phenotype	  can	  be	  observed	  in	  the	  cells,	  which	  is	  similar	  to	  the	  one	  known	  after	  oncogene	  over-­‐expression.	  	  	   In	  order	  to	  study	  the	  effect	  of	  CKS	  over-­‐expression	  on	  cell	  growth	  and	  checkpoint	  arrest,	  a	  retroviral	  system	  was	  applied	  to	  introduce	  stable	  expression	  of	  the	  CKS	  genes.	  The	  pBABE	  PURO	  vector,	  containing	  the	  virus	  LTR	  as	  a	  promoter,	  was	  used	  as	  retroviral	  backbone	  vector.	  Genes	  cloned	  into	  the	  vector	  are	  thus	  expressed	  constitutively.	  For	  the	  selection	  of	   infected	  cells	   the	  pBABE	  vector	  carries	  a	  puromycin	  resistance	  gene.	  Only	  cells,	   which	   integrate	   the	   vector	   DNA	   into	   their	   genome,	   survive	   the	   selection	   with	  puromycin.	  CKS1,	  CKS2	   and	   their	   non-­‐CDK	  binding	  mutants	  CKS1E63Q	   and	  CKS2E63Q	  were	   cloned	   into	   pBABE	   PURO	   (Figure	   4.1	   A).	   IMR90	   cells	   were	   infected	   with	   the	  resulting	  retroviral	  vectors	  to	  over-­‐express	  the	  CKS	  proteins.	  Cells	  were	  selected	  for	  one	  week	  and	  plated	  for	  analyses	  thereafter	  (Figure	  4.2	  B).	  	  	   Correct	   expression	  of	  CKS	  proteins	  was	  assayed	  by	  Western	  blot	   analysis	   (Figure	  4.1	  B).	  CKS	  over-­‐expression	  was	  satisfactory	  for	  all	  CKS	  variants	  except	  for	  CKS2E63Q.	  	  	   To	   ensure	   that	   lower	   protein	   expression	   is	   not	   due	   to	   imperfections	   in	   the	  CKS2E63Q	  vectors,	  both,	  the	  pBABE	  PURO	  as	  well	  as	  the	  pBABE	  sin	  tet	  CKS2E63Q	  PURO	  vector	  were	  sequenced	   (Figure	  2.1).	  Since	  no	   irregularities	  could	  be	  detected,	   the	   low	  expression	  of	  CKS2E63Q	  is	  most	  likely	  to	  be	  explained	  by	  a	  lower	  stability	  of	  the	  protein,	  a	   higher	   sensitivity	   of	   cells	   in	   response	   to	   the	   protein	   or	   a	  mechanism	   of	   the	   cells	   to	  down-­‐regulate	   the	   gene.	   The	   lower	   levels	   of	   expression	   were	   therefore	   always	  considered	  when	  results	  obtained	  from	  the	  CKS2E63Q	  expressing	  cells	  were	  analysed.	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  Figure	  4.1	  pBABE	  CKS	  PURO	  vector	  for	  the	  expression	  of	  the	  different	  CKS	  proteins.	  (A)	  The	  sequences	  encoding	   for	   each	   of	   the	   CKS	   variants	   CKS1,	   CKS1E63Q,	   CKS2	   or	   CKS2E63Q,	   which	   were	   FLAG	   and	   His	  tagged,	   were	   cloned	   separately	   into	   the	   retroviral	   vector	   pBABE.	   The	   vector	   contains	   a	   puromycin	  resistance	  (total	  size	  of	  the	  vector:	  5845	  bp).	  (B)	  The	  expression	  of	  the	  indicated	  CKS	  variants	  in	  IMR90	  was	  confirmed	  by	  Western	  blot	  analysis.	   IMR90	   fibroblasts	  were	   transduced	  with	   the	  appropriate	  pBabe	  CKS	  PURO	  vector	  and	  selected	  for	  puromycin	  resistance	  for	  seven	  days.	  Cells	  transduced	  with	  an	  empty	  vector	  were	   used	   as	   control.	   Cell	   extracts	  were	  made	   and	   proteins	   separated	   by	   SDS	   PAGE.	   CKS	   proteins	  were	  detected	  using	  antibodies	  either	  against	  the	  FLAG	  tag	  or	  an	  antibody	  that	  recognises	  both	  CKS1	  and	  CKS2.	  Ectopic	  CKS	  expression	  was	  satisfactory	  in	  all	  but	  the	  IMR90	  CKS2E63Q	  cells.	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the	  expected	  oncogenic	  effect	  on	  cells,	  tumour	  suppressor	  pathways	  would	  be	  activated	  in	   these	   checkpoint	   competent	   cells.	   Pathway	   activation	   would	   result	   for	   example	   in	  apoptosis	  or	  growth	  arrest	  like	  senescence.	  Growth	  arrest	  that	  is	  caused	  by	  oncogenes	  can	   be	   bypassed	   by	   disrupting	   the	   pathway,	   which	   counteracts	   the	   oncogenic	   effect	  (Braig	  and	  Schmitt,	  2006;	  Hahn	  et	  al.,	  1999).	  To	  see	  whether	   this	  was	   the	  case	   in	  CKS	  over-­‐expressing	  IMR90	  cells,	  the	  two	  important	  tumour	  suppressor	  genes,	  p53	  and	  RB,	  were	   down-­‐regulated	   by	   introducing	   the	   human	   papilloma	   virus	   proteins	   E6	   and	   E7.	  The	   effect	   of	   CKS	   over-­‐expression	   on	   proliferation	   in	   these	   checkpoint-­‐inhibited	   cells	  was	   assessed	   and	   the	   ability	   of	   CKS	   proteins	   to	   transform	   these	   cells	   was	   analysed	  (Figure	  4.2	  A).	  	  	   For	  the	  initial	  analyses	  in	  primary	  cells,	  IMR90	  human	  fibroblasts	  were	  transduced	  with	   an	   empty	   vector	   control	   or	   with	   the	   CKS	   bearing	   constructs.	   As	   a	   tumour	  suppressor	  pathway	  inducing	  control,	  oncogenic	  RAS	  (HRASG12V)	  was	  over-­‐expressed.	  
HRASG12V	   expression	   is	   known	   to	   result	   in	   senescence	   in	   human	   and	   mouse	   cells	  (Serrano	  et	   al.,	   1997).	  Three	  days	  after	   transduction	  with	  CKS	  and	  control	   constructs,	  cells	  were	   selected	   by	   adding	   puromycin	   for	   approximately	   7	   days	   and	   subsequently	  analysed	  regarding	  checkpoint	  activation	  and	  proliferative	  capacity	  (Figure	  4.2	  B).	  	  	   As	   evaluated	   by	   colony	   formation	   assay	   and	   BrdU	   incorporation	   assay,	   CKS	  expression	  caused	  a	  decrease	  in	  the	  number	  and	  growth	  of	  IMR90	  cells.	  For	  the	  colony	  formation	  assay,	  cells	  were	  plated	  at	  a	   low	  confluence	  (around	  10%)	  and	  cultured	   for	  approximately	   14	   days.	   Cells	   were	   fixed	   and	   stained	  with	   the	   DNA	   dye	   crystal	   violet	  (Figure	   4.2	   C).	   As	   expected,	   in	   the	   negative	   control	   panel	   (labelled,	   Vector),	   cells	  proliferated	   to	   a	   high	   extent.	   Introduction	   of	   the	   positive	   control	   oncoprotein,	  HRASG12V,	   inhibited	   proliferation	   of	   these	   cells	   almost	   completely.	   Wild-­‐type	   CKS1	  similarly	   inhibited	   proliferation,	   as	   did	   CKS2	   and	   the	   E63Q	   variants.	   The	   BrdU	  incorporation	   assay	   confirmed	   a	   decrease	   in	   proliferation	   since	   less	   CKS	   over-­‐expressing	   cells	   were	   able	   to	   take	   up	   BrdU,	   indicating	   a	   lower	   number	   of	   actively	  replicating	   cells.	  When	   compared	   to	   the	   number	   of	   BrdU	   incorporating	   empty	   vector	  cells	  (set	  as	  1)	  only	  a	  fraction	  of	  CKS1	  (0.67)	  and	  CKS2	  (0.57)	  positive	  cells	  was	  able	  to	  replicate	  and	  enter	  S-­‐phase.	  The	  effect	  of	  both	  E63Q	  variants	  (0.76	   for	  CKS1E63Q	  and	  0.85	   for	   CKS2E63Q)	   does	   not	   seem	   to	   be	   as	   strong	   as	   the	   one	   of	   the	   wild-­‐type	   CKS	  proteins	  (Figure	  4.2	  D).	  As	  described	  before	  oncogenic	  RAS	  over-­‐expression	   led	   to	   the	  highest	  inhibition	  of	  replication	  in	  IMR90	  fibroblasts	  (0.38).	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  Figure	  4.2	  Over-­‐expression	   of	   CKS	   proteins	   induces	   growth	   arrest	   in	   IMR90	   fibroblasts.	   (A)	  Model	  displaying	   the	  approach	  used	   to	   test	   the	  oncogenic	  effect	  of	  CKS	  proteins:	  Primary	   IMR90	   fibroblasts	  are	  subjected	  to	  CKS	  as	  well	  as	  control	  oncogene	  over-­‐expression.	  Oncogene	  activation	  causes	  the	  activation	  of	  checkpoint	   proteins,	   which	   might	   result	   in	   senescence	   or	   apoptosis.	   Inhibition	   of	   the	   responsible	  checkpoint	   proteins	   consequently	   leads	   to	   the	   alleviation	   of	   the	   suppressive	   phenotype	   and	   favours	   the	  transformation	  of	  primary	  cells	   towards	  cancer	  cells.	   (B)	  Timeline	  of	   the	  experiments	  presented	  in	   figure	  4.2,	   figure	   4.3	   and	   figure	   4.4.	   IMR90	   fibroblasts	  were	   transduced	  with	   the	   retroviral	   vectors	   bearing	   the	  sequences	   coding	   for	   CKS1,	   CKS1E63Q,	   CKS2,	   CKS2E63Q	   or	   the	   control	   oncogene	   RAS.	   3	   days	   after	  transduction,	  cells	  were	  selected	  for	  7	  days	  and	  subsequently	  seeded	  for	  experiments.	  (C)	  Quantification	  of	  BrdU	   incorporation	   in	   IMR90	   cells	   transduced	  with	   CKS	   constructs	   and	   the	   RAS	   oncogene	   control.	   Cells	  were	  incubated	  with	  50	  µM	  BrdU	  over	  night	  and	  stained	  with	  an	  anti	  BrdU	  antibody.	  Images	  were	  acquired	  using	   the	   IN	  Cell	  Analyzer	  1000	  and	  the	  percentage	  of	  BrdU	  positive	  cells	  determined	  using	  high	  content	  analysis	  as	  described	  in	  Material	  and	  Methods.	  The	  percentage	  of	  BrdU	  positive	  empty	  vector	  transduced	  control	  cells	  was	  set	  as	  one.	  (D)	  Images	  and	  quantification	  of	  crystal	  violet	  staining	  in	  the	  indicated	  IMR90	  CKS	   cells.	   Cells	   were	   seeded	   at	   a	   low	   density	   and	   stained	   with	   crystal	   violet	   two	   weeks	   later.	   For	  quantification	  the	  dye	  was	  solubilised	  using	  10%	  acetic	  acid	  and	  the	  absorbance	  of	   the	  resulting	  solution	  measured	  at	  595	  nm.	  The	  absorbance	  of	  the	  empty	  vector	  control	  was	  set	  as	  one.	  Images	  correspond	  to	  one	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representative	  experiment	  (n=3).	  Error	  bars	  in	  C	  and	  D	  correspond	  to	  three	  independent	  experiments.	  An	  unpaired	   t-­‐test	  was	  performed	   to	   test	   significance	  of	   the	  down-­‐regulation	  of	   proliferation	   in	  CKS	  or	  RAS	  over-­‐expressing	  IMR90	  cells	  in	  comparison	  with	  control	  vector	  transduced	  cells	  (*P	  <	  0.05;	  **P	  <	  0.01;	  ***P	  <	  0.001).	  	  	  	   The	  RAS	  oncogene	  is	  known	  to	  arrest	  cells	  and	  cause	  a	  senescent	  phenotype	  when	  over-­‐expressed	   in	   primary	   cells	   in	   a	   process	   known	   as	   oncogene-­‐induced	   senescence	  (Serrano	   et	   al.,	   1997).	   Senescent	   cells	   typically	   have	   a	   flat	   and	   enlarged	   appearance.	  Thus	   I	   monitored	   cell	   growth	   and	   analysed	   the	   morphology	   of	   CKS	   over-­‐expressing	  IMR90	   fibroblasts	   regarding	   these	   phenotypical	   characteristics	   of	   senescence	   (Figure	  4.3	  A).	   IMR90	  cells	  bearing	   the	  control	  vector	  were	  rather	  small.	  CKS	   transduced	  cells	  displayed	   the	   morphology	   that	   resembled	   that	   of	   senescent	   cells.	   Additionally	  
HRASG12V	   expressing	   cells	   often	   displayed	   a	   high	   number	   of	   vacuoles.	   To	   further	  investigate	  whether	  the	  CKS	  induced	  growth	  arrest	  showed	  any	  other	  characteristics	  of	  senescence,	  cells	  were	  stained	  for	  senescence-­‐associated	  β-­‐galactosidase	  activity	  (SA-­‐β-­‐Gal),	  which	  is	  a	  widely	  used	  marker	  for	  the	  identification	  of	  senescent	  cells	  (Dimri	  et	  al.,	  1995).	  95%	  of	  the	  IMR90	  cells,	  which	  were	  infected	  with	  HRASG12V	  displayed	  SA	  β-­‐gal	  activity.	  CKS	  over-­‐expression	  still	   led	   to	  an	  elevated	  β-­‐galactosidase	  activity	   in	  around	  three-­‐quarter	  of	  the	  transduced	  cells.	  	   Additionally	   the	   presence	   of	   senescence	   associated	   heterochromatic	   foci	   (SAHF)	  was	   determined.	   SAHF	   were	   detectable	   in	   more	   than	   twice	   as	   many	   CKS	   over-­‐expressing	   cells	   (CKS1:	   44.9%;	   CKS1E63Q:	   43.4%;	   CKS2:	   41.7%)	   than	   in	   the	   vector	  control	  cells	  (17.5%).	  In	  the	  less	  efficiently	  expressing	  CKS2E63Q	  cells	  SAHF	  formation	  could	   be	   observed	   in	   32.5%.	  Together	   these	   results	   suggest	   that	  CKS	   over-­‐expression	  induces	   senescence	   in	   human	   diploid	   fibroblasts	   with	   intact	   tumour	   suppressor	  pathways.	  	  	  	  
4.1.2	  Levels	  of	  senescence	  mediators	  during	  CKS	  induced	  senescence	  To	   identify	   the	   pathways	   responsible	   for	   senescence	   induced	   by	   high	   levels	   of	   CKS	  proteins,	   the	   expression	   of	   different	   senescence	   effectors	   was	   analysed	   by	  immunofluorescence	   staining	   followed	   by	   high	   content	   analysis.	   Two	   important	  regulators	  of	  senescence,	  p53	  and	  its	  downstream	  effector	  p21Cip1,	  were	  up-­‐regulated	  in	  
CKS	   transduced	   cells	   (Figure	   4.4	  A	   and	  B).	  Whereas	   only	   8%	  of	   empty	   vector	   control	  cells	   were	   positive	   for	   p53,	   above	   60%	   of	   cells	   expressing	   one	   of	   the	   CKS	   variants	  showed	   elevated	   levels	   of	   this	   crucial	   initiator	   of	   senescence.	   p21Cip1	   levels	   were	   up-­‐regulated	  as	  well	  but	  were	  more	  variable	  between	  experiments.	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   The	   other	   pathway	   leading	   to	   cell	   cycle	   arrest	   and	   senescence	   is	   regulated	   by	  p16INK4a.	   p16INK4a	   however	   was	   only	   up-­‐regulated	   in	   the	  HRASG12V	   oncogene	   control	  cells	   (Figure	   4.4	   C).	   Thus,	   senescence	   as	   a	   result	   of	   CKS	   over-­‐expression	   is	   mainly	  triggered	  by	  the	  p53	  pathway.	  
	  
	  	  Figure	  4.3	  IMR90	  cells	  over-­‐expressing	  CKS	  proteins	  present	  characteristics	  of	  senescence.	  (A)	  Bright	  field	   images	   showing	   the	   morphology	   of	   primary	   IMR90	   fibroblasts	   transduced	   with	   the	   empty	   vector	  control,	  CKS	  constructs	  and	  RAS	  control	  oncogene	  after	  being	  kept	  in	  puromycin	  containing	  medium	  for	  10	  days.	   (B)	  Representative	   images	  and	  quantitative	  analysis	  of	  stainings	   for	  elevated	  senescence-­‐associated	  
β-­‐galactosidase	  activity	  (SA	  β-­‐Gal)	   in	  IMR90	  cells	  transduced	  with	  the	  indicated	  vectors.	  Transduced	  cells	  were	   selected	   for	   seven	   days,	   fixed	  with	   glutaraldehyde	   and	   stained	  with	   X-­‐gal	   solution	   as	   described	   in	  Material	   and	   Methods.	   For	   the	   quantification	   approximately	   200	   cells	   were	   counted	   in	   each	   of	   three	  independent	  experiments.	  Scale	  bar,	  30	  µm.	  (C)	  Images	  display	  DAPI	  stainings	  of	  virally	  transduced	  IMR90	  fibroblasts	  illustrating	  the	  formation	  of	  senescence-­‐associated	  heterochromatic	  foci	  (SAHF)	  in	  CKS	  and	  RAS	  over-­‐expressing	  cells.	  Quantification	  of	  SAHF	  was	  performed	  for	   three	   independent	  experiments	  using	   IN	  Cell	  Analyser	  1000	  and	  the	  IN	  Cell	  Investigator	  software.	  Areas	  of	  DAPI	  stained	  nuclei	  with	  high	  intensity	  were	   identified	  using	  a	  minimal	  area	  of	  0.5	  μm.	  Nuclei	   containing	  more	   than	  5	  high	   intensity	  areas	  were	  scored	  as	  positive.	  	  An	  unpaired	  t-­‐test	  was	  performed	  to	  test	  significance	  of	  the	  up-­‐regulation	  of	  senescence	  markers	   in	  CKS	  or	  RAS	  over-­‐expressing	   	   IMR90	  cells	   in	  comparison	  with	  control	  vector	   	   transduced	   	  cells	  (*P	  <	  0.05;	  **P	  <	  0.01;	  ***P	  <	  0.001).	  




 Figure	   4.4	  The	   p53/p21Cip1	   pathway	   is	   activated	   upon	   CKS	   over-­‐expression.	   (A-­‐C)	   p21Cip1,	   p53	   and	  p16INK4a	  stainings	  of	  IMR90	  fibroblasts	  transduced	  with	  the	  empty	  vector	  control,	  CKS	  constructs	  and	  RAS	  control	  after	  seven	  days	  of	  selection.	  Images	  were	  acquired	  using	  the	  IN	  Cell	  Analyzer	  1000	  (upper	  panels).	  Percentage	  of	  positive	  cells	  was	  determined	  by	  high	  content	  analysis	  as	  described	   in	   the	  methods	  (lower	  panels).	  Error	  bars	  correspond	  to	  three	  independent	  experiments.	  An	  unpaired	  t-­‐test	  was	  performed	  to	  test	  significance	  of	  the	  up-­‐regulation	  of	  p21Cip1,	  p53	  and	  p16INK4a	  in	  CKS	  or	  RAS	  over-­‐expressing	  IMR90	  cells	  in	  comparison	  with	  control	  vector	  transduced	  cells	  (*P	  <	  0.05;	  **P	  <	  0.01;	  ***P	  <	  0.001). 
	  
4.2	   Response	   to	   CKS	   over-­‐expression	   in	   human	   fibroblasts	   with	  
inhibited	  tumour	  suppressor	  proteins	  
	  
4.2.1	  Inhibition	  of	  checkpoint	  proteins	  alleviates	  growth	  arrest	  in	  IMR90	  cells	  Growth	  arrest,	  which	   is	  caused	  by	  oncogene	  activation,	  can	  be	  bypassed	  by	  disrupting	  the	  pathway,	  which	  counteracts	  the	  oncogenic	  effect	  (Braig	  and	  Schmitt,	  2006;	  Hahn	  et	  al.,	   1999).	   To	   identify	  whether	   this	   is	   the	   case	   for	   the	   growth	   arrest	   observed	   in	  CKS	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over-­‐expressing	   cells,	   regulators	   of	   senescence	   typically	   activated	   by	   oncogenes	  were	  down-­‐regulated	  in	  IMR90	  cells.	  	  	   IMR90	   cells	   enter	   a	   state	   called	   replicative	   senescence	   after	   about	   58	   population	  doublings	   (Ouellette	  et	  al.,	  1999).	  This	   is	  caused	  by	   telomere	  shortening.	  To	  avoid	   the	  onset	   of	   replicative	   senescence	   in	   an	   experimental	   setting,	   telomerase	   activity	   was	  induced	   using	   a	   viral	   vector	   coding	   for	   human	   telomerase	   reverse	   transcriptase	  (hTERT)	  (Lee	  et	  al.,	  2004).	   	  The	  resulting	  IMR90	  TERT	  cell	   line	  was	  now	  immortalised	  and	  able	  to	  replicate	  independently	  of	  telomere	  shortening.	  As	  the	  immunofluorescence	  analysis	  suggested	  that	  p53	  is	  one	  of	  the	  up-­‐regulated	  tumour	  suppressors	  in	  CKS	  over-­‐expressing	   IMR90,	   p53	   as	  well	   as	   one	   of	   its	   downstream	   regulators,	   RB,	  were	   down-­‐regulated	  in	  the	  IMR90	  TERT	  cells.	  Down-­‐regulation	  of	  these	  tumour	  suppressors	  was	  achieved	  by	  the	  infection	  of	  the	  IMR90	  TERT	  fibroblasts	  with	  retroviral	  vectors	  coding	  for	  E6	  and	  E7	  (Figure	  4.5	  A).	  E6	  and	  E7	  are	  human	  papillomavirus	  oncoproteins,	  which	  bind	  and	  inactivate	  p53	  and	  RB	  respectively.	  Upon	  tumour	  suppressor	  down-­‐regulation,	  
CKS	   over-­‐expressing	   cells	   were	   able	   to	   resume	   growth	   (Figure	   4.5	   B,C).	   Cells	   do	   not	  show	   a	   senescent	   morphology	   anymore	   and	   show	   no	   impairment	   of	   growth	   in	   the	  colony	   formation	  assay.	  These	  results	  suggest	   that	  high	   levels	  of	  CKS	   lead	  to	  a	  growth	  arrest	   induced	   by	   the	   activation	   of	   tumour	   suppressor	   genes	   in	   primary	   IMR90	   cells.	  Down-­‐regulation	  of	  these	  tumour	  suppressor	  genes	  lifts	  the	  growth	  inhibition.	  	  	  
4.2.2	  Transforming	  ability	  of	  CKS	  In	   cancer	   cells,	   p53,	   RB	   or	   upstream	   and	   downstream	   regulators	   of	   these	   tumour	  suppressors	  are	  commonly	  impaired.	  In	  this	  setting	  oncogenes	  are	  able	  to	  unfold	  their	  whole	   transformational	   potential.	   To	   see	  whether	   CKS	   proteins	   are	   able	   to	   transform	  IMR90	   E6	   E7	   TERT	   cells	   into	   cancer-­‐like	   cells,	   I	   looked	   for	   the	   presence	   of	   typical	  markers	   of	   transformation.	   First,	   the	   effect	   of	   CKS	   proteins	   on	   proliferation	   was	  assessed.	  I	  analysed	  the	  growth	  of	  CKS	  over-­‐expressing	  primary	  IMR90	  fibroblasts	  and	  checkpoint-­‐inhibited	   IMR90	   E6	   E7	   TERT	   cells	   (Figure	   4.6	   A).	   Growth	   curves	   were	  obtained	  by	  measuring	  the	  relative	  cell	  number	  on	  every	  second	  day	  over	  the	  course	  of	  twelve	  days	  for	  IMR90	  cells	  and	  eight	  days	  for	  IMR90	  E6	  E7	  TERT	  cells.	  The	  number	  of	  empty	  vector	  control	  cells	  on	  the	   last	  day	  of	  the	  time	  course	  was	  set	  as	  one.	  In	  IMR90	  cells,	  proliferation	  slowed	  down	  moderately	  upon	  up-­‐regulation	  of	  all	  CKS	  variants.	  The	  proliferation	  rate	  of	  the	  single	  CKS	  variant	  expressing	  IMR90	  fibroblast	  does	  not	  differ	  significantly	  from	  each	  other.	  Only	  cells	  transduced	  with	  pBABE	  CKS2	  PURO	  showed	  an	  even	  more	  pronounced	  growth	  	  inhibition	  than	  	  the	  others.	  In	  	  comparison	  to	  the	  IMR90	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  Figure	   4.5	   Inhibition	   of	   checkpoint	   proteins	   alleviates	   the	   growth	   arrest	   in	   CKS	   over-­‐expressing	  
IMR90.	  Fibroblasts	  were	  transduced	  subsequently	  with	  pWZL	  hTERT	  BLAST,	  LXSN	  E6	  E7	  NEO	  and	  pBABE	  CKS	   PURO,	   selected	   for	   the	   appropriate	   amount	   of	   time	   and	   plated	   for	   the	   particular	   experiments.	   (A)	  Western	  blot	  analyses	  showing	  the	  expression	  of	  hTERT	  and	  E7	  as	  well	  as	  the	  down-­‐regulation	  of	  p53	  and	  RB	   in	   IMR90	   E6	   E7	   hTERT	   cells	   transduced	   with	   the	   vector	   control	   or	   pBABE	   CKS	   PURO	   (left	   panel).	  Additionally	   ectopic	   CKS	   expression	   was	   checked	   in	   IMR90	   E6	   E7	   hTERT	   cells	   after	   they	   have	   been	  transduced	   with	   the	   appropriate	   pBABE	   CKS	   PURO	   vector	   and	   selected	   for	   7	   days	   (right	   panel).	   (B)	  Brightfield	  images	  were	  taken	  of	  IMR90	  E6	  E7	  hTERT	  CKS	  cells	  growing	  in	  culture.	  Scale	  bar,	  100	  µm.	  (C)	  To	  assess	  the	  proliferative	  capacity	  of	  IMR90	  E6	  E7	  hTERT	  CKS	  cells,	  they	  were	  plated	  at	  a	  low	  density	  and	  stained	   with	   crystal	   violet	   14	   days	   later.	   Representative	   images	   were	   taken	   (n=3)	   and	   the	   staining	  quantitatively	   analysed	   as	   described	   in	   Material	   and	   Methods.	   Error	   bars	   correspond	   to	   3	   independent	  experiments.	  	  fibroblasts,	   	  CKS	  over-­‐expression	  in	  IMR90	  E6	  E7	  TERT	  cells	  led	  to	  a	  slightly	  increased	  growth	  compared	  to	  the	  vector	  control.	  Again,	  the	  CKS	  variants	  among	  one	  another	  do	  not	  differ	  significantly.	  	   A	   more	   prominent	   characteristic	   of	   cancer	   cells	   than	   an	   increased	   proliferative	  capacity	   is	   the	   ability	   of	   cells	   to	   exhibit	   anchorage	   independent	   growth	   (Jove	   and	  Hanafusa,	   1987).	   	   I	   tested	   whether	   CKS	   proteins	   are	   able	   to	   induce	   anchorage	  independent	   growth	   in	   IMR90	   TERT	   E6	   E7	   cells	   using	   a	   soft	   agar	   assay	   for	   colony	  formation	  (Figure	  4.6	  B).	   In	  this	  assay,	   the	  CKS	  over-­‐expressing	  cells	  were	  seeded	   in	  a	  viscous	  agar	  and	  cultured	  for	  3	  weeks.	  Colony	  formation	  was	  observed	  for	  IMR90	  TERT	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E6	  E7	  cells	  which	  expressed	  the	  oncogenes	  small	  T	   (Yu	  et	  al.,	  2001),	  HRASG12V	  and	  c-­‐
MYC.	  Cells	  over-­‐expressing	  the	  CKS	  variants	  were	  not	  able	   to	   form	  colonies.	  Therefore	  
CKS	  expression	  in	  this	  background	  leads	  to	  a	  proliferative	  advantage	  but	  is	  not	  sufficient	  to	  induce	  anchorage	  independent	  growth.	  
	  Figure	  4.6	  Transforming	  ability	  of	  CKS.	  (A)	  The	  proliferative	  capacity	  of	  CKS	  over-­‐expressing	  IMR90	  (left	  panel)	   and	   IMR90	   E6	   E7	   hTERT	   fibroblasts	   (right	   panel)	   was	   compared	   after	   both	   cell	   lines	   were	  transduced	  with	  the	  indicated	  CKS	  constructs	  and	  selected	  for	  seven	  days.	  Growth	  curves	  were	  obtained	  by	  seeding	  the	  transduced	  cells	  in	  duplicates	  in	  24	  well	  plates.	  One	  plate	  was	  fixed	  every	  two	  days	  and	  stained	  with	  crystal	  violet	  at	  the	  end	  of	  the	  time	  course.	  The	  staining	  was	  quantified	  as	  described	  in	  Material	  and	  Methods.	   The	   relative	   cell	   number	   corresponds	   to	   the	   absorbance	   at	   each	   time	   point	   relative	   to	   the	  absorbance	   of	   the	   empty	   vector	   control	   at	   the	   end	   of	   the	   time	   course.	   Error	   bars	   correspond	   to	   two	  independent	  experiments.	  Levels	  of	  significance	  (unpaired	  t-­‐test)	  for	  the	  altered	  proliferation	  of	  CKS	  over-­‐expressing	  	  cells	  	  in	  	  relation	  to	  the	  vector	  control	  	  transduced	  cells	  	  are	  illustrated	  	  by	  *	  for	  	  P	  <	  0.05,	  **	  for	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4.3	  Discussion	  Previously	  an	  oncogenic	  effect	  of	  CKS	  proteins	  was	  predicted	  since	  they	  were	  reported	  to	  be	  over-­‐expressed	   in	  a	  variety	  of	  cancers.	   	  So	   far,	   studies	  were	  mostly	  restricted	   to	  gene	  and	  protein	  analysis	  of	  tissue	  samples	  from	  cancer	  patients	  or	  in	  vitro	  and	  in	  vivo	  assays	   with	   cancer	   cells	   showing	   a	   lower	   proliferation	   rate	   when	   inhibiting	   CKS	  expression.	  In	  a	  recent	  study,	  Cks1	  was	  over-­‐expressed	  in	  primary	  B	  cells	  derived	  from	  a	  bone	  marrow	  transplant	   in	  mice.	  Here	  Cks	   over-­‐expressing	  B	  cells	  did	  not	   lead	   to	  any	  increase	  in	  proliferation	  or	  showed	  any	  other	  kind	  of	  transformational	  change	  (Kratzat	  et	  al.,	  2012).	  Therefore	  the	  first	  objective	  of	  this	  study	  was	  to	  investigate	  whether	  it	  was	  only	   the	   lack	   of	   the	   cell	   cycle	   protein	   CKS,	  which	   gave	   cancerous	   cells	   from	   previous	  studies	   a	   proliferative	   disadvantage	   or	   whether	   CKS	   itself	   could	   contribute	   to	   the	  transformation	   of	   primary	   cells	   and	   act	   as	   an	   oncogene.	   For	   this	   purpose	   cancer	  development	  was	  mimicked	  commencing	  with	  primary	  IMR90	  fibroblasts	  and	  finishing	  with	  immortalised	  p53	  and	  RB	  inhibited	  cells.	   In	  this	  background	  CKS	  over-­‐expression	  was	   imposed	   on	   the	   cells	   and	   the	   ability	   of	   CKS	   to	   transform	   the	   cells	  was	   assessed.	  Previously	  the	  effect	  of	   the	  RAS	  oncogene	  was	  studied	   in	  this	  kind	  of	  setting.	  Whereas	  RAS	  leads	  to	  oncogene	  induced	  senescence	  in	  primary	  cells,	  it	  leads	  to	  transformation	  in	  immortalised	  p53	  and	  RB	  inhibited	  cells	  (Hahn	  et	  al.,	  1999;	  Hahn	  and	  Weinberg,	  2002).	  Nevertheless	   attention	   needs	   to	   be	   paid,	   since	   different	   cells	   and	   different	   oncogenes	  behave	  in	  different	  ways.	  Using	  young	  IMR90	  fibroblasts,	  a	  well-­‐established	  cell	  line	  in	  the	  field	  of	  oncogene	  studies,	  facilitated	  the	  interpretation	  of	  results.	  In	  these	  cells	  CKS	  over-­‐expression	   led	   to	   reduced	  growth	  as	  well	   as	   characteristics	  of	  oncogene	   induced	  senescence	   like	   senescence-­‐associated	   β-­‐galactosidase	   and	   senescence-­‐associated	  heterochromatic	   foci	   formation.	   Thus	   CKS	   seems	   to	   act	   like	   a	   typical	   oncogene	   by	  inducing	  oncogenic	  stress	  and	  senescence	  in	  cells	  with	  intact	  checkpoints.	  	  	   The	   control	   oncogene	   HRASG12V	   showed	   the	   most	   pronounced	   features	   of	  senescence	   in	   all	   sets	   of	   experiments	  performed.	  HRASG12V	   is	   a	  mutated	   form	  of	   the	  HRAS	  protein,	  often	  found	  in	  skin	  cancer.	  Its	  mutation	  leads	  to	  a	  low	  GTPase	  activity	  and	  a	   strong	   ability	   to	   bind	   GTP	   (Pylayeva-­‐Gupta	   et	   al.,	   2011).	   These	   changes	   lead	   to	   a	  constitutively	   active	   HRAS.	   It	   acts	   as	   an	   oncogene	   in	   several	   ways.	   It	   promotes	  proliferation	   by	   acting	   on	   a	   variety	   of	   pathways	   leading	   to	   the	   activation	   of	   growth	  factor	   signalling	   cascades,	   up-­‐regulation	   of	   growth	   factors	   themselves,	   inhibition	   of	  TGFβ	   and	   cyclin	   dependent	   kinase	   inhibitors	   and	   the	   stimulation	   of	   cyclin	   D1	  expression	   (Pylayeva-­‐Gupta	   et	   al.,	   2011).	   These	   proliferative	   signals	   alone	   result	   in	   a	  high	  level	  of	  replicative	  stress	  and	  thus	  a	  strong	  activation	  of	  checkpoint	  proteins.	  CKS	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however	  might	  only	  influence	  proliferation	  by	  direct	  interaction	  with	  cell	  cycle	  proteins	  and	  their	  regulators	  and	  therefor	   induces	  checkpoint	  pathways	  to	  a	  moderate	  but	   less	  pronounced	  degree	  than	  active	  RAS	  does.	  	  	   In	   contrast	   to	  RAS,	  CKS	  proteins	  did	  not	  activate	   the	  p16INK4a	  pathway.	  As	  part	  of	  the	   RAS-­‐MAP	   kinase	   pathway,	   RAS	   leads	   to	   the	   up-­‐regulation	   of	   a	   variety	   of	  transcription	  factors	  including	  for	  example	  the	  Ets	  family	  of	  transcription	  factors.	  Ets1	  and	   Ets2	   in	   turn	   increase	   transcription	   of	   p16INK4a	   (Rayess	   et	   al.,	   2012).	   It	   was	   also	  shown	  that	  oncogenic	  RAS	  leads	  to	  an	  up-­‐regulation	  of	  the	  JMJD3	  demethylase,	  which	  in	  turn	   contributes	   to	   the	   epigenetic	   control	   of	   the	   INK4a/ARF	   locus	   (Barradas	   et	   al.,	  2009).	   p53	   again	   is	   mainly	   activated	   by	   replicative	   stress	   and	   DNA	   damage,	   which	  activates	   the	   ATM/ATR	   pathways	   (Mallette	   and	   Ferbeyre,	   2007).	   This	  would	   support	  the	   idea	   that	   CKS	   proteins	   activate	   oncogene	   induced	   senescence	   by	   their	   direct	  influence	   on	   the	   cell	   cycle	   rather	   than	   having	   an	   impact	   on	   growth	   factor	   signalling	  pathways	  which	  lead	  to	  the	  up-­‐regulation	  of	  transcription	  factors.	  	   In	  the	  assays	  performed	  to	  show	  lower	  proliferation	  and	  onset	  of	  senescence	  in	  CKS	  over-­‐expressing	   cells,	   the	   E63Q	   variants	   of	   CKS1	   and	   2	   showed	   a	   slightly	   but	   not	  significantly	   weaker	   reaction.	   CKS	   binding	   to	   CDK2	   was	   shown	   to	   be	   reduced	   by	  approximately	  80%	  in	  the	  E63Q	  variants	  compared	  to	  the	  wild-­‐type	  proteins	  (Watson	  et	  al.,	  1996).	  A	  slightly	  less	  pronounced	  ability	  to	  induce	  oncogene	  induced	  senescence	  in	   CKSE63Q	   over-­‐expressing	   IMR90	   fibroblasts	   might	   implicate	   a	   role	   of	   CKS	   CDK	  interaction	   in	   an	   oncogenic	   function	   of	   CKS.	   That	   the	   difference	   between	  mutant	   and	  wild-­‐type	  proteins	  is	  not	  very	  distinctive	  might	  be	  due	  to	  the	  amount	  of	  mutant	  CKS	  still	  interacting	  with	  CDK.	  On	  the	  other	  hand	   it	  might	  be	  possible	   that	  CDK	  dependent	  and	  independent	  functions	  lead	  to	  the	  induction	  of	  senescence.	  	  	  	   As	  seen	  before	  in	  the	  attempt	  to	  establish	  an	  inducible	  system	  for	  CKS	  expression	  in	  IMR90	   fibroblasts,	   the	  expression	  of	  CKS2E63Q	  was	   to	  a	  high	  degree	   less	  pronounced	  when	   compared	   to	   all	   other	   CKS	   variants.	   Apart	   from	   the	   induction	   of	   senescence	  associated	  heterochromatic	  foci	  however	  the	  CKS2E63Q	  expressing	  cells	  hardly	  differed	  from	  CKS1E63Q	   expressing	  cells.	  Thus	   the	   lower	  expression	   is	   sufficient	   to	   induce	   the	  senescent	  phenotype	  in	  the	  primary	  IMR90	  cells.	  CKS2E63Q	  might	  even	  have	  a	  stronger	  impact	   on	   the	   cells	   than	   the	   CKS2	   wild-­‐type	   protein	   has,	   leading	   to	   its	   rapid	  degradation.	   This	   could	   be	   the	   case	   when	   a	   CDK	   independent	   function	   of	   CKS	   has	   a	  strong	  effect	  on	  the	  cells.	  Not	  being	  able	  to	  bind	  CDK,	  more	  CKS2	  would	  be	  available	  to	  conduct	   this	   task.	   This	  might	   be	   a	   function	   similar	   to	   the	   one	   of	   CKS1	   in	   the	   SCFSkp2	  ubiquitin	   ligase,	   which	   is	   involved	   in	   the	   degradation	   of	   the	   CDK2	   inhibitor	   p27Kip1	  (Spruck	  et	  al.,	  2001).	  Loss	  of	  p27Kip1	  then	  leads	  to	  an	  up-­‐regulation	  of	  CDK2	  activity	  and	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consequently	   replicative	   stress.	   Another	   possibility	   would	   be	   that	   CKS2E63Q	   has	   a	  dominant	  negative	  effect	  on	  a	  function	  of	  CDK2.	  For	  example	  cyclin	  A	  is	  ubiquitinated	  by	  the	  APC/C	  with	  the	  help	  of	  CKS.	  Here	  cyclin	  A	  binds	  to	  CDK2	  which	  is	  in	  a	  complex	  with	  CKS	  and	  CKS	  in	  turn	  binds	  via	  its	  anion	  binding	  site	  to	  the	  phosphorylated	  APC	  complex	  and	  thus	  brings	  cyclin	  A	  into	  close	  proximity	  to	  the	  ubiquitin	  ligase	  APC/C	  (Di	  Fiore	  and	  Pines,	  2010).	  When	  CKS	   is	  not	  able	   to	  bind	  CDK	  but	  APC	  this	  CKS	  variant	  might	  block	  the	   access	   to	   the	   APC	   for	   functional	   CKS-­‐CDK-­‐cyclin	   A	   complexes.	   This	  would	   lead	   to	  excessive	   cyclin	   A,	   replicative	   stress	   and	   checkpoint	   activation,	  which	   the	   cells	  might	  want	  to	  evade	  by	  degrading	  this	  CKS	  variant.	  In	  this	  particular	  case	  a	  CKS	  variant	  with	  CDK	  and	  anion	  binding	   site	  mutation	  would	  give	   the	  answer	   to	  whether	  a	   function	   in	  which	   CKS	   acts	   as	   adaptor	   protein	   between	   CDK	   complexes	   and	   phosphoproteins	   is	  disrupted	  by	  the	  E63Q	  mutation.	  	   Following	   the	   observation	   that	   CKS	   over-­‐expression	   leads	   to	   a	   senescent	  phenotype,	   which	   is	   accompanied	   by	   high	   p53	   levels,	   the	   p53	   pathway	   should	   be	  switched	  off,	  to	  see	  whether	  growth	  arrest	  can	  be	  circumvented.	  p53	  itself	  and	  RB,	  the	  negative	   transcriptional	   regulator	   downstream	   of	   p53	   and	   p16INK4a,	   have	   been	   down-­‐regulated	   in	  my	  setting.	  When	  both	  main	  checkpoint	  proteins	   involved	   in	   the	  onset	  of	  senescence	  were	  not	  functional,	  CKS	  over-­‐expression	  did	  not	  lead	  to	  a	  growth	  arrest	  in	  the	  fibroblasts.	  Therefore	  it	  can	  be	  assumed	  that	  the	  up-­‐regulation	  of	  p53	  was	  at	   least	  one	   of	   the	  main	   reasons	   for	   arresting	   IMR90	   cells	   with	   high	   CKS	   levels.	   	   Checkpoint	  inhibited	  IMR90	  TERT	  CKS	  cells	  showed	  a	  slightly	  increased	  growth	  rate	  in	  comparison	  to	  the	  control	  cells.	  In	  a	  transformation	  assay,	  which	  examined	  the	  ability	  of	  the	  cells	  to	  grow	  anchorage	  independent,	  CKS	  over-­‐expression	  did	  not	  lead	  to	  the	  acquisition	  of	  this	  feature.	   Whether	   the	   slight	   growth	   advantage	   is	   the	   only	   reason	   leading	   to	   p53	  activation	  would	   need	   to	   be	   investigated.	   A	  migration	   assay	   for	   example	   could	   reveal	  whether	  CKS	  might	  allow	  the	  p53	  and	  RB	  negative	  cells	  to	  migrate.	  	  	   That	  CKS	  proteins	  were	  not	  able	  to	  transform	  the	  cells	  completely	  is	  not	  surprising	  since	  the	  development	  of	  cancer	  is	  a	  multistep	  process	  and	  was	  simplified	  in	  the	  model	  used.	  An	  oncogene	  like	  RAS,	  which	  acts	  on	  multiple	  pathways,	  is	  able	  to	  transform	  cells	  completely	   in	   this	   setting.	   Other	   oncogenes,	   like	   possibly	   CKS,	   have	   more	   restricted	  actions,	  like	  cell	  cycle	  progression	  or	  the	  ability	  to	  invade	  other	  tissues.	  Here	  a	  variety	  of	  other	  changes	  have	  to	  take	  place	  for	  a	  cell	  to	  become	  cancerous.	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Chapter	  5	  –	  Molecular	  analyses	  of	  the	  mechanism	  underlying	  
checkpoint	  activation	  in	  CKS	  over-­‐expressing	  IMR90	  fibroblasts	  	  
5.1	  CDK2	  activity	  in	  CKS	  over-­‐expressing	  senescent	  cells	  Analysis	   of	  CKS	   over-­‐expression	   in	   primary	   IMR90	   cells	   showed	   that	   high	   CKS	   levels	  cause	   senescence	   and	   growth	   arrest.	   p53	   up-­‐regulation	   was	   proposed	   to	   be	   the	  underlying	  reason.	  This	  was	  confirmed	  when	  CKS	  over-­‐expressing	  cells	  resumed	  growth	  upon	  down-­‐regulation	  of	  p53	  and	  its	  downstream	  effector	  RB.	  Cells,	  in	  which	  inhibition	  of	  the	  p53	  pathway	  was	  introduced,	  actually	  had	  a	  slightly	  higher	  proliferative	  capacity	  after	  CKS	  over-­‐expression.	  As	  part	  of	  the	  G1/S-­‐phase	  checkpoint,	  p53	  is	  often	  activated	  by	   replicative	   stress	   which	   causes	   stalled	   or	   collapsed	   replication	   forks.	   Replicative	  stress	  might	   be	   due	   to	   cell	   cycle	   deregulation	   and	   incorrect	   regulation	   of	   replication	  (Halazonetis	   et	   al.,	   2008).	   In	   my	   next	   set	   of	   experiments	   I	   wanted	   to	   investigate,	  whether	  this	   is	   the	  reason	  for	  checkpoint	  activation	  and	  p53	  up-­‐regulation	   in	  primary	  IMR90	   cells.	   Progression	   through	   the	   cell	   cycle	   and	   activation	   of	   specific	   checkpoints	  were	   examined	   by	   determining	   protein	   levels	   of	   cell	   cycle	   regulators	   in	   CKS	   over-­‐expressing	   fibroblasts.	   Additionally,	   the	   activity	   of	   CDK2	   was	   analysed.	   CDK2	   is	   the	  cyclin	  dependent	  kinase	  initiating	  and	  regulating	  replication	  (Halazonetis	  et	  al.,	  2008).	  CDK2	  was	  also	  reported	  to	  interact	  with	  and	  be	  kept	  active	  by	  CKS	  proteins	  (Bourne	  et	  al.,	  1996;	  Liberal	  et	  al.,	  2011).	  	  Regulation	   of	   replication	   was	   investigated	   in	   CKS	   over-­‐expressing	   IMR90	   cells	   as	  follows.	   IMR90	   fibroblasts	   were	   transduced	   with	   retroviral	   vectors	   bearing	   CKS	   or	  empty	   vector	   controls	   as	   described	   in	   Material	   and	   Methods.	   After	   seven	   days	   of	  selection,	  proteins	  were	   isolated	  for	  Western	  blot	  analysis.	  Protein	   lysates	  at	   this	  time	  point	   were	   also	   used	   for	   the	   isolation	   of	   the	   cyclin	   A/CDK2/CKS	   complex	   by	  immunoprecipitation	  (IP)	  using	  cyclin	  A	  antibodies.	  The	  success	  of	   the	  IP	  was	  verified	  by	   checking	   the	  presence	  of	  CDK2	   in	   the	   immunoprecipitated	   complex	   (Figure	  5.1	  A).	  For	   this	   purpose	   the	   complexes	   immunoprecipitated	   from	   empty	   vector	   control	   cells	  and	  CKS1	  and	  CKS2	  over-­‐expressing	  cells	  were	  separated	  by	  SDS	  page	  and	  analysed	  by	  Western	  blot	  analysis	  using	  a	  CDK2	  antibody.	  These	  complexes	  were	  also	  used	  in	  kinase	  activity	  assays	  with	  Histone	  1	  (H1)	  as	  a	  substrate.	  These	  kinase	  assays	  should	  provide	  information	  about	  what	  effect	  CKS	  over-­‐expression	  has	  on	  CDK2	  activity.	  CKS1	  and	  CKS2	  over-­‐expressing	  cells	  showed	  a	  reduced	  kinase	  activity	   in	  comparison	  to	  empty	  vector	  control	   cells	   (Figure	   5.1	  B).	   Ectopic	  CKS2	   expression	   led	   to	   a	   slight	   decrease	   in	   CDK2	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activity	   (P	   =	   0.28,	   t-­‐test).	   The	   CDK2	   activity	   in	   CKS1	   over-­‐expressing	   fibroblasts	   was	  even	   more	   affected	   with	   a	   significant	   reduction	   of	   activity	   of	   40%	   (P	   =	   0.04,	   t-­‐test).	  Western	  blot	  analyses	  revealed	  that	  p53	  and	  p21Cip1	  were	  up-­‐regulated	  in	  these	  IMR90	  cells	   upon	   CKS	   over-­‐expression	   for	   one	   week	   (Figure	   5.1	   C).	   This	   confirms	   the	   data	  obtained	  by	  immunofluorescence	  staining	  (Figure	  4.4).	  Therefore,	  a	  lower	  CDK2	  activity	  could	   be	   due	   to	   CDK2	   inhibition	   by	   the	   checkpoint	   proteins	   p53	   and	   p21Cip1	   and	   a	  general	  G1	  arrest.	  To	  verify	   this,	   the	  kinase	  assay	  was	  repeated	  with	  CDK2	  complexes	  immunoprecipitated	   using	   an	   anti-­‐cyclin	   E	   antibody.	   Cyclin	   E	   activates	   CDK2	   during	  G1/S	  transition	  (Woo	  and	  Poon,	  2003)	  and	  an	  observed	  inhibition	  of	  the	  kinase	  complex	  in	  cells	  with	  high	  CKS	   levels	  could	   indicate	  a	  general	  problem	  in	  the	  progression	  from	  G1	  to	  S-­‐phase.	  	  	   Results	  obtained	  with	  cyclin	  E-­‐CDK2	  complexes	  were	  variable	  (Figure	  5.1	  B).	  CKS	  over-­‐expression	  led	  to	  a	  non-­‐significant	  decrease	  in	  CDK2	  activity	  (PCKS1	  =	  0.19;	  PCKS2	  =	  0.8,	   t-­‐test)	   The	   kinase	   isolated	   from	   CKS1	   over-­‐expressing	   cells	   was	   moderately	   less	  active	   than	   the	   one	   from	   control	   cells.	   CKS2	   over-­‐expressing	   cells	   showed	   a	   5%	  reduction	  in	  CDK2-­‐cyclin	  E	  activity.	  The	  lower	  activity	  of	  CDK2	  in	  complex	  with	  cyclin	  A	  and	  the	  slightly	  less	  pronounced	  cyclin	  E	  associated	  CDK2	  activity	  support	  the	  idea	  that	  
CKS	   over-­‐expression	   in	   primary	   fibroblasts	   leads	   to	   checkpoint	   activation	   and	  consequently	  G1	  arrest	  in	  primary	  fibroblasts.	  	  
5.2	  A	   short	  period	  of	  CKS	   over-­‐expression	   leads	   to	   the	  activation	  of	  
the	  G1/S-­‐phase	  checkpoint	  in	  primary	  fibroblasts	  
	  In	  a	  next	  step	  it	  was	  investigated	  whether	  checkpoint	  activation	  and	  CDK2	  inhibition	  is	  set	  early	  after	  initiation	  of	  CKS	  over-­‐expression	  or	  only	  after	  extended	  periods	  of	  over-­‐expression.	  For	  these	  studies	  analysis	  was	  performed	  the	  day	  after	  transduction	  of	  the	  IMR90	  cells	  with	  the	  CKS1	  and	  2	  constructs.	  The	  analysis	  of	  various	  cell	  cycle	  regulators	  pointed	  out	   that	  one	  day	  after	  expression	  of	  ectopic	  CKS1	  and	  CKS2,	  p53	  was	  already	  considerably	  elevated	  (Figure	  5.2	  A).	  p21Cip1	  also	  showed	  a	  slight	  up-­‐regulation.	  These	  results	  indicate	  that	  expression	  of	  CKS	  proteins	  leads	  to	  an	  acute	  checkpoint	  activation	  in	  primary	  IMR90	  cells.	  p53	  and	  p21Cip1	  are	  effector	  proteins	  of	  the	  G1/S-­‐phase	  as	  well	  as	  intra	  S-­‐phase	  checkpoints,	  which	  impair	  the	  progression	  from	  early	  stages	  of	  the	  cell	  cycle	   through	  S-­‐	  and	   towards	  G2-­‐	  and	  M-­‐phase	   (Bartek	  and	  Lukas,	  2001;	  Gartel	   et	   al.,	  1996).	  This	  is	  in	  accordance	  with	  a	  slight	  elevation	  of	  cyclin	  D1,	  a	  G1	  phase	  cyclin,	  that	  I	  have	  observed	   in	   these	  studies	   in	  CKS1	   and	  2	  over-­‐expressing	   IMR90	  cells	   (Figure	  5.2	  A).	  Cyclin	  B1	   in	  contrast,	   an	   important	  cyclin	  during	   late	  S	  and	  G2	  phase,	  was	  slightly	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decreased.	  No	  change	  could	  be	  observed	  in	  the	  overall	  amount	  of	  the	  S-­‐phase	  cyclins	  E	  and	  A	  as	  well	  as	  MCM2,	  which	  is	  part	  of	  the	  pre-­‐replication	  complex.	  	  	   A	  slightly	  lower	  activity	  of	  CDK2-­‐cyclin	  A	  complexes	  also	  indicated	  the	  activation	  of	  the	  G1/S	  phase	  checkpoint	  upon	  one	  day	  of	  CKS	  over-­‐expression	  in	  IMR90	  cells	  (Figure	  5.2	   B	   and	   C).	   However	   CDK2	   activity	   in	   CKS1	   over-­‐expressing	   cells	   was	   not	   yet	  significantly	  lower	  than	  in	  control	  cells	  (Figure	  5.2	  C).	  	  	   Together	  with	  the	  elevation	  of	  G1	  cyclins	  as	  well	  as	  p53	  and	  p21Cip1	  up-­‐regulation	  after	  one	  day	  of	  CKS	  over-­‐expression	   the	  data	  points	  out	   that	  one	  cell	   cycle	   is	  already	  enough	  to	  activate	  the	  G1/S	  checkpoint	  in	  primary	  fibroblasts.	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It	  was	  shown	  in	  previous	  publications	  that	  the	  G1/S-­‐phase	  checkpoint	  can	  be	  activated	  by	  stress	  occurring	  early	  during	  replication	  or	  DNA	  damage,	  accompanied	  by	  high	  levels	  of	  RPA	  and	  γH2AX	  (Boye	  et	  al.,	  2009;	  Liu	  et	  al.,	  2012).	  The	  RPA	  protein	  binds	  to	  single	  stranded	  DNA,	  which	  is	  present	  in	  higher	  ratios	  at	  stalled	  forks	  during	  replicative	  stress	  (Oakley	  and	  Patrick,	  2010).	  Stalled	  forks	  also	  lead	  to	  the	  creation	  of	  DNA	  double	  strand	  breaks	  and	  phosphorylation	  of	  histone	  H2AX	  (γ-­‐H2AX)	  (Fillingham	  et	  al.,	  2006).	  	  	   To	  determine	   if	   the	  G1/S	  phase	   checkpoint	  was	   activated	   in	  CKS	   over-­‐expressing	  cells	  by	  replicative	  stress,	  RPA	  and	  γ-­‐H2AX	  levels	  were	  analysed.	  Levels	  of	  RPA	  and	  γ-­‐H2AX	   in	  CKS	  over-­‐expressing	  cells	  however	  were	  not	  altered	  (Figure	  5.2	  A).	  Thus,	   the	  reason	  for	  p53	  and	  p21Cip1	  up-­‐regulation	  needs	  to	  be	  further	  investigated.	  	  	  To	  study	  whether	  CKS	  over-­‐expression	  affects	  cell	  cycle	  regulation	  and	  CDK2	  activity	  via	  mechanisms	   independent	   to	   the	   down-­‐regulation	   of	   CDK	   activity	   by	   G1/S	   checkpoint	  activation,	   I	   used	   HEK	   293T	   cells	   as	   this	   cell	   line	   is	   deficient	   in	   the	   G1/S	   checkpoint	  (Ahuja	   et	   al.,	   2005;	   DuBridge	   et	   al.,	   1987).	   HEK	   293T	   cells	   are	   derived	   from	   human	  embryonic	   kidney	   cultures	   and	   contain	   chromosomal	   abnormalities	   as	   well	   as	   gene	  expression	   for	   the	  SV40	  Large	  T-­‐antigen	  (SV40	  TAg).	  SV40	  TAg	   inhibits	   the	  activity	  of	  p53	   and	   RB	   (An	   et	   al.,	   2012).	   For	   the	   inhibition	   of	   p53	   SV40	   TAg	   binds	   to	   p53	   and	  inhibits	   it	   transcriptional	   activity.	   Transcriptional	   targets	   like	   p21Cip1	   are	   therefor	   not	  transcribed.	   Via	   the	   binding	   to	   p53	   TAg	   stabilises	   p53.	   SV40-­‐transformed	   cells	   thus	  harbour	   generally	  high	  p53	   levels.	   Inhibition	  of	  RB	   leads	   to	   the	   general	   expression	  of	  E2F	  transcription	  factor	  regulated	  genes	  (An	  et	  al.,	  2012).	  As	  expected,	  no	  p53	  or	  p21Cip1	  up-­‐regulation	   could	   be	   observed	  when	  CKS	  was	   over-­‐expressed	   in	   these	   cells	   (Figure	  5.2	  A).	   Kinase	   assays	  were	   performed	  with	   complexes	   isolated	   via	   cyclin	  A	   IPs	   in	   the	  same	  way	   as	   described	   above,	  with	  Histone	  H1	   as	   the	   CDK2	   substrate.	   The	   ability	   of	  CDK2	   to	   phosphorylate	   Histone	   H1	   was	   neither	   significantly	   up-­‐	   or	   down-­‐regulated	  upon	  CKS	   over-­‐expression.	  As	  observed	  before	   in	   IMR90	   fibroblasts,	  RPA	  and	  γ-­‐H2AX	  levels	  were	  not	  increased	  (Figure	  5.2	  A).	  	  	   The	   level	   of	   the	   CDK2	   inhibitor	   p27Kip1	   was	   also	   determined	   in	   293T	   cells.	   It	   is	  known	  that	  p27Kip1	  is	  marked	  for	  degradation	  by	  ubiquitination	  via	  the	  SCFSkp2	  ubiquitin	  ligase.	   During	   this	   process	   CKS1	   acts	   as	   a	   linker	   protein	   between	   the	   ubiquitin	   ligase	  and	   p27Kip1	   and	   therefore	   facilitates	   its	   degradation	   (Spruck	   et	   al.,	   2001).	   Previous	  studies	  in	  cancer	  cells	  show	  that	  high	  CKS1	  levels	  are	  often	  correlated	  with	  low	  p27Kip1	  levels.	   Thus	   p27Kip1	   down-­‐regulation	   was	   suggested	   to	   be	   one	   mechanism	   by	   which	  CKS1	  promotes	  proliferation	  in	  cancer	  cells	  (Kitajima	  et	  al.,	  2004;	  Lee	  et	  al.,	  2011;	  Wang	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et	   al.,	   2009).	   In	   my	   setting	   p27Kip1	   levels	   were	   unchanged	   after	   one	   day	   of	   CKS	   up-­‐regulation	  in	  293T	  cells.	  	  	   In	   experiments	   on	   G1/S	   checkpoint	   deficient	   293T	   cells,	  CKS	   over-­‐expression	   for	  one	   day	   had	   no	   direct	   influence	   on	   the	   CDK2	   activity.	   Likewise	   an	   indirect	   effect	   on	  CDK2	  activity	  due	  to	  p27Kip1	  down-­‐regulation	  can	  be	  excluded.	  	   Overall,	  cell	  cycle	  protein	  analyses	  performed	  confirmed	  the	  activation	  of	  the	  G1/S	  checkpoint	   in	   IMR90	   fibroblasts.	   Checkpoint	   activation	   supports	   the	   idea	   of	   CKS	  exhibiting	   oncogenic	   activity.	   p53	   activation	   is	   in	   agreement	   with	   the	   observed	  reduction	   in	  CDK2	  activity	   in	  primary	   cells.	   Studies	   in	   checkpoint	  deficient	  293T	  cells	  did	  not	  show	  a	  significant	  effect	  of	  CKS	  on	  CDK2	  activity.	  At	  a	  time	  point	  of	  one	  day	  after	  
CKS	   over-­‐expression	   the	   effect	   this	   over-­‐expression	   has	   on	   cells	   seems	   to	   be	   p27Kip1	  independent.	  	  
	  
5.3	  Phospho-­‐protein	  binding	  by	  CKS	  proteins	  Earlier	   in	   the	   project,	   the	   up-­‐regulation	   of	   senescence	   markers	   upon	   CKS	   over-­‐expression	  was	   presented.	   In	   these	   experiments	   the	   CKSE63Q	  mutants,	  which	   have	   a	  reduced	  ability	  to	  bind	  to	  CDK1	  and	  2,	  showed	  a	  slightly	  less	  pronounced	  phenotype	  for	  the	   appearance	   of	   SAHF,	   inhibition	   of	   proliferation	   and	   β-­‐galactosidase	   activity	  compared	   to	   wt	   CKS	   proteins.	   The	   lower	   levels	   of	   senescence	   markers	   in	   CKSE63Q-­‐expressing	  cells,	  might	  suggest	  that	  a	  CDK-­‐dependent	  oncogenic	  effect	  of	  CKS	  proteins	  cannot	  be	  excluded.	  	   To	   determine	   whether	   CKS	   might	   support	   CDK	   activity	   by	   functioning	   as	   an	  adaptor	   protein	   between	  CDK	   and	   its	   phosphorylated	   targets,	  mutated	   forms	  of	  CKS1	  and	   2	   were	   constructed	   by	   site	   directed	  mutagenesis.	   These	  mutants	   are	   not	   able	   to	  bind	   to	   phospho-­‐proteins	   via	   their	   anion-­‐binding	   site	   and	   are	   thus	   called	   CKS	   anion	  mutant	  (CKS1AM	  and	  CKS2AM).	  As	  in	  the	  CKS	  wt	  constructs,	  CKS1AM	  and	  CKS2AM	  have	  been	  FLAG-­‐tagged.	  To	  test	  for	  the	  efficient	  expression	  of	  these	  constructs	  in	  IMR90	  cells,	  quantitative	  real	  time	  PCR	  as	  well	  as	  Western	  blot	  analyses	  were	  performed.	  Although	  transcription	   levels	   of	  CKS1AM	   and	  CKS2AM	  were	  higher	   than	   that	   observed	   for	   their	  wild-­‐type	  and	  E63Q	  forms	  (Figure	  5.3	  A),	  the	  FLAG-­‐tagged	  CKSAM	  proteins	  could	  not	  be	  detected	  by	  Western	  blot.	  	   DNA	  sequences	  of	   the	  vectors	  were	  obtained	  to	  ensure	  accuracy	  of	   the	  constructs	  (Figure	  2.1,	  Material	  and	  Methods).	  As	  transcription	  levels	  of	  CKS1AM	  and	  CKS2AM	  were	  satisfactory	   a	   higher	   degradation	   rate	   was	   assumed	   as	   a	   reason	   for	   the	   lack	   of	  detectable	   CKSAM	   proteins.	   To	   test	   whether	   these	   CKS	   mutants	   were	   targeted	   to	   a	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higher	  degree	   for	  proteasomal	  degradation,	  cells	  were	   incubated	  with	  the	  proteasome	  inhibitor	  MG132.	  Upon	  treatment	  for	  5	  hours,	  both	  CKS1AM	  and	  CKS2AM	  were	  clearly	  detectable	  (Figure	  5.3	  B).	   It	   is	  worth	  mentioning,	   that	   levels	  of	   the	  CKS2E63Q	  protein,	  which	  showed	  only	  low	  expression	  levels	  before,	  could	  also	  be	  increased	  by	  proteasome	  inhibition.	  I	  therefore	  conclude	  that	  the	  inability	  of	  CKS2	  to	  bind	  CDK	  and	  the	  lack	  of	  the	  phosphoprotein	   binding	   site	   in	   both	   CKS	   homologues	   results	   in	   an	   enhanced	  proteasomal	  degradation	  of	  the	  proteins.	  
Figure	  5.2	  CKS	  over-­‐expression	  leads	  to	  checkpoint	  activation	  and	  reduced	  kinase	  activity	  within	  one	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Figure	  5.3	  Mutations	  in	  the	  anion-­‐binding	  site	  of	  CKS1	  and	  2	  lead	  to	  degradation	  of	  CKS	  proteins	  via	  
the	  proteasome.	   IMR90	  fibroblasts	  were	  transduced	  with	  retroviral	  constructs	  bearing	  the	  sequences	  for	  
wt	  CKS1	  and	  2,	  CKS1E63Q	  and	  CKS2E63Q	  as	  well	  as	  CKS1AM	  and	  2AM	  which	  code	  for	  CKS	  variants	  unable	  to	  bind	   phospho-­‐proteins.	   Cells	   were	   selected	   for	   seven	   days	   in	   medium	   containing	   puromycin.	   (A)	  Quantitative	   RT-­‐PCR	   showing	   mRNA	   of	   ectopic	   CKS1	   and	   2	   in	   IMR90	   fibroblasts	   over-­‐expressing	   the	  indicated	  CKS	  variants	  (left	  panel).	  Western	  blot	  analysis	  detecting	  the	  FLAG-­‐tagged	  CKS	  proteins	  in	  protein	  samples	  derived	  from	  the	  indicated	  cell	  lines	  after	  seven	  days	  in	  selection.	  (B)	  Before	  isolation	  of	  proteins	  for	  Western	  blot	  analysis	  cells	  were	  treated	  for	  5	  hours	  with	  10	  µM	  MG132.	  IMR90	  cells	  transduced	  with	  the	   empty	   vector	   control,	   CKS1	   and	   2	   vectors	   as	   well	   as	   CKS1AM	   and	   CKS2AM	   vectors	   were	   examined	  regarding	   the	  expression	  of	  FLAG-­‐	   tagged	  protein	  and	  overall	  CKS1	  and	  2	  (upper	  panel).	  The	  experiment	  was	  repeated	  for	  all	  CKS	  variants	  using	  an	  antibody	  detecting	  CKS1	  and	  2	  (lower	  panel).  
 
 
5.4	  Discussion	  Initial	  analyses	  have	  been	  conducted	  to	  elucidate	  how	  high	  levels	  of	  CKS	  proteins	  might	  cause	  G1/S	  checkpoint	  activation.	  In	  previous	  studies	  G1/S	  checkpoint	  activation	  was	  a	  result	  of	  deregulated	  initiation	  of	  replication	  via	  an	  altered	  CDK2	  activity	  (Branzei	  and	  Foiani,	   2009;	   Kilbey	   et	   al.,	   1999;	   Neganova	   et	   al.,	   2011;	   Zhao	   et	   al.,	   2012).	   Therefore	  CDK2	  kinase	  activity	  assays	  were	  performed.	  In	  the	  first	  instance	  the	  suspected	  down-­‐regulation	  of	  the	  activity	  of	  the	  cyclin	  A-­‐CDK2-­‐CKS	  complex	  upon	  a	   long	  period	  of	  CKS	  over-­‐expression	   in	  primary	   fibroblasts	  was	  confirmed.	  The	   lower	  CDK2	  activity	  was	  a	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result	   of	   the	   onset	   of	   senescence	   in	   these	   cells.	   Earlier	   in	   this	   study	   I	   showed	   that	  primary	   IMR90	   fibroblasts	   have	   entered	   a	   senescent	   state	   already	   one	   week	   after	  transduction	  with	   the	   CKS	   constructs.	   This	   state	   is	   accompanied	   by	   the	   expression	   of	  CDK2	  inhibitors	  like	  p21Cip1,	  which	  was	  confirmed	  here	  by	  Western	  blot	  analysis.	  	  	   To	  study	  the	  effect	  of	  CKS	  over-­‐expression	  on	  CDK2	  activity	  upon	  a	  short	  period	  of	  time,	  an	  earlier	  time	  point	  for	  the	  kinase	  activity	  assays	  was	  chosen.	  After	  only	  one	  day	  of	   ectopic	   CKS	   expression,	   IMR90	   cells	   showed	   a	   reduced	   CDK2	   activity.	   This	   is	   an	  interesting	  observation	  as	  previous	  studies	  suggested	  that	  CKS	  has	  a	  positive	  influence	  on	  CDK2	  activity	  possibly	  by	  keeping	  CDK2	   in	   an	   active	   form	   (Liberal	   et	   al.,	   2011)	  or	  down-­‐regulating	  one	  of	  its	  inhibitors	  (Spruck	  et	  al.,	  2001).	  However	  those	  studies	  were	  not	  conducted	   in	  primary	  human	  cell	   cultures.	   In	   the	  primary	   IMR90	  cells	  used	   in	  my	  study,	   an	   up-­‐regulation	   of	   p53	   and	   p21Cip1	   could	   be	   observed	   already	   the	   day	   after	  transfecting	   the	   cells	   with	   CKS	   constructs.	   High	   p53	   and	   p21Cip1	   levels	   therefore	  contributed	  to	  the	  low	  kinase	  activity.	  	  	   Checkpoint	  activation	  suggests	  preceding	  DNA	  damage	  or	  other	  events	  caused	  by	  deregulated	   replication	   like	   stalled	   and	   collapsed	   forks.	   H2AX,	   a	   marker	   for	   DNA	  damage,	  becomes	  phosphorylated	  by	  kinases	  such	  as	  ATM	  at	  the	  appearance	  of	  a	  DNA	  break.	   ATM	   binds	   to	   the	   DNA	   upon	   double	   strand	   breaks	   and	   is	   then	   able	   to	  phosphorylate	  the	  histone	  variant,	  which	  is	  then	  designated	  γ-­‐H2AX.	  Whereas	  this	  has	  been	   well	   documented	   for	   double	   strand	   break	   formation	   upon	   radiation,	   the	  involvement	  of	   γ-­‐H2AX	   in	  other	   replication	   stress	   responses	  has	  not	  been	  proven	   (de	  Feraudy	  et	  al.,	  2010;	  Revet	  et	  al.,	  2011).	   	  Therefore,	   the	   lack	  of	  an	   increase	   in	  γ-­‐H2AX	  after	  initial	  CKS	  expression	  might	  not	  indicate	  a	  lack	  of	  impaired	  replication	  in	  CKS	  over-­‐expressing	  cells.	  Thus	  another	  marker	   for	   the	  detection	  of	  replicative	  stress,	  RPA,	  was	  tested.	  During	  unperturbed	  replication	  RPA	  binds	  to	  single	  stranded	  DNA	  and	  keeps	  it	  from	  winding	  back	  (Wold	  and	  Kelly,	  1988).	  During	  replicative	  stress	  RPA	  binds	   to	   the	  accumulating	   long	   stretches	   of	   single	   stranded	   DNA	   and	   is	   believed	   to	   take	   part	   in	  replication	   stress	   responses	   like	   fork	   stabilization,	   fork	   restart	   and	   finally	   checkpoint	  activation	   (Fanning	   et	   al.,	   2006;	   Zou	   et	   al.,	   2006).	   In	   the	   IMR90	   cells	   used	   here,	   CKS	  over-­‐expression	   did	   not	   lead	   to	   an	   overall	   accumulation	   of	   RPA.	   During	   replicative	  stress	   response,	   RPA	   is	   hyperphosphorylated	   on	   specific	   residues	   by	  members	   of	   the	  phosphatidylinositol	   3-­‐kinase-­‐like	   kinases	   like	   ATR	   (Block	   et	   al.,	   2004).	   In	   further	  experiments,	  antibodies	  specific	  for	  these	  phosphorylation	  sites	  could	  be	  used	  to	  detect	  potential	   replicative	   stress	   induction	   caused	   by	   CKS	   over-­‐expression	   in	   IMR90	   cells.	  	  Furthermore,	   IMR90	   cells	   expressing	   different	   oncogenes,	   which	   result	   in	   replicative	  stress	  should	  be	  used	  as	  controls	  to	  facilitate	  the	  analyses.	  Additionally	  the	  presence	  of	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other	  markers	  for	  replication	  stress	  like	  other	  phosphorylated	  downstream	  effectors	  of	  ATR	   could	   be	   analysed.	   Cell	   cycle	   studies	   via	   flow	   cytometry	   and	   protein	   expression	  analyses	   in	   the	   single	   cell	   cycle	   phases	  would	   help	   to	   detect	   exactly	  when	   in	   the	   cell	  cycle	  CKS	  over-­‐expressing	  cells	  arrest.	  	   In	   transformed	  HEK	  293T	  cells,	   in	  which	   the	  TAg	   inhibits	  G1/S	  phase	   checkpoint	  activation	  as	  described	  above,	  p53	  and	  p21Cip1	  up-­‐regulation	  was	  not	  observed.	  Kinase	  activity	  in	  CKS	  over-­‐expressing	  293T	  cells	  was	  not	  down-­‐regulated	  indicating	  once	  more	  that	   G1/S	   checkpoint	   activation	   led	   to	   CDK2	   inhibition	   in	   fibroblasts	   with	   intact	  checkpoints.	  	  	   CDK2	   activity	   in	  CKS	   over-­‐expressing	   293T	   cells	   did	   also	   not	   significantly	   exceed	  that	  measured	  for	  empty	  vector	  control	  cells.	  This	  might	  suggest	  an	  effect	  of	  CKS,	  which	  is	  independent	  of	  direct	  interaction	  with	  CDK2.	  	  It	  needs	  to	  be	  mentioned	  however,	  that	  the	  used	  kinase	  activity	   assay	  was	  mainly	  designed	   to	  detect	  CDK	  activity	  per	   se.	  The	  assay	  might	  not	  be	  suitable	  to	  detect	  specific	  varieties	  of	  enhanced	  CDK	  activity.	  	  In	  my	  studies	   the	   kinase	   complex	   was	   isolated	   via	   immunoprecipitation	   from	   CKS	   over-­‐expressing	   cell	   lysates	   and	  measured	   by	   its	   ability	   to	   phosphorylate	   histone	   H1.	   The	  assay	   can	   therefore	   detect	   altered	   CDK2	   activity	   when	   it	   is	   due	   to	   conformational	  changes	   of	   CDK2	   as	   it	   was	   proposed	   earlier	   (Liberal	   et	   al.,	   2011),	   regulation	   of	  inhibitory	  or	  activating	  phosphorylation	  of	  CDK2	  or	  direct	  inhibition	  by	  CDK	  inhibitory	  proteins.	   One	   possibility	   is	   if	   CKS	   enhances	   CDK2	   activity	   by	   acting	   as	   an	   adaptor	  protein	  between	  CDK2	  and	  certain	  phospho-­‐proteins,	   this	  would	  not	  be	  recognised	  by	  the	   assay,	   unless	   the	   substrate	   for	   which	   the	   phosphorylation	   by	   CDK2	   is	   facilitated,	  happens	  to	  be	  histone	  H1.	  To	  test	  whether	  CKS	  facilitates	  the	  phosphorylation	  of	  certain	  substrates	  by	  acting	  as	  an	  adaptor	  protein,	  different	  CDK2	  target	  proteins	  could	  be	  used	  in	   a	   kinase	   assay	   screen.	   Alternatively	   the	   phosphorylation	   status	   of	   these	   target	  proteins	  could	  be	  analysed	  via	  Western	  blot	  analysis.	  	  	  	   Investigations	  into	  the	  importance	  of	  phospho-­‐protein	  binding	  by	  the	  CKS	  proteins	  should	   have	   been	   performed	   in	   the	   present	   study	   as	   well.	   Therefore	   CKS	   variants	  (CKS1AM	  and	  CKS2AM)	  were	  produced,	  which	   are	  not	   able	   to	  bind	  phospho-­‐proteins	  due	  to	  mutations	  in	  their	  anion-­‐binding	  site.	  This	  would	  presumably	  prevent	  CKS	  from	  functioning	  as	  an	  adaptor	  protein	  between	  enzymes	  like	  CDK2	  or	  the	  SCFSkp2	  ubiquitin	  ligase	  and	   their	  phosphorylated	   target	  proteins.	  The	  aim	  was	   to	   investigate	  a	  possible	  role	   for	   phospho-­‐protein	   binding	   in	   the	   induction	   of	   senescence	   in	   primary	   cells	   and	  enhanced	   proliferation	   in	   transformed,	   checkpoint-­‐inhibited	   cells.	   Protein	   analysis	  revealed	  however,	  that	  neither	  the	  CKS1AM	  nor	  CKS2AM	  transduced	  cells	  were	  able	  to	  express	   the	   protein.	   The	   anion	   binding	   site	   mutant	   was	   quickly	   degraded	   by	   the	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proteasome	   as	   observed	   before	   for	   the	   CKS2E63Q	   variant.	   Only	   the	   addition	   of	   the	  proteasome	   inhibitor	   MG132	   prevented	   the	   degradation	   of	   CKS2E63Q	   as	   well	   as	   the	  CKSAM	  mutants.	  The	   cells	   do	  not	   seem	   to	   tolerate	   the	   expression	  of	   the	  proteins	   and	  promote	  their	  fast	  degradation.	  This	  may	  be	  a	  result	  of	  the	  mutant	  proteins	  disrupting	  essential	   pathways	   in	   the	   cells	   by	   preventing	   binding	   of	   not	   previously	   described	  phospho-­‐proteins.	  Another	  cell	  damaging	  effect	  might	  be	  caused	  by	  excessive	  amounts	  of	  CKS	  proteins,	  which	  are	  available	  for	  anion	  binding	  site	  independent	  functions	  of	  CKS.	  Boosting	  these	  anion	  binding	  site	  independent	  functions	  might	  not	  be	  tolerable	  for	  the	  cells.	   Further	   experiments	   would	   be	   necessary	   to	   reveal	   the	   importance	   of	   phospho-­‐protein	  binding	  in	  the	  oncogenic	  function	  of	  CKS.	  The	  use	  of	  the	  proteasome	  inhibitors	  in	   cell	   cycle	   analyses	   however	   would	   impair	   the	   analysis.	   Additionally,	   experiments	  running	  for	  longer	  periods	  of	  times,	   like	  the	  ones	  necessary	  to	  investigate	  the	  onset	  of	  senescence,	   are	   not	   applicable.	   Instead,	   experiments	   in	   which	   the	   anion	   binding	   site	  mutant	  is	  expressed	  for	  a	  short	  time	  in	  the	  presence	  of	  the	  proteasome	  inhibitor	  might	  reveal	   further	   functions	   involving	   the	   ability	   of	   CKS	   proteins	   to	   bind	   to	   phospho-­‐proteins.	  These	   experiments	  would	   involve	   the	   analyses	  of	   cell	   cycle	  protein	   levels	   as	  well	  as	  their	  phosphorylation	  and	  ubiquitination	  status.	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Chapter	  6	  –	  Final	  discussion	  
	  
6.1	  CKS	  as	  oncogenes	  
CKS1	  and	  CKS2	  over-­‐expression	  has	  been	  described	  in	  a	  variety	  of	  cancers	  (Calvisi	  et	  al.,	  2009;	  Chang	  et	  al.,	  2010;	  Chen	  et	  al.,	  2011;	  de	  Wit	  et	  al.,	  2005;	  Fonseca	  et	  al.,	  2006;	  Inui	  et	  al.,	  2003;	  Lan	  et	  al.,	  2008;	  Lee	  et	  al.,	  2011;	  Li	  et	  al.,	  2004;	  Liu	  et	  al.,	  2008;	  Lyng	  et	  al.,	  2006;	  Masuda	   et	   al.,	   2003;	   Shapira	   et	   al.,	   2005;	   Slotky	   et	   al.,	   2005;	   van	   't	   Veer	   et	   al.,	  2002;	   Wang	   et	   al.,	   2009;	   Westbrook	   et	   al.,	   2009;	   Zhan	   et	   al.,	   2007).	   	   In	   addition	   to	  expression	  analysis	   in	  tumour	  samples,	  studies	  in	  which	  a	  potential	  oncogenic	  role	  for	  CKS	   proteins	   was	   investigated	   were	   performed	   in	   vitro.	   The	   in	   vitro	   systems	   used	  however,	   were	   almost	   exclusively	   based	   on	   existing	   cancer	   cell	   lines	   expressing	   high	  levels	  of	  CKS	  proteins.	  In	  these	  cell	  lines,	  the	  role	  of	  CKS	  proteins	  as	  oncogenes	  has	  been	  mainly	   studied	   by	   down-­‐regulating	  CKS1	   and	  CKS2.	   In	   cell	   cultures	   derived	   from	  oral	  squamous	   cell	   carcinomas	   it	  was	   shown	   for	   example,	   that	   a	   down-­‐regulation	   of	  CKS1	  leads	  to	  a	  decrease	  in	  proliferation	   in	  vitro.	  A	  lower	  proliferation	  was	  also	  observed	  in	  tumours	  derived	  from	  mice,	  which	  have	  been	  injected	  with	  these	  cells	  (Kitajima	  2004).	  	   Similarly,	   Lan	   and	   colleagues	   showed	   that	   down-­‐regulation	   of	  CKS1	   in	   otherwise	  CKS1-­‐high	   AT3	   prostate	   cancer	   cells	   led	   to	   a	   decrease	   in	   cell	   growth.	   They	   also	  described	  an	  inhibition	  of	  anchorage-­‐independent	  growth	  due	  to	  the	  loss	  of	  CKS1.	  In	  the	  same	  study	  down-­‐regulation	  of	  CKS2	   in	  prostate	  tumour	  cells	  derived	  from	  transgenic	  adenocarcinomas	   of	   the	   mouse	   prostate	   (TRAMP),	   led	   to	   an	   enhanced	   apoptotic	  phenotype	  of	   the	   cells.	   CKS2	   inhibition	   in	  TRAMP	   cells,	  which	  were	   transplanted	   into	  mice,	  resulted	  in	  a	  decreased	  tumorigenicity	  in	  comparison	  to	  CKS2	  expressing	  TRAMP	  transplants	  (Lan	  2008).	  	  	   Wang	   et	   al.	   also	   showed	   a	   reduced	   growth	   and	   invasion	   ability	   of	   MDA-­‐MB-­‐231	  breast	  cancer	  cells	  after	  CKS1	  knockdown	  by	  RNA	  inference	  (Wang	  2009).	  	  	   In	  a	   later	  study	  CKS1	  knock-­‐down	  in	  hepatocellular	  carcinoma	  cells	  was	  shown	  to	  result	   in	   a	   lower	   proliferation	   rate	   as	   well	   as	   decreased	   tumorigenicity,	   which	   was	  associated	   with	   down-­‐regulation	   of	   IL8	   (Lee	   2011).	   These	   studies	   all	   indicate	   that	  higher	  levels	  of	  CKS	  proteins	  confer	  proliferative	  advantage	  for	  many	  cancer	  cells.	  As	  it	  was	  shown	  that	  CKS	  proteins	  have	  various	  functions	  within	  the	  cell	  cycle,	  this	  was	  to	  be	  expected.	  The	  observed	  reduction	  in	  the	  ability	  of	  invasion	  and	  anchorage	  independent	  growth	  when	  CKS	  is	  decreased	  could	  also	  be	  a	  result	  of	  a	  slower	  proliferation.	  	  	   Therefore	  it	  is	  not	  understood	  whether	  CKS	  acts	  as	  a	  real	  oncogene,	  contributing	  to	  the	  transformation	  process	  of	  primary	  cells	  to	  cancer	  cells.	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   During	  my	  studies	   I	  approached	   this	  question	  by	  over-­‐expressing	  CKS	  proteins	   in	  primary	   IMR90	   fibroblasts,	   which	   were	   undergoing	   a	   transformation	   process	   from	  primary	  fibroblasts	  to	  tumour	  suppressor-­‐inhibited	  cells.	  I	  have	  shown	  that	  high	  levels	  of	  CKS	  proteins	  lead	  to	  an	  impact	  on	  G1/S	  phase	  transition	  and	  the	  activation	  of	  tumour	  suppressor	   pathways	   in	   primary	   IMR90	   fibroblasts	   resulting	   in	   a	   senescent	   state.	  Induction	  of	  senescence	  in	  otherwise	  unperturbed	  cells	  also	  occurs	  upon	  the	  activation	  of	   a	   range	   of	   oncogenes	   such	   as	   RAS,	   RAF,	   AKT	   and	   cyclin	   E	   (Bartkova	   et	   al.,	   2006;	  Michaloglou	  et	  al.,	  2005;	  Minamino	  et	  al.,	  2004;	  Serrano	  et	  al.,	  1997).	  CKS	  proteins	  thus	  have	   the	   same	   impact	   as	   oncogenes	   on	   cells	   with	   normal	   tumour	   suppressor	   gene	  function.	   In	   the	   next	   step	   I	   was	   able	   to	   show	   that	   inhibition	   of	   tumour	   suppressor	  pathways	   in	  CKS	   over-­‐expressing	   cells	   alleviates	   growth	   arrest	   and	   leads	   to	   a	  modest	  proliferative	   advantage	   in	   CKS	   over-­‐expressing	   checkpoint	   inhibited	   cells.	   Complete	  transformation	  of	  the	  cells,	   leading	  to	  the	  ability	  to	  grow	  in	  an	  anchorage	  independent	  way,	   however	   could	   not	   be	   achieved	   by	   CKS	   over-­‐expression	   alone.	   These	   results	  suggest	  that	  CKS	  proteins	  act	  as	  oncogenes	  by	  their	  positive	  influence	  on	  proliferation.	  CKS	   therefore	  may	   act	   early	   in	   the	   oncogenic	   pathway	  during	  multistage	   tumorigenic	  transformation	   (Figure	   6.1).	   Together	  with	   events	   like	   the	   activation	   of	   other	   growth	  sustaining	   signalling	   pathways	   as	   well	   as	   the	   activation	   of	   TERT	   and	   inhibition	   of	  growth	   inhibiting	   tumour	   suppressor	   genes,	   the	   up-­‐regulation	   of	   CKS	   proteins	  contributes	   to	   the	  high	  and	   indefinite	  proliferative	  capacity	  of	  neoplastic	  cells.	  For	   the	  further	  establishment	  of	   the	  growing	  tumour	  additional	  steps	  are	  necessary	  (Hanahan	  and	   Weinberg,	   2011).	   To	   allow	   sufficient	   supply	   of	   nutrients	   and	   oxygen,	   growing	  tumours	   undergo	   an	   angiogenic	   switch	   induced	   by	   the	   activation	   of	   VEGF	   (Carmeliet,	  2005;	   Hanahan	   and	   Weinberg,	   2011).	   In	   the	   next	   step	   of	   multistage	   tumorigenesis,	  neoplastic	   cells	   acquire	   the	   ability	   to	   invade	   their	   surrounding	   tissues	   and	   form	  metastases	   in	   distant	   organs.	   This	   program,	   which	   is	   referred	   to	   as	   epithelial-­‐mesenchymal	  transition	  (EMT),	  is	  characterised	  by	  the	  expression	  of	  matrix	  degrading	  enzymes	   like	  Matrix	  metalloproteinases	   and	   loss	  of	  E-­‐cadherin,	  which	   leads	   to	   loss	  of	  adherent	   junctions	   (Compagni	   and	   Christofori,	   2000;	   Hanahan	   and	  Weinberg,	   2011).	  Whereas	   oncogenic	   RAS	   has	   been	   reported	   to	   be	   involved	   in	   the	   regulation	   of	   EMT	  (Janda	   et	   al.,	   2002a)	   and	   is	   thus	   able	   to	   transform	   neoplastic	   cells	   completely,	   the	  function	   of	   CKS	   in	   cancer	   development	   seems	   to	   be	   restricted	   to	   its	   contribution	   to	  enhance	  proliferation.	  As	  a	  high	  proliferative	  rate	   is	  one	  of	   the	  main	  characteristics	  of	  aggressive	  cancers,	  CKS	  proteins	  may	  provide	  a	  therapeutic	  target	  in	  cancer	  treatment.	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  Figure	  6.1	  Simplified	  model	   indicating	   the	   role	   of	   CKS	   proteins	   during	  multi	   stage	   carcinogenesis.	  The	   process	   of	   cell	   transformation	   is	   a	   multi-­‐step	   process	   and	   involves	   several	   alterations	   within	   the	  signalling	  networks	  of	  a	  cell.	  During	  early	  events	  cells	  gain	  the	  ability	  of	  unrestricted	  growth.	  By	  mutations	  in	  cell	  cycle	  activating	  signalling	  pathways	  they	  become	  independent	  of	  growth	  signals.	  Often	  proliferation	  is	   accelerated.	   One	   component	   contributing	   to	   this	   accelerated	   growth	   of	   these	   neoplastic	   cells	   are	   high	  levels	  of	  CKS.	  At	   the	  same	  time	  mechanisms	  evolve	   in	   the	  cell	   to	  evade	  growth	  suppression	  and	  negative	  feedbackloops	   to	   sustain	   high	   proliferation	   (Hanahan	   and	   Weinberg,	   2011).	   An	   activated	   telomerase	  ensures	   the	   preservation	   of	   telomers	   and	   prevents	   replicative	   senescence	   (Belgiovine	   et	   al.,	   2008).	   The	  growing	   tumour	   tissue	   ensures	   its	   supply	   with	   nutrients	   and	   oxygen	   by	   the	   activation	   of	   angiogenic	  signalling	  which	   results	   in	   the	   formation	   of	   tumour	   associated	   neovasculature	   (Hanahan	   and	  Weinberg,	  2011).	  To	  be	  able	  to	  invade	  other	  tissues	  and	  to	  grow	  anchorage	  independent,	  the	  tumour	  cell	  finally	  needs	  to	  undergo	  the	  process	  of	  epithelial-­‐mesenchymal	  transition.	  Here	  adherens	  junctions	  are	  lost	  and	  the	  cell	  receives	   the	   ability	   to	   migrate	   and	   to	   grow	   anchorage	   independent	   (Hanahan	   and	   Weinberg,	   2011).	  Whereas	   the	   well	   studied	   oncoprotein	   RAS	   is	   involved	   in	   multiple	   steps	   in	   this	   model	   of	   multistage	  carcinogenesis	   (Hanahan	  and	  Weinberg,	  2011;	   Janda	  et	   al.,	   2002a;	   Janda	  et	   al.,	   2002b),	   the	  effect	  of	  high	  CKS	  levels	  emerges	  early	  during	  tumorigenesis.	  	  
6.2	   The	   effect	   of	   CKS	   over-­‐expression	   is	   dependent	   on	   cellular	  
context	  The	   observations	   of	   my	   study	   that	   high	   levels	   of	   CKS	   proteins	   confer	   a	   proliferative	  advantage	  in	  checkpoint	   inhibited	  but	  not	   in	  primary	  fibroblasts	  go	  along	  with	  studies	  conducted	  by	  members	  of	  the	  Keller	  laboratory	  (Keller	  et	  al.,	  2007;	  Kratzat	  et	  al.,	  2012).	  They	   showed	   that	   CKS1	   over-­‐expression	   alone	   does	   not	   necessarily	   lead	   to	   higher	  proliferation	   of	   B	   cells	   transplanted	   into	   wild-­‐type	   mice	   and	   is	   unable	   to	   induce	  lymphoma	  development.	  However,	  knocking	  out	  CKS1	  in	  precancerous	  B	  cells	  as	  well	  as	  lymphoma	  cells	  derived	  from	  mice,	  did	  lead	  to	  a	  decrease	  in	  proliferation	  (Keller	  et	  al.,	  2007;	  Kratzat	  et	  al.,	  2012).	  Thus	  the	  studies	  of	  the	  Keller	  laboratory	  as	  well	  as	  my	  study	  indicate	   that	   the	   effect	   of	   high	   levels	   of	   CKS	   is	   dependent	   on	   the	   cellular	   context.	  My	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model	  showed	  that	  in	  primary	  cells	  with	  intact	  checkpoints,	  CKS	  over-­‐expression	  leads	  to	  cell	  cycle	  deregulation	  and	  cell	  cycle	  arrest	  and	  CKS	  therefore	  cannot	  execute	  its	  cell	  cycle	  promoting	  activity.	  Upon	  checkpoint	  inhibition	  however,	  high	  levels	  of	  CKS	  lead	  to	  a	  proliferative	  advantage	  for	  the	  cells.	  This	  is	  in	  accordance	  with	  the	  discussed	  work	  in	  cancer	  cell	  lines	  with	  high	  CKS	  levels,	  in	  which	  CKS	  down-­‐regulation	  leads	  to	  the	  decline	  of	   their	   proliferative	   capacity	   (Kitajima	   et	   al.,	   2004;	   Lan	   et	   al.,	   2008;	   Lee	   et	   al.,	   2011;	  Wang	  et	  al.,	  2012).	  	   A	   study	   presented	   by	   the	  Reed	   laboratory	   (Liberal	   et	   al.,	   2011)	   showed	   that	  CKS	  over-­‐expression	   in	   transformed	   HEK293A	   cells	   and	   immortalised	   human	   mammary	  epithelial	  cells	  did	  not	  have	  an	  impact	  on	  the	  cell	  cycle.	  	  They	  observed	  however	  that	  in	  comparison	   to	   non	   CKS	   over-­‐expressing	   HEK293A	   cells,	   those	   cells	   which	   did	   over-­‐express	   CKS	   did	   not	   properly	   arrest	   in	   G1	   after	   treatment	   with	   the	   ribonucleotide	  reductase	  inhibitors	  thymidine	  or	  hydroxyurea	  (HU).	  This	  study	  therefore	  suggests,	  that	  not	  only	  the	  tumour	  suppressor	  gene	  background	  of	  a	  cell,	  but	  also	  the	  conditions	  the	  cell	  is	  under	  are	  important	  to	  the	  effect	  high	  levels	  of	  CKS	  have	  on	  the	  cell.	  	  	   The	   Reed	   laboratory	   showed,	   that,	   although	   checkpoint	   proteins	   are	   activated	   in	  the	   CKS	   over-­‐expressing	   HEK293A	   cells	   upon	   treatment	   with	   HU,	   origin	   firing	   was	  greatly	  elevated	  when	  compared	  to	  HU-­‐treated	  control	  cells.	  Thus,	  CKS	  over-­‐expressing	  HEK293A	   cells	   showed	   a	   proliferative	   advantage	   by	   overriding	   the	   G1/S	   checkpoint	  upon	  replicative	  stress	  caused	  by	  ribonucleotide	  reductase	  inhibitors.	  They	  suggested	  a	  model	  in	  which	  CKS1	  and	  CKS2	  help	  to	  override	  this	  checkpoint	  by	  keeping	  CDK2	  in	  an	  active	  form.	  To	  show	  that	  CDK2	  from	  CKS	  over-­‐expressing	  cells	  possess	  a	  high	  activity	  despite	  checkpoint	  activation	  by	  dNTP	  pool	  deprivation,	  they	  performed	  kinase	  activity	  assays	  with	  CDK2	   isolated	   from	  CKS2	  over-­‐expressing	  or	  control	  cells	  upon	  thymidine	  block.	  In	  their	  assay,	  the	  ability	  of	  CDK2	  to	  phosphorylate	  RB	  was	  higher	  in	  the	  presence	  of	   the	   CKS	   proteins.	   As	   the	   observed	   phenotype	  was	   shown	   in	   CKS2	   over-­‐expressing	  cells	  and	  CKS2	  is	  not	  part	  of	  the	  SCFSkp2	  ubiquitin	  ligase,	  they	  excluded	  an	  effect,	  which	  is	  due	   to	   lower	   p27Kip1	   levels.	   They	   did	   not	   observe	   any	   effects	   on	   the	   cell	   cycle	   in	  CKS	  over-­‐expressing	   cells	   without	   the	   addition	   of	   thymidine.	   In	   my	   study,	   CKS	   over-­‐expression	   alone	   led	   to	   checkpoint	   activation	   in	   primary	   IMR90	   fibroblasts	   without	  thymidine	   treatment.	   This	   checkpoint	   activation	   led	   to	   CDK	   inhibition	   and	   cell	   cycle	  arrest.	   If	   the	  model	  suggested	  by	  the	  Reed	  laboratory	  holds	  true,	   it	  only	  applies	  to	  the	  context	   of	   a	   ribonucleotide	   reductase	   inhibitor	   related	   S-­‐phase	   checkpoint	   in	   the	  context	  of	  a	  transformed	  cell	  line	  like	  HEK293A	  or	  possibly	  cancer	  cells.	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6.3	  Possible	  domains	  involved	  in	  CKS	  related	  transformation	  I	  confirmed	  the	  suspected	  oncogenic	  effect	  of	  CKS	  proteins,	  which	  results	  in	  replicative	  stress	  and	  checkpoint	  activation.	  I	  also	  showed	  that	  high	  expression	  is	  of	  advantage	  for	  cells	  lacking	  certain	  tumour	  suppressor	  pathways.	  In	  the	  next	  step	  I	  set	  out	  to	  identify	  the	   underlying	   pathway	   involving	   CKS.	   The	   domains	   of	   CKS	   proteins	   important	   in	  causing	  G1/S	  deregulation	  should	  be	  revealed	  and	  possible	  substrates	  important	  in	  CKS	  related	  transformation	  identified.	  	  	  Previous	  studies	  often	  suggested	  the	  involvement	  of	  CKS1	  in	  the	  down-­‐regulation	  of	  the	  CDK2	  inhibitor	  p27Kip1	  as	  the	  main	  reason	  for	  the	  proliferative	  advantage	  of	  CKS1-­‐high	  cancer	   cells	   (Kitajima	   et	   al.,	   2004;	   Lee	   et	   al.,	   2011;	   Masuda	   et	   al.,	   2003;	  Wang	   et	   al.,	  2009).	   Initially	   p27Kip1	   is	   phosphorylated	   by	   CDK2	   on	   Threonine	   187.	   As	   part	   of	   the	  SCFSkp2	  ubiquitin	  ligase,	  CKS1	  but	  not	  CKS2	  recognises	  phosphorylated	  p27Kip1	  and	  binds	  to	   it,	   together	   with	   the	   F	   box	   protein	   Skp2.	   This	   is	   followed	   by	   ubiquitination	   and	  degradation	  of	  p27Kip1	   (Spruck	  et	  al.,	  2001).	   Studies	   in	   cancer	  cell	   lines	  often	  show	  an	  accumulation	  of	  p27Kip1	  upon	  CKS1	   knockdown,	  which	   is	   accompanied	  by	  a	  decreased	  proliferative	  capacity	  (Kitajima	  et	  al.,	  2004;	  Lee	  et	  al.,	  2011;	  Wang	  et	  al.,	  2009).	  Results	  obtained	  during	  my	  work	   indicate	   that	  p27Kip1	  down-­‐regulation	   is	  not	   the	   sole	   reason	  for	  faster	  growth	  in	  cancer	  cells	  with	  high	  CKS	  levels.	  In	  my	  studies	  CKS1	  and	  CKS2	  show	  similar	   effects	   upon	   over-­‐expression	   in	   primary	   IMR90	   cells.	   Additionally,	   checkpoint	  activation	  in	  these	  IMR90	  cells	  was	  already	  observed	  one	  day	  after	  transfection	  with	  the	  CKSwt	   constructs,	   a	   time	   point	   at	   which	   p27Kip1	   down-­‐regulation	   could	   not	   yet	   be	  detected.	   Furthermore,	   CKS2,	  which	   is	   not	   involved	   in	   p27Kip1	   degradation,	   leads	   to	   a	  slightly	  more	   increased	  proliferation	   in	   checkpoint	   inhibited	   IMR90	  E6	  E7	  TERT	   cells	  than	   CKS1	   does.	   Thus,	   an	   oncogenic	   function	   exists,	   which	   leads	   to	   an	   elevation	   of	  proliferation	  in	  transformed	  cells	  and	  is	  likely	  to	  be	  independent	  of	  the	  degradation	  of	  p27Kip1.	   This	   would	   be	   in	   good	   agreement	   with	   observations	   made	   by	   Höllein	   et	   al.	  Höllein	  saw	  that	  MEFs	  lacking	  CKS1	  showed	  a	  lower	  proliferative	  capacity	  characterised	  by	  less	  actively	  replicating	  cells	  in	  S-­‐phase	  and	  cells	  accumulating	  in	  G1	  and	  G2.	  Loss	  of	  p27Kip1	   could	  not	   reverse	   this	  S-­‐phase	  defect	  but	   led	   to	  a	   reduction	  of	   the	  cells,	  which	  accumulated	  in	  G2	  (Hoellein	  et	  al.,	  2012).	  His	  results	  would	  suggest	  that	  degradation	  of	  p27Kip1	  with	  the	  help	  of	  CKS1	  is	  more	  important	  for	  G2/M	  transition	  and	  that	  the	  effect	  of	  CKS1	  on	  G1/S	  transition	  is	  mediated	  by	  other	  mechanisms.	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Another	  mechanism	  by	  which	  CKS	  proteins	  could	  lead	  to	  a	  deregulated	  G1/S	  transition	  might	   be	   by	   direct	   interaction	   with	   CDK.	   This	   interaction	   is	   well	   known	   and	   might	  change	  CDK	  activity	  possibly	  by	  supporting	  binding	  to	  specific	  substrates	  (Bourne	  et	  al.,	  1996).	   To	   address	   the	   question	   of	   whether	   CKS	   proteins	   do	   affect	   CDK	   activity	   by	  directly	   interacting	  with	   the	   kinase	   in	  my	   settings,	   CKSE63Q	  mutants	  were	   used.	   The	  binding	   capacity	   of	   CKSE63Q	   mutants	   towards	   CDK	   was	   previously	   shown	   to	   be	  decreased	   to	   20%	   of	   the	   wild-­‐type	   protein	   (Bourne	   et	   al.,	   1996).	   In	   the	   experiments	  performed	   during	   my	   study	   cells,	   over-­‐expressing	   the	   E63Q	   or	   wt	   variants	   were	  compared	  with	  empty	  vector	  control	  cells.	  	  	   Over-­‐expression	   of	   CKSwt	   as	   well	   as	   the	   CKSE63Q	   mutants	   led	   to	   checkpoint	  activation	   and	   a	   pronounced	   growth	   arrest	   in	   IMR90	   fibroblasts.	   This	   suggests	   that	   a	  function	  of	  CKS	  proteins,	  which	  is	  independent	  of	  direct	  CDK	  binding,	  contributes	  to	  the	  development	  of	  deregulated	  cell	  cycle	  progression	  during	  early	  steps	  of	  tumorigenesis.	  	  A	  function	  of	  CKS,	  which	  is	   independent	  of	  direct	  CDK	  binding,	   is	  the	  discussed	  role	  of	  CKS	   as	   adaptor	   protein	   between	   the	   SCFSkp2	   ubiquitin	   ligase	   and	   its	   substrate	   p27Kip1.	  Moreover	   the	  ubiquitination	  of	  cyclin	  A	  by	  the	  APC/C	  ubiquitin	   ligase	   is	   facilitated	  via	  CKS	  proteins	  (Di	  Fiore	  and	  Pines,	  2010).	  In	  both	  cases	  the	  anion-­‐binding	  site	  of	  CKS	  is	  required.	  My	  studies	  to	  whether	  the	  anion-­‐binding	  site	  is	  of	  importance	  in	  the	  induction	  of	   deregulated	   replication	   by	   CKS	   remained	   inconclusive.	   	   Assuming	   that	   the	   anion-­‐binding	  site	  is	  essential	  and	  endogenous	  CKS	  acts	  as	  an	  adaptor	  protein,	  excessive	  CKS	  protein	  levels	  might	  counteract	  the	  actual	  function	  of	  CKS	  as	  adaptor.	  Whereas	  a	  subset	  of	  CKS	  proteins	  binds	  solely	  to	  the	  target	  protein	  another	  subset	  binds	  to	  the	  ubiquitin	  ligase	   consequently	   hindering	   enzyme	   and	   target	   interaction	   (Figure	   6.2).	   Thus	   high	  levels	  of	  CKS	  proteins	  may	  exert	   a	  dominant	  negative	  mechanism	   leading	   to	   a	  G1	   cell	  cycle	  arrest	  for	  which	  the	  mechanism	  is	  not	  known	  yet.	  The	  competition	  for	  substrates	  by	  excessive	  CKS	  proteins	  might	  not	  only	  effect	  the	  well	  studied	  functions	  of	  CKS	  within	  protein	   degradation	   or	   regulation	   of	   CDK	   activity	   but	   also	   metabolic	   pathways	  (Radulovic	  et	  al.,	  2010)	  or	  other	  yet	  unknown	  CKS	  involving	  pathways.	  A	   possible	   dominant	   negative	   effect	   of	   CKS	   proteins	   is	   independent	   of	   a	   direct	  interaction	  of	  CKS	  proteins	  with	  CDK	  and	  might	  explain	   the	  growth	  arrest,	  which	  was	  observed	  in	  wt	  CKS	  as	  well	  as	  CKSE63Q	  mutant	  over-­‐expressing	  cells.	  When	  the	  effect	  of	  wt	   CKS	   proteins	   and	   CKSE63Q	   mutant	   proteins	   on	   primary	   IMR90	   fibroblasts	   were	  compared	   however,	   little	   differences	   in	   the	   resulting	   phenotype	   of	   IMR90	   fibroblasts	  were	  noticed.	  A	  slightly	  less	  pronounced	  phenotype	  for	  growth	  inhibition	  as	  well	  as	  for	  other	   senescent	  markers	   like	   SA-­‐β-­‐Gal	   activity	   was	   observed	   for	   cells	   expressing	   the	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  Figure	  6.2	  Model	  illustrating	  a	  possible	  dominant	  negative	  effect	  of	  excessive	  CKS	  using	  the	  example	  
of	  CKS	  dependent	  substrate	  ubiquitination.	  When	  CKS	  protein	  levels	  are	  tightly	  regulated,	  CKS	  function	  as	   adaptor	   proteins	   to	   promote	   the	   binding	   of	   specific	   substrates	   to	   their	   ubiquitin	   ligases.	   Upon	   an	  increase	  of	  CKS	  availability	  in	  the	  cell,	  the	  access	  of	  the	  specific	  substrate	  to	  the	  ubiquitin	  ligase	  is	  blocked	  as	  excess	  of	  CKS	  proteins	  causes	  the	  substrates	  being	  sequestered	  by	  CKS	  that	  are	  not	  able	  to	  interact	  with	  the	  ligase	  due	  to	  the	  fact	  that	  their	  docking	  site	  is	  taken	  by	  other	  CKS	  	  (right).	  	  	  	  
E63Q	   variant.	   Thus	   checkpoint	   activation	   upon	   CKS	   over-­‐expression	   in	   IMR90	  fibroblasts	  could	  be	  partly	  due	  to	  the	  ability	  of	  CKS	  to	  directly	  bind	  CDK.	  This	  would	  go	  along	  with	  studies	  conducted	  in	  yeast	  showing	  the	  importance	  of	  CKS	  for	  the	  activity	  of	  CDK-­‐G1	  cyclin	  complexes	  (Reynard	  et	  al.,	  2000).	  It	  would	  also	  be	  in	  agreement	  with	  the	  study	  discussed	  earlier	  in	  which	  CKS	  but	  not	  CKSE63Q	  over-­‐expression	  leads	  to	  higher	  CDK2	  activity	  (Liberal	  et	  al.,	  2011).	  	  	   A	  CDK2-­‐dependent	  function	  of	  CKS	  proteins	  was	  also	  shown	  by	  Di	  Fiore	  and	  Pines,	  who	  proposed	  a	  model	  for	  the	  ubiquitination	  of	  cyclin	  A.	  In	  their	  model	  cyclin	  A,	  which	  is	   in	   complex	  with	   CDK/CKS,	   binds	   the	   APC/C	   cofactor	   CDC20	   and	   is	   directed	   to	   the	  APC/C	  via	   the	   interaction	  of	  CKS	  with	   the	  phosphorylated	  APC/C	   (Di	  Fiore	  and	  Pines,	  2010).	  According	  to	  this,	  CKS	  proteins	  act	  as	  adaptor	  proteins	  between	  CDK	  complexes	  and	   the	   phosphorylated	   ubiquitin	   ligase	   APC/C	   promoting	   the	   function	   of	   APC/C.	   A	  similar	   model	   would	   be	   conceivable	   for	   a	   CDK	   promoting	   function	   of	   CKS.	   Here	   CKS	  could	  interact	  with	  phosphorylated	  target	  proteins	  of	  CDK	  thus	  bringing	  CDK	  into	  close	  proximity	  to	  their	  target	  proteins.	  In	  my	  model	  I	  could	  not	  detect	  a	  significantly	  elevated	  CDK2	  activity	  after	  over-­‐expression	  of	  CKS	  even	  when	  using	  transformed	  293T	  cells.	  As	  mentioned	  before,	  this	  could	  be	  due	  to	  the	  design	  of	  the	  kinase	  assay	  in	  which	  histone	  H1	  was	  used	  as	  target	  protein.	  When	  CKS	  proteins	  might	  increase	  CDK	  activity	  by	  acting	  as	   an	   adaptor	   between	   the	   CDK	   complex	   and	   its	   substrate,	   CKS	  would	   show	   a	   higher	  affinity	  towards	  specific	  targets.	  Thus	  histone	  H1	  might	  not	  be	  a	  specific	  target	  for	  the	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potential	   adaptor	   protein	   CKS	   within	   the	   CDK2-­‐cyclin	   A	   complex.	   In	   the	   Reed	  laboratory,	  where	  in	  vitro	  assays	  showed	  that	  CDK2	  was	  kept	  active	  by	  addition	  of	  CKS	  proteins,	   RB	  was	   used	   as	   target	   instead.	   Thus,	   an	   adaptor	   function	  within	   the	   CDK2-­‐cyclin	  A	   complex	  might	   lead	   to	   the	  phosphorylation	  of	  proteins	   like	  RB	  and	   therefore	  would	  promote	  S-­‐phase.	  My	  studies	  of	  whether	  phospho-­‐protein	  binding	  is	  involved	  in	  a	  cancer	   promoting	   function	   of	   CKS	   failed	   however,	   due	   to	   the	   fast	   degradation	   of	   the	  phospho-­‐protein	  binding	  mutant	  CKS	  AM	  by	  the	  proteasome.	  	  	  
6.4	  Future	  work	  Further	  studies	  would	  need	  to	  be	  made	  to	  investigate	  the	  involvement	  of	  the	  phospho-­‐protein	  binding	  site	  of	  CKS	  in	  CKS	  related	  transformation.	  	  	   Preferably	   these	   studies	   should	   be	   conducted	   using	   an	   inducible	   system	   for	   CKS	  expression.	  In	  this	  way,	  effects	  of	  CKS	  over-­‐expression	  could	  be	  examined	  within	  hours	  upon	   the	   induction	   of	   the	   protein	   and	   furthermore	   degradation	   of	   the	  mutant	   forms	  might	   be	   avoidable.	   Initially	   cell	   cycle	   studies,	   including	   flow	   cytometry	   and	  Western	  blot	  analyses	  of	  cell	  cycle	  proteins,	  could	  be	  conducted	  to	  see	  whether	  wt	  CKS	  and	  anion	  binding	   site	   mutant	   expression	   in	   primary	   IMR90	   fibroblasts	   had	   an	   effect	   on	  progression	   into	  and	   through	  S-­‐phase.	  An	   initial	   experiment	  was	  performed	  using	   the	  IMR90	  TERT	   cells,	   transduced	  with	   tetracycline	   inducible	   CKS1	   vectors	   resulting	   in	   a	  heterogeneous	   cell	   population	   for	   CKS1	   expression.	   Upon	   synchronisation	   by	   contact	  inhibition	  and	   induction	  of	  CKS	  expression	   for	   two	  days,	   these	  cells	   showed	  a	   slightly	  delayed	   entry	   into	   S-­‐phase	   upon	   re-­‐plating	   at	   low	   density	   (Supplemental	   figure	   7.3).	  This	  effect	  is	  possibly	  due	  to	  the	  described	  checkpoint	  activation	  and	  might	  be	  avoidable	  when	  early	  time	  points	  are	  chosen.	  	  	   If	   over-­‐expression	  of	   the	   anion	  binding	   site	  mutant	  would	  not	   lead	   to	   checkpoint	  activation	  a	  possible	  dominant	  negative	  effect	  of	  CKS	  proteins	  involving	  the	  blockage	  of	  enzyme	  binding	  to	  their	  phosphorylated	  substrates	  could	  further	  be	  investigated.	  	  	   Also	   a	   possible	   function	   of	   CKS	   as	   adaptor	   protein	   for	   CDK2	   and	   their	   target	  proteins	  could	  be	  further	  analysed	  in	  a	  kinase	  assay	  screen	  with	  different	  CDK2	  target	  proteins	  as	  substrates.	  	  
6.5	  Concluding	  remark	  Since	   their	   discovery,	   CKS	   proteins	   have	   been	   studied	   extensively.	   They	   exhibit	   an	  important	  function	  in	  the	  degradation	  of	  cyclin	  A	  via	  the	  APC/C	  and	  the	  degradation	  of	  p27Kip1	   via	   the	   SCFSkp2	   ubiquitin	   ligases.	   Despite	   these	   well-­‐established	   roles,	   CKS	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proteins	   are	   involved	   in	   a	   variety	   of	   cell	   cycle	   processes	   for	   which	   the	   underlying	  molecular	  mechanism	  still	  needs	  to	  be	  revealed.	  	  	   In	   previous	   studies	   inhibition	   of	   CKS	   protein	   expression	   in	   cancer	   cells	   has	   been	  shown	  to	  impair	  cell	  proliferation	  and	  tumorigenicity.	  In	  case	  of	  CKS1	  the	  positive	  effect	  on	   proliferation	   in	   cancer	   cells	   was	   assumed	   to	   be	   dependent	   on	   the	   role	   of	   CKS	   in	  p27Kip1	  down-­‐regulation	  by	  the	  SCFSkp2	  ubiquitin	  ligase.	  	  	   The	   presented	   study	   supports	   a	   role	   of	   CKS	   as	   oncogene.	   This	   role	   seems	   to	   be	  solely	  due	  to	  the	  effect	  of	  CKS	  on	  the	  cell	  cycle.	  The	  oncogenic	  effect	  does	  not	  seem	  to	  involve	   cyclin	   A	   or	   p27Kip1	   degradation.	   High	   levels	   of	   CKS	   might	   either	   enforce	   the	  function	  of	  CKS	  as	  adaptor	  protein	  or	  lead	  to	  a	  dominant	  negative	  effect	  and	  blockage	  of	  CKS	  functions,	  which	  remain	  to	  be	  identified.	  	  	   It	   has	   to	   be	   noted	   that	   although	   CKS1	   and	   CKS2	   over-­‐expression	   in	   primary	  fibroblasts	  resulted	  in	  checkpoint	  activation	  and	  senescence	  it	   is	  possible	  that	  they	  act	  on	   different	   pathways	   within	   the	   cell	   to	   cause	   cell	   cycle	   deregulation.	   CKS1	   and	   2	  proteins	   might	   regulate	   the	   function	   of	   several	   enzymes	   in	   different	   ways	   and	   the	  converged	  action	  of	  all,	  results	  in	  the	  observed	  phenotype	  of	  cell	  cycle	  arrest	  in	  primary	  cells.	   Further	   investigations	   will	   provide	   further	   understanding	   into	   which	   CKS	  dependent	  enzymes	  and	  substrates	  are	  involved	  during	  this	  early	  step	  of	  the	  oncogenic	  pathway	  when	  CKS	  is	  over-­‐expressed.	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  Figure	  7.1	  Induction	  of	  CKS	  protein	  expression	   in	   IMR90	  TERT	  cells	  using	   the	  pBABE	  sin	   tet	  PURO	  
system	  does	   not	   lead	   to	   cell	   cycle	   arrest.	   (A)	  Western	  blot	  analysis	  displaying	  ectopic	  CKS	  expression	  upon	   viral	   transduction	   of	   the	   IMR90	   TERT	   cells	  with	   the	   pBABE	   sin	   tet	   CKS	   construct.	   Expression	  was	  induced	  with	  40	  µg/ml	  of	  doxycycline	  and	  cells	  were	  harvested	  for	  Western	  blot	  analysis	  at	  the	  indicated	  time	  points.	  Over-­‐expressed	  CKS	  proteins	  were	  detected	  using	  an	  anti-­‐Flag	  antibody.	  (B)	  IMR90	  TERT	  cells	  with	  induced	  CKS	  expression	  were	  compared	  with	  non-­‐induced	  cells	  regarding	  their	  proliferative	  capacity.	  Cells	  were	  seeded	  at	  a	  low	  density	  and	  fixed	  with	  glutaraldehyde	  two	  weeks	  later	  for	  crystal	  violet	  staining.	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  Figure	  7.2	  Over-­‐expression	  of	  CKS	  proteins	   in	  primary	   IMR90	  cells	  via	   the	  pBABE	  sin	   tet	  
CKS	  PURO	  system	  does	  not	  lead	  to	  checkpoint	  activation	  and	  cell	  cycle	  arrest.	  (A)	  Primary	  IMR90	   cells	  were	   transduced	  with	   the	   pBABE	   sin	   tet	   CKS	   PURO	   constructs,	   selected	   and	   CKS	  expression	  was	  induced	  using	  the	  indicated	  concentrations	  of	  doxycycline.	  Cells	  were	  plated	  the	  following	  week	   and	   fixed	   the	   day	   after.	   Immunofluorescence	   staining	  was	   performed	  with	   an	  antibody	  against	  p53.	   Images	  were	  acquired	  with	   the	   IN	  Cell	  Analyzer	  1000	  and	  quantitatively	  evaluated	  using	  high	  content	  analysis	  as	  described	  in	  Material	  and	  Methods.	  (B)	  The	  proliferative	  capacity	  of	  pBABE	  sin	  tet	  CKS	  PURO	  transduced	  IMR90	  cells	  was	  assessed	  using	  a	  crystal	  violet	  assay.	  Therefor	  CKS	  expression	  was	  induced	  using	  4	  µg/ml	  of	  doxycycline.	  Cells	  were	  plated	  at	  a	  low	  density	  the	  following	  week	  and	  fixed	  for	  crystal	  violet	  staining	  two	  weeks	  later.	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  Figure	   7.3	  Cell	   cycle	   analysis	   upon	   induction	   of	   CKS	   expression.	   IMR90	   TERT	   cells	   transduced	  with	  pBABE-­‐sin-­‐tet-­‐Puro-­‐CKS	  were	  kept	  at	  100%	  confluence	  for	  5	  days	  to	  allow	  cells	  to	  arrest	  in	  G1.	  Cells	  were	  kept	   in	  medium	   either	  with	   or	  without	   doxycycline	   from	   day	   4	   onwards.	   To	   allow	   progression	   from	  G1	  through	  the	  cell	  cycle,	  cells	  were	  seeded	  at	  a	  lower	  density.	  Cells	  were	  pulsed	  with	  BrdU	  for	  one	  hour	  at	  the	  given	   time	   points,	   fixed	   and	   stained	   with	   propidium	   iodid	   and	   an	   anti-­‐BrdU	   antibody	   thereafter.	   Flow	  cytometry	   was	   performed	   (upper	   panel)	   and	   cell	   populations	   were	   gated	   into	   G1,	   S	   and	   G2-­‐phase.	   The	  diagram	  presented	  (lower	  panel)	  shows	  the	  proportion	  of	  CKS1	  induced	  and	  non	  induced	  IMR90	  TERT	  cells	  in	  S-­‐phase	  at	  the	  given	  timepoints.	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